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Summary
Class n major histocompatibility complex antigens are cell surface ap-heterodimeric
glycoproteins which function as important immune recognition molecules for the stimulation
of CD4+-T lymphocyte-mediated immune responses. Their expression by tumour cells, and
the possible implications, has been the subject of much debate. In this investigation aspects of
the cytokine-mediated regulation of the transcription of the gene of the human class nMHC
molecule lll..A-DRa were investigated in human cell lines derived from colorectal and neural
tumours.
The transcriptional regulation of lll..A-DRa has been shown to be controlled through
discrete promoter elements termed the W, X and Y boxes; the W and X elements were
investigated here. Nuclear proteins were purified from inducible (colo 201, colo 205 and
U373MG) and non-inducible (caco-2 and LS180) cell lines and were shown to associate with
oligonucleotide probes corresponding to the W and X regulatory elements of the lll..A-DRa
promoter using bandshift (gel retardation) experiments. Differences were observed in the
populations ofW and X box-binding proteins between the cell lines. The IFN-y treatment of
class n inducible colorectal cell lines resulted in the binding of different populations of
transcription factors to these probes: novel factors were bound as well as proposed repressor
proteins dissociating from these probes.
When a promoter probe corresponding to the 470 base pairs upstream of the cap site
was employed, differences in the binding of factors between inducible and non-inducible cell
lines were again observed. Treatment of the colorectal tumour cell line colo 205 with IFN-y
resulted in the appearance of a novel binding factor after 6hr treatment. Longer treatment
resulted in the net loss of binding factors from the W-X box region in addition to the loss of a
postulated "maintenance repressor factor" which associated less specifically with the W-X-Y
box region.
The use of reporter gene assays in the glioblastoma cell line U138MG showed that
IFN-ap and TGF-p are both capable of suppression of IFN-y-induced CAT expression
through a 680bp and a 320bp HLA-DRa promoter fragment. The levels of IFN-y-induced
CAT expression were also greater for the 320bp promoter fragment expression vector. The
suppression observed was greater with the larger promoter fragment. Concurrent IFN-y
(IU/ml; 48hr) and IFN-ap (100U/ml; 48hr) reduced DRa680CAT expression to 47% and
DRa320CAT expression to 84% of that observed with IFN-y alone; simultaneous treatment
(with lU/ml IFN-y and 1000U/ml IFN-ap) of cells transiently transfected with
pDRa320CAT resulted in CAT expression being 26% of that observed with IFN-y alone. For
TGF-p (lOOU/ml) cotreatment with lU/ml IFN-y, the expression of CAT was 27% and 55%
of that observed for IFN-y-treatment alone with pDRa680CAT and pDRa320CAT-
transfected U138MG, respectively. It was concluded that the 680bp fragment contained a
repressor element absent form the truncated form. The 680bp fragment contained a putative
IFN-ap response element which was removed by its truncation to yield the 320bp promoter
region. The colorectal tumour cell lines were unable to express CAT driven by either
lll..A-DRa promoter fragment. It was hypothesised that a tissue-specific enhancer element
was absent from both of these promoter fragments.
This study demonstrated a variety of aspects of the cytokine-mediated regulation of
HLA-DRa gene expression. Tissue-specific differences in the regulation of expression were
shown between cells of neural and colorectal origin when they were interrogated with regards
to their abilities for IFN-y-induced lll..A-DRa promoter-driven gene expression. The binding
of nuclear proteins to important regulatory elements of the lll..A-DRa promoter also
confirmed that tissue- and cell-line-specific differences occurred with this respect.
xix
CHAPTER 1
CHAPTER 1: INTRODUCTION
Opening remarks: The nature and control of gene expression in
mammalian cells
Unlike the environment of microorganisms, the internal milieu of higher
multicellular organisms such as mammals is, in metabolic terms, very constant.
As such, there is little demand for abrupt and substantial changes in the
biochemistry of cells of such organisms. There is, therefore, little day to day
alteration in the amounts of enzymes of, for example, the glycolytic pathway
although short term changes in the activity of the enzymes may occur.
However, adaptive changes do occur, and an example of this is the response to
the attempted colonisation by pathogenic microorganisms: the immune
response. The cells of the immune system can show very large changes in
their properties: new functions are induced, and dramatic changes in the
physiology of the cells of the immune system do occur. An example is the
activation of the resting B lymphocyte to become a metabolically very active
plasma cell, secreting large amounts of immunoglobulin.
These changes in cellular physiology are to a large extent due to
changes in gene expression. Transcription is a major level at which gene
expression is regulated in eukaryotes. It follows that for comprehension of the
nature of adaptive changes in the immune system - mammalian cells in general
- the elucidation of the mechanisms that control the initiation of transcription is
central (La Thangue and Rigby, 1988).
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Mammalian gene expression follows the dogma of "transcription" of the
gene into message and translation of the message into protein. The structure
of mammalian genes is complex, and their organisation into chromosomes adds
a further level of complexity: the nuclear location of DNA requires
post-transcriptional mechanisms to transport the message to the site of
translation. There are elaborate processes to ensure that the resulting protein
is delivered to its appropriate location within or without the cell and modified as
necessary. Mammalian physiology is highly elaborate, with many different cell
systems interacting directly and via diffusible factors to influence each other:
and this influence is very much exerted at the level of gene expression to
change the constellation of proteins produced within a cell.
It is possible to make a generalisation about the control of gene
expression equivalent to the central dogma about the mechanism of gene
expression: that is that a primary level of control is through the efficiency of
transcription of the gene, this is exerted by the interaction of specific proteins -
transcription factors - with particular sequences of the gene - response
elements - located usually upstream of the structural gene.
The binding of transcription factors to the promoters of eukaryotic genes
during the control of expression is under the control of many stimuli. Certain
transcription factors are described as being "general" in that they bind to the
same cis-acting sequence in many promoters (for example, the TATA and
CCAAT boxes). The plasticity of gene expression by eukaryotic cells enables
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them to respond to environmental change and as a result they can alter their
physiological status to adapt. The maximal control of gene expression often
requires the binding of additional transcription factors upstream of the TATA
and CeMT boxes. The binding of additional transcription factors to a promoter
sequence is frequently seen to be under the control of stimuli external to the
cell.
Described in section 1.5. are the mechanisms for the interaction of
transcription factors with their specific sequence elements and the subsequent
effects on transcription. Many transcription factors only bind to their sequence
element upon stimulation by factors exogenous to the cell, for example binding
of steroids to their receptor, phosphorylation of CREB after cAMP-induced
protein kinase activation. One important type of stimulation is that observed
from the binding of cytokines to the specific cell surface receptors of target cells
where binding activates cellular genes through intracellular signalling systems
targeted on transcription factors (Morris, 1995). The genes induced by
cytokines are particularly important in the control of immune responses as well
as other non-immunological functions. Hence, the consequences of
cytokine-induced gene expression are of great importance to the whole animal.
The present study investigated aspects of the roles of the cytokines,
interferon-y (IFN-y), interferon-aj3 (IFN-aj3) and transforming growth tactor-B
(TGF-j3) in the control of the expression of the gene for the human leukocyte
antigen ORa (HLA-ORa). The following sections describe the functions of
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immune recognition molecules encoded within the major histocompatibility
complex in immune responses. Further on, the transcriptional regulation of
genes whose products are essential for an effective immune response against a
foreign antigen is discussed.
1.1. Antigens of the major histocompatibility complex of man
Transplantation antigens were initially defined as the cell surface
molecules whose polymorphism led to rejection of allogeneic grafts (Gorer,
1937). Such molecules have been found to be encoded in a similar genetic
region, called the major histocompatibility complex (MHC), in all vertebrate
species examined (Snell, 1981), including man (Oausset, 1981). The MHC is
about 4 mega bases in size and encodes about 100 genes. Genes included in
this region are those which encode immune response genes (Benacerraf,
1981), which determine an animal's response to a specific antigen (now known
to be MHC antigen genes), and some of the components of the complement
system. The MHC also encodes genes involved in the processing of foreign
antigens, such as those encoding transporter proteins involved in the delivery of
peptides to the ER in which their association with MHC antigens occurs (see
figure 1.1.).
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Figure 1.1. Map of the major histocompatibility complex of man
THE CLASS II REGION
Kbp: 0
ORA
1000
LMP1,2
THE CLASS III REGION
1000 1500 2000
THE CLASS I REGION about 18 new genes FA G
B C E II I
TUBB
I I II I I2000 3000 4000
Notes:
The major histocompatibility complex of man is encoded on chromosome 6 and covers
approximately 4 megabases of DNA. In this diagram the MIle has been split into
class II, III and I regions. Long stalks represent genes for histocompatibility antigens,
short stalks are other genes. TAP1 and 2 are genes encoding "transporters associated
with antigen presentation", the class II region also encodes proteasome genes. The class
III region encodes genes of the complement system: e2, e4A and B and Bf (factor B).
This region also encodes tumour necrosis factor a. and f3(TNF A and B) and genes for
heat shock protein 70s. Other genes in the class III region encode genes whose functions
are still to be elucidated.· The class I region encodes genes for classical class I MIle
antigens as wen as the f3-tubulingene (TUBB). About 18 new genes have recently been
discovered in this region whose functions are yet to be elucidated. Diagram compiled
fromMorris, et al., 1994.
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The best known of the genes of the MHC are those which encode the
class I and II histocompatibility antigens. It is these antigens which are
responsible for the rejection of allogeneic grafts which first led to their
identification. Their physiological rOle, however, is the presentation of peptide
antigen to T lymphocytes, which is achieved by the formation of complexes
between small peptide fragments of foreign antigen and the histocompatibility
antigen expressed at the surface of the antigen presenting cell (APC) where the
complex is recognised by the receptor of the appropriate T-cell.
The following sections outline the roles played by class I and class II
MHC antigens in the presentation of peptide antigens to T-lymphocytes and the
generation of the subsequent immune responses.
For a T-Iymphocyte to be activated, it must recognise antigens presented
on the surface of the cell in physical association with the polypeptide products
of MHC genes. The rOles of class I and class II MHC molecules is to present
antigens in a context recognisable by either of the two major functional types of
T-Iymphocytes, cytotoxic and helper. Cytotoxic T-Iymphocytes (Te) recognise
antigens in association with class I MHC molecules, whereas helper
T-Iymphocytes (Th) recognise those antigens in the context of class II MHC.
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1.1.1. Class I MHC antigens and CDS+T-cell responses
Class I MHC genes encode the a chain of an alJl heterodimer in which
the p chain is P2-microglobulin encoded at a different locus. The classical
class I genes (human leukocyte antigens (HLA)-A, -8 and -C in man) are
involved in the presentation of endogenously synthesised "foreign" antigens to
the immune system, for example antigens arising from a viral infection.
The overall structure of class I genes and antigens is strongly conserved
between (and within) mammalian species. The proteins are highly polymorphic
integral membrane glycoproteins of 44 kD (Ploegh, et al., 1981). The protein
structure is immunoglobulin-like and each class I a-chain is defined by five
distinct domains, three extracellular "a" domains, a transmembrane sequence
and a cytoplasmic region, each of which is encoded by its own exon. It is the
diversity in class I MHC structure which allows their association with an equally
diverse possibility of foreign peptide antigens.
The formation of the cell surface "class I" molecule requires the a-chain's
non-covalent association with the non-polymorphic, non-glycosylated 12 kD
P2-microglobulin polypeptide. This association occurs within the endoplasmic
reticulum after peptide binding and is essential for the final folding of the
complex and its transport to the cell surface.
A schematic representation of the association of peptide antigen and
P2-microglobulin with a class I molecule is given in figure 1.2.
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Figure 1.2. Schematic representation of the interaction of moieties in the
formation of the class I MHC
Notes:
This diagram represents the major structural domains of class I hllIC molecules and the
associated Jh-microglobulin Oh-M). The extracellular domains of the class I hllIC
molecule are represented by a1-a3. S-S represents the intrapeptide covalent disulphide
bonds.
Class I bound peptide epitopes are limited to 8 or 9 amino acids and
there appears to be allelic-associated patterns of sequences of naturally bound
peptides. Three-dimensional crystal structures of the interaction of class I
molecules and peptide antigens have revealed that such association occurs
between the class I side chains and the peptide backbone. High resolution data
have described six pockets or sub-sites, designated 'A' to 'F'. of diverse shape
and composition in the antigen-binding groove which might provide specificity
for interactions with the peptide side chains (Saper, et al., 1991). Substitution
mutations of specific amino acids along the peptide binding groove have
allowed the investigation of each of the specificity pockets (Moots, et al., 1991,
1992; Latron, et al., 1991, 1992; Morrison, et el., 1992; Moss, et al., 1991).
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Predictions of the properties of Class I-binding peptides are possible from the
defined characteristics of these pockets. The elution of natural peptides from
Class I MHC molecules and their subsequent sequencing have implicated
certain consensus amino acid residues which will allow peptide association in
the MHC binding groove. It has been suggested that T-cell receptor (TCR)
recognition occurs not only because of specific peptide residues (Falk, et al.,
1992; Jardetzky, et al., 1991), but also because of conformational changes
induced in the class I molecule by the binding of peptide (Rotzschke & Falk,
1991).
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The CD8+ T-cell response
The surface expression of the class I MHC molecule and associated
foreign peptide and Prmicroglobulin allows a cell's recognition by COS+
cytotoxic T cells. Mutational analysis of class I proteins have shown that
binding of COSwith the class I molecule occurs within an acidic loop of the a3
domain (Moots, et al., 1992; Salter, et al., 1990; Connolly, et al., 1990). It has
been suggested that the heterodimeric COSmolecule has the ability to bind two
class I MHC at once, enhancing the affinity of the interaction with the TCR. No
definitive study has been able to identify the interaction of the TCR with
MHC/peptide structure.
Recognition of MHC class I-bearing cells by appropriate COS+ T
lymphocytes is the first step in a chain events which leads to the removal of the
antigen-presenting cell. However, the initial contact between Te and target cell
is non-specific, i.e., it does not involve the TCR and target antigen, rather it is
mediated by accessory molecules of the T cell C02 and LFA-1 (leukocyte
function associated antigen - 1). The respective target cell ligands for these
molecules are LFA-3 and ICAM-1 (intercellular adhesion molecule - 1).
Binding of T, to the target cell results in its activation through a complex
Ca2+-dependent intracellular signalling system transduced from the TCR-CD3
complex. Activation of the T-lymphocyte results in extensive rearrangement of
its cytoplasm and the reorientation of the microtubule organising centre and
Golgi apparatus towards the contact site between Teand target cell. Vesicular
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components are accumulated in the region in proximity with the contact site.
The "lethal hit" is delivered by the secretion of granules containing serine
proteases and Ca2+ pore-forming proteins assumed to form lethal holes in the
membranes of the target cells. The studies leading to these conclusions are
reviewed by Terhorst, et al., (1988).
The activation of T-cells leads to production of interleukin-2 (IL-2) which
binds to its receptor on the cytotoxic T cell. This binding leads to progression of
the lymphocyte through the cell cycle and proliferation (Morris, 1995).
1.1.2. Class II MHC antigens and CD4+T-cell responses
The class" MHC antigens of man are described by the human leukocyte
antigen 0 (HLA-D) loci (HLA-DR, -DO & -DP). The proteins are heterodimers
consisting of closely related a and P chains whose respective genes are paired
within the HLA-D locus. The a and P chains of class" proteins have a domain
structure similar to that of the class I MHC a chain in which the polypeptide is
split into two extracellular "a" (or "P") regions, a transmembrane sequence and
a carboxy-terminal cytoplasmic domain (see figure 1.3.). Both chains are
glycosylated and are covalently linked intramolecularly via disulphide bonds.
The HLA-DR, -DO and -DP genes display varying degrees of variability, for
example, DRP displays almost all the polymorphism observed for HLA-DR, with
56 different DRP chains being sequenced (Marsh and Bodmer, 1992), whereas
ORa is virtually invariant. However, DO a and P chains display similar degrees
of variance with 12 DOa and 17 DOP chain sequences (Marsh and Bodmer,
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1992; reviewed in Morris, et al., 1994}.
Figure 1.3. Domain structures of HLA-D a and ~ chains
j}-2 I TM I Cyt I
CD4
Notes:
A schematic representation of the a. and p chains of the class II MHC molecule
Ill.A-DRI. Glycosylation sites are indicated, as are intramolecular disulphide bridges.
The probable CD4 binding site within the P-2 domain is indicated. Diagram taken from
Morris, et aI., (1994).
Class II MHC molecules associate with endocytosed peptide fragments
during their processing in the endocytic pathway. The binding of endogenous
cellular peptides to the class II MHC is prevented by its association with the
invariant chain (Ii) during targetting from the endoplasmic reticulum to the
endocytic pathway (Harnmerlinq and Moreno, 1990).
The peptides bound by class II MHC molecules are generally 17 or 18
amino acids in length (Rudensky, et al., 1991). Such peptides, as a
consequence of MHC class II tissue distribution, are derived from exogenous
protein antigens which have been internalised by and processed by
Chapter I 14
macrophages. Interaction between the MHC and peptide appears to be via
hydrogen bonding to the backbone of the peptide and the requirement for a
specific primary amino acid side chain sequence is under little constraint except
for the presence of certain amino terminal "anchor" residues whose presence
affects a peptide's ability to sit in the MHC molecule binding groove with the C
terminal residues displaying heterogeneity (Rudensky, et al., 1991). Brown, et
al., 1993 hypothesised that fragments bind within the Class II groove with the
amino terminus fixed, whilst the carboxyl terminus end of the peptide remains
open to further trimming by exopeptidases. Amino and carboxy terminal
trimming of bound peptides has been shown by other workers (Vignali, et al.,
1993; Nelson, et al., 1992), suggesting that both ends of the Class II-bound
peptide are open to peptidase action.
The CD4+ T-cell responses
Contacts between C04+ T cells and antigen presenting cells and B cells
are promoted via LFA-1 and C02 (Figdor, et al., 1990) - as is the case for CDS+
T cell-mediated responses. Interaction between the TCR and MHC class II
antigen is optimised by association of C04.
Recognition of a specific MHC class II antigen complex by the Th
lymphocyte TCR results in signal transduction through the TCR-C03 complex
leading to T cell activation as well as activation of the APC. Activation of
macrophages results in production of IL-1. Interleukin-1 stimulation of Thresults
in their ability to respond to IL-2 stimulation such that they themselves express
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IL-2 and its receptor. The secretion of IL-2 by activated T-cells is wide-reaching
and will promote the proliferation of any T-cell which has receptors for IL-2.
Hence, activation of Thvia their interaction with class II MHC presenting
specific peptide antigen results in the stimulation and recruitment of many
T-cells such that the antigen can be eliminated.
The above accounts of T cell activation are simplified (Raitt, 1994), yet
they illustrate the necessity of the recognition of antigens in the context of the
MHC in order that a complete immune response may be mounted. The
following sections describe the tissue distribution and regulation of expression
of MHC antigens and the regulation of their expression both at the cellular and
genetic level.
Chapter 1 16
1.2. Tissue distribution of MHCmolecules
1.2.1. Constitutive expression of MHC antigens
Constitutive expression is defined here as the surface expression of
antigens by cells which is observed in the absence of cytokines, or other
induction brought about by viral infection or any other external stimuli. Such
knowledge was gained by the staining of tissue sections with monoclonal
antibodies against framework determinants of class I or II MHC antigens. Due
to the inducibility of MHC antigens, the possibility of false positives due to local
inflammation in tissues should not be ignored.
In humans the class I MHC antigens, HLA-A, -B, -C, are expressed by a
wide range of cell types including nearly all types of haematopoietic cells
(except erythrocytes), fibroblasts, endothelial cells, keratinocytes, peripheral
neurones and most epithelial cells. Few tissues contain cells which do not
express class I, these include the central nervous system neurones,
hepatocytes and some glandular epithelial cells.
Antigens encoded by the HLA-D loci are expressed by a restricted group
of tissues. Constitutive expression of class II MHC molecules is only observed
by B cells and dendritic cells.
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1.2.2. "Induced" expression of MHC antigens
Although normal tissues have a restricted expression of MHC antigens,
especially in the case of class II, their expression can be augmented or
upregulated in various situations.
1.2.2.1. Infection
The most common of these is infection where MHC antigens are
produced inresponse to foreign antigens. Here, local production of cytokines,
in particular interferons (IFNs) -ap and ~, results in augmentation of class I
(IFN-ap and IFN~) and class II MHC (IFN-y, alone). The induction of class II
MHC antigens by IFN-y occurs in the cells of many tissues, for example,
activated T-cells, macrophages, granulocytes, endothelial cells, keratinocytes,
fibroblasts, glandular epithelial cells and glial cells. In the case of infection, the
expression of MHC antigens by cells is critical in the removal of the pathogen as
discussed in section 1.1. above. Here, class I expression by virally infected
cells results in their removal by cytotoxic T cell action. The interaction of
soluble antigen with specific membrane-bound immunoglobulin of 8 cells results
in its internalisation and processing into the class" MHC-associated surface
antigen resulting in the CD4+Th response.
1.2.2.2. Autoimmunity
Certain autoimmune conditions have been associated with the
inappropriate expression of MHC antigens (Feldmann, 1989). Here it is
assumed that MHC molecules become associated with "self antigens and their
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expression at the cell surface invokes the local immune response against the
cell. HLA expression or overexpression has been implicated in ulcerative colitis
(McDonald and Jewell, 1987), autoimmune thyroiditis (Piccinini, et al., 1987),
and multiple sclerosis (Traugott, 1987). In all of these cases, class II (and class
I in multiple sclerosis glial cells) are expressed where the cells involved are
usually negative. This expression of MHC antigens is also associated with
heavy infiltration of the affected tissues by inflammatory cells (reviewed in
Morris, et al., 1994).
1.2.2.3. Malignant disease
In malignant disease class I antigens may be lost by tumour cells such
that non-expressing cells within a tumour will be "selected" for due to their
evasion of detection by cytotoxic T cells. Tumour cells may also gain class II
expression. This is usually restricted to a few cells within the tumour in usually
less than half of the incidences of a particular cancer.
In the case of colorectal carcinoma, studies have shown the induction of
HLA-DR in greater than half of the tumours investigated (MOiler, et al., 1991).
whereas HLA-A, -B, -C expression was absent in 9% and reduced in 35% of
tumours. This observation, supported by other studies, is indicative of the
expression of MHC antigens being affected by the neoplastic state and/or the
infiltration of tumours by lymphocytes; the colon epithelium is usually negative
for class II MHC, yet is constitutive for class I expression. Donnellan, et al.,
(1995) showed that the ability of colorectal tumour cells to express HLA-DR is
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abolished despite the infiltration of the tumour by activated T cells.
The implications of MHC antigen expression by tumour cells for
prognosis are unclear and conflicting evidence exists as to whether MHC
expression leads to a favourable outcome. For example, in melanoma HLA-OR
expression by primary tumours was associated with poorer prospects of
disease-free survival than those primaries which were negative for HLA-OR
(Zaloudik, et al., 1988). In contrast, loss of MHC class II antigens by B cell
lymphomas correlates with significantly shorter survival (Spier, et al., 1988). In
the case of colorectal carcinoma, expression of MHC antigens appears to be of
little consequence in the prognosis of patient outcome.
1.3. Regulation of MHC class II antigen surface expression
The above section described how the surface expression of MHC
antigens is modulated in certain conditions of infection or disease. Of interest is
the regulated expression of class II MHC antigens since they are only observed
in a limited selection of tissues prior to their "induction" and their augmented
expression can have the implications mentioned in section 1.2.2. Expression
of class II MHC antigens is also modulated on haematopoietic cells as well as
those from non-haematopoietic origin, this modulation is discussed in the
following sections.
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1.3.1. Cytokine mediated class II MHC expression
Cytokines can be considered as polypeptide "hormones" which have a
short-range action in, generally, mediating immune responses. They are
produced largely by cells of the immune system such as activated T
lymphocytes and macrophages (Morris, 1995). Due to the augmented
expression of MHC antigens at the sites of inflammation, and the presence of
activated T cells and macrophages therein, much research into regulation of
MHC expression has concentrated on cytokines although these are by no
means the only physiological factors which have a role in this regulation.
The most potent inducer of class II MHC antigen expression is
interferon-y (IFN-y) which can affect many cell types of haematopoietic and
non-haematopoietic origin (reviewed in Morris, et al., 1994 and Cogswell,
et al.,1991). Class I MHC antigens can be induced on many cell types by
IFN-a.J3as well as IFN-y.
Other cytokines having a positive effect on MHC class II expression are:
interleukin-4 (ll-4) in B cells; granulocyte-monocyte colony stimulating factor
(GM-CSF) in monocytes; tumour necrosis factor-a. (TNF-a.) can synergise with
IFN-y to increase induced class II in a variety of cell types.
A number of cytokines have been identified which have a negative effect
on the expression of class II MHC. Although IFN-a.J3induces class I expression,
it is a potent inhibitor of class II expression (Morris and Tomkins, 1989).
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Transforming growth factor-B (TGF-P) is an inhibitory factor produced by
many cell types which displays immunosuppressive (Wrann, et al., 1987) as
well as growth-inhibitory effects on many untransformed cell types (Morris,
(1995)). This "cytckine" has been shown to inhibit the IFN-y-induced surface
expression of HLA-D in many human tumour cell lines (Darley, et al., 1993).
TGF-p has been shown to be produced by many cell types including activated T
lymphocytes (Morris, (1995)) and certain tumour cells (Barrett-Lee, 1990;
Coffey, et al., 1987) and its expression has been demonstrated to be altered
by activated ras oncogene (Glick, et al., 1991). The implications for such a
potent immunosuppressor and growth inhibitor to be produced within tumours
are vast in that any immune surveillance by tumour infiltrating lymphocytes
might not be possible due to the TGF-p-inhibited expression of HLA-O by the
tumour cells. This digression illustrates the interaction between tissues, and
the cytokines ("growth" factors) which they produce, in the regulation of MHC
class II expression.
1.3.2. The effects of non-cytokine factors on class II MHC expression
The effects of other physiological molecules upon the IFN-y-induced
expression of class II MHC antigens has been studied. Hormones of the
endocrine system; noradrenaline (Loughlin, et al., 1993), thymosin (Baxevanis,
et al., 1992), and thyroid stimulating hormone (Todd, et al., 1987), have all been
shown to augment IFN-y-induced expression. Conversely, corticosteroids
suppress macrophage expression, and induced MHC expression has been
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shown to be inhibited by growth factors (Todd, et al., 1990), prostaglandins
(Snyder, et al., 1982; Ivashkiv and Glimcher, 1991) and lipopolysaccharide
(Koerner, et al., 1987).
From the evidence cited above, it is clear that modulated expression of
class II MHC antigens in human tissues is a complicated situation orchestrated
by many participants which interact synergistically or in an inhibitory fashion
with the major inducer IFN-y. Not mentioned, but implicated, is the altered
expression of HLA by cells in the neoplastic state. The presence of the
activated ras oncogene has been associated with up-regulation of class II MHC
in melanocytes (Albino, et al., 1986) class " negative variants of
B-Iymphoblastoid lines (Kara and Glimcher, 1991; Hume, et el., 1987) and
murine primary fibroblasts (Darley and Morris, 1993). Activated ras is present in
many tumours ranging from 90% of adenocarcinomas of the pancreas to 30% of
lung tumours and myeloid leukaemias (Forrester, et al., 1987; Base, et al.,
1987; Bos, 1989;). Transfection of the c-Ha-ras oncogene into a poorly
differentiated colorectal carcinoma cell line rendered it resistant to natural killer
(NK) cell lysis (Bagli, et al., 1990). The influence of MHC antigen expression by
colorectal tumours on survival was reported by Moller, et al., (1991) where it
was concluded that loss of expression of these molecules bared little relevance
to patient survival. Therefore, the regulation of class II MHC antigen expression
by non-haematopoietic cell types is of interest due to the implications for
diseases apart from their rOle in the presentation of foreign antigens to T-
lymphocytes in the eradication of a pathogen.
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1.4. Mechanisms for the cellular action of interferons (IFNs)
The following sections will go on to discuss the mechanisms by which
the expression of the human class II MHC gene HLA-DRa is regulated at the
genetic level. Of interest is the IFN-y-induced expression, and to appreciate the
complicated nature of this gene's activation by IFN-y, it is necessary to describe
the current knowledge of the IFN-y-induced transcription of genes.
1.4.1. Signal transduction through the interferon receptors
A direct signal transduction mechanism pathway leading from the
receptors for IFN-a and IFN-y has been recently elucidated (Darnell, et al.,
1994). Binding of IFN-y or IFN-a to its respective receptor results in the
phosphorylation of a population of proteins at the cytoplasmic face of the
transmembrane receptor.
IFN-a stimulation results in the activation of Jak 1 (Janus kinase) and
Tyk 2 by tyrosine phosphorylation (MOiler, et al., 1993). These activated
proteins then mediate tyrosine phosphorylation of 113kD, 91kD and 84kD
proteins (named p113, p91 and p84 respectively) of the a-subunit of interferon
stimulated gene factor-3 (ISGF-3; Fu, et al., 1990). The phosphorylated
moieties p113 and p91 (or p84) dimerise and combine with the y-subunit,
termed p48, and the trimeric protein translocates across the nuclear membrane
where it can activated gene transcription through interferon response elements
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in the promoters of responsive genes (Muller, et al.,1993; Darnell, et al., 1994).
The stimulation of cells with IFN-y involves similar proteins from the same
"family". Interferon-a and -y stimulation of the guanylate binding protein gene
was investigated by Decker, et al., (1989). Subsequently IFN-y-mediated
activation of a cytoplasmic DNA-binding factor (termed GAF for "gamma
activated factor") was implicated as a primary step in the stimulated expression
of this gene (Decker, et al., 1991). The binding of IFN-y to its receptor results in
the phosphorylation of p91, or its truncated splice-variant p84, which is
mediated by activated Jak 1 and Jak 2 tyrosine kinases. Phosphorylation
results in dimerisation and translocation into the cell's nucleus where it binds to
y-activated sequences (GASs) in the promoters of responsive genes (Darnell, et
aI, (1994».
The mechanism by which Jak-family tyrosine kinase-mediated signal
transduction results in the transcriptional response within the nucleus has led
the mediators, e.g. ISGF-3 and GAF, to be termed generically as ·STATs· for
signal transducers and activators of transcription. A schematic diagram
representing the interplay between receptor binding, phosphorylation and gene
activation is given in figure 1.4.
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Figure 1.4. Representation of the Jak-5TAT signal transduction pathway
for the interferons
cytoplasm nucleus
Jak 1
r--~- _ ....~ ____.
Jak2
~~~ r
GAS
~;3r
GAS
Notes:
The binding of IFN-a. and IFN-y to their respective cell surface receptors activates the
protein tyrosine kinases Jak 1, Tyk 2 (for IFN-a.) and Jak 1 and Jak 2 (for IFN-y) by
phosphorylation. Tyrosine phosphorylation (indicated by "P") of STAT proteins p91
(p84), and pl13 leads to their respective interactions with each other, and p48 (for
IFN-a.) prior to their translocation into the nucleus to activate transcription of the
appropriate genes.
ISRE=interferon stimulated response element; GAS=gamma activated sequence
Diagram reproduced from Darnell, et al., (1994)
From the work by researchers such as Darnell, many questions have
been answered with regard to the mode of action of the interferons. A number
of members of the STAT family of proteins have been elucidated and other
peptide ligands also use this mechanism to exact the appropriate cellular
response.
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1.4.2. Jak-STAT signal transduction pathways and interferon-induced
expression of class I MHC and ICAM-1
Do the mechanisms of interferon action described above translate to the
transcription of MHC genes? Section 1.6. will discuss the genetic regulation of
the class II MHC gene HLA-DRa with attention being paid to the IFN-y-induced
transcription of this gene. This section will describe the involvement of
Jak-STAT signalling mechanisms in the induction of MHC class I genes and the
gene encoding the intercellular adhesion molecule-1 (ICAM-1) whose major rOle
is the initial interaction between T-lymphocytes, bearing LFA-1 (leukocyte
function associated antigen-1) and their targets (Dustin, et al., 1986).
Class I MHC
The genetic structure of class I MHC promoters is well defined and a
number of protein transcription factors which bind to discrete sequence
elements have also been elucidated. Class I gene expression can be induced
by either IFN-af3 or IFN-y and the promoter contains a consensus interferon
response element which has been shown to bind IRF (interferon regulatory
factor). This factor is defined as one of the p48 family of transcription factors in
Darnell, et al., (1994). IFN-y also has a rOle to play in the activation of class I
MHC genes, yet there is no consensus element for the binding of p91 or any
other defined IFN-y-induced factor to this promoter. It is possible that IFN-y
treatment of cells results in the activation of the gene encoding a secondary
transcription factor(s) which then mediate transcription of class I, such a
possibility is borne-out by the requirement for de novo transcription. Figure 1.5
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is a schematic representation of class I MHC promoters indicating some of the
transcription factors which are known to be involved in transcriptional
regulation.
Figure 1.5. Schematic representation of class I MHC promoters
enhA enh B
RII RI NRE IRE ._ _.
-200 CAATCAAT TATAA cap,
1
t t
NF-1d3 IRF
KBF1
H-2RIIBP
CREB CREB
AP-1 AP-1
Notes:
Important regions of nuclear factor binding sites are indicated by blocks. Enh A B are
enhancers A and B. RI and II and regions I and II of enhancer A:, NRE is a negative
regulatory element; IRE is the interferon response element. The transcription factors and
their approximate regions of association are indicated beneath the promoter structure.
Redrawn from Morris, et al., (1994)
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ICAM-1
The intercellular adhesion molecule-1 (ICAM-1), like class II MHC
antigens, is expressed on limited number of cell types but its expression can be
induced by a number of inflammatory cytokines including IFN-y, TNF-a and IL-6.
The regulation of gene expression with respect to cytokine-induced expression
has been fruitful in determining the mechanisms by which induced expression is
brought about at the genetic level.
The promoter for the human ICAM-1 was cloned and sequenced as
reported by Stade, et al., (1990). The region of DNA cloned spanned the
nucleotides from -477 to +700, relative to the proposed cap site, and putative
consensus sequences for the binding of transcription factors were identified.
The proposed sequences for the binding of transcription factors included those
for SP-1, AP-1, NF-lCB as well as interferon and retinoic acid response
elements, these sites being dispersed through the 5' untranscribed promoter
region and with proposed NF-lCB,SP-1 and retinoic acid receptor binding sites
occurring within the first intron.
Since this initial report, much research has concentrated upon
determining the functional promoter elements involved in this gene's regulation.
An IFN-y-responsive region was identified which also serves as an IL-6
response element. This palindromic sequence, termed pIRE, shows close
homology to the defined y-activated sequence (GAS) of the human guanylate
binding protein gene. It has been determined that the 91kD component of
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ISGF3 is induced by both IFN-y and IL-6 in the induction of ICAM-1 expression
(Caldenhoven, et al., 1994; Look, et al., 1994). A schematic diagram of the
ICAM-1 regulatory sequence is shown in figure 1.6.
Figure 1.6. Schematic representation of the ICAM-1 promoter region
-1000
I •
+NF-ICB
•t
NF-ICB
Notes:
The potential cis-acting elements of the ICAM-I promoter, indicated by solid blocks, are:
TATA boxes, TPA-responsive element, AP-2, NF-lCB, and pIRE site. The start of
transcription is indicated by the arrow.
1.4.3. Summary
The interferon-induced gene expression of MHC class I antigens and
ICAM-1 involves the binding of STATs to defined regulatory elements of
promoters. These factors are members of a growing family which transduce the
IFN signal from its receptor at the plasma membrane to the nucleus to control
gene expression. Activation of STATs requires their phosphorylation by Jak
tyrosine kinases, themselves activated by phosphorylation upon binding of
ligand to its receptor. The following sections will describe how there is no clear
involvement of Jak-STAT signalling pathways in the IFN-y-induced expression
of class" MHC genes, specifically that encoding HLA-DRa.
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1.5. Regulation of gene expression at the transcriptional level
Before describing the current knowledge of the transcriptional regulation
of HLA-DRa. gene expression, this section will describe the types of
transcription factors known to associate with regulatory sequences of eukaryotic
promoters and how this binding occurs.
1.5.1. Transcription factor interactions with DNA
Major motifs which are essential for the binding of transcription factors
with cis-acting response elements have been identified after nuclear factors
have been purified, cloned and sequenced. Other sequence motifs of
transcription factors have been identified which are responsible for their
association with other transcription factors and "transactivation". The following
sections summarise some important elements of protein-DNA and
protein-protein interactions which influence the events at the start of
transcription.
DNA binding motifs
i) Helix-loop-helix
This motif was first identified in bacterial DNA regulatory proteins such as
era and were characterised by X-ray crystallography. Studies into the binding
of eukaryotic transcription factors have identified this motif in a number of
transcription factors. In eukaryotes, this binding motif was first identified in
Drosophila homeotic genes which specify master regulatory proteins controlling
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the expression of body plan genes. As a result, the DNA and amino acid
sequence of a transcription factor which contains a helix-loop-helix motif is
called the homeobox. This region contains many basic amino acids which
enables interaction with the DNA phosphate moiety. It appears that one of the
a.-helices recognises the nucleotide sequence of the DNA while the other
interacts with the phosphate-sugar backbone (see Struhl, 1989; Dressler, 1989;
Marx, 1988). The helix-loop-helix DNA binding motif has been identified in a
number of mammalian transcription factors including members of the POU (Pit
1, Oct 1/2, Unc 80) family (for review see Faisst and Meyer, 1992).
ii) Zinc finger proteins
This type of DNA binding motif was discovered in TFIIIA of Xenopus
whose activity is dependent on and which contains zinc (Struhl, 1989; Evans
and Hollenberg, 1988). In this type of DNA binding motif zinc-stabilised loops
are formed by the coordination of the metallic ligand between cysteine and
histidine residues within the amino acid sequence of the polypeptide. This type
of transcription factor has a variable number of zinc fingers which interact with
DNA in a manner such that they interdigitate with the sequence element, with
adjacent fingers making contact with opposite sides of the DNA helix. Many
zinc finger proteins have been identified, not all of which are involved in DNA
binding, including SP1, steroid, thyroid and retinoid receptors in mammals and
the adenovirus-encoded E1A protein.
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iii) Leucine zippers
Certain transcription factors contain a domain which is required for their
interaction with other, similar, proteins. This domain has been described as a
leucine zipper which consists of a 35aa a-helix with every seventh residue
being a leucine (Struhl, 1989; Landschultz, et al., 1988). This can interact
with a similar helix form a another protein molecule to "zip" together and form
a dimer. The DNA-binding domain is adjacent to the a-helix and can only
associate with the sequence element upon dimerisation. Dimers can be hetero-
or homodimeric, for example the fos~un heterodimer or the junljun homodimer
forming the transcription factor AP1.
1.5.2. Activation of transcription
Thus the sequence-specific interactions of transcription factors with
response elements can be mediated by an array of DNA-binding motifs
conferred upon the complex structures of proteins. However, the binding of
transcription factors alone does not result in transcriptional effects, transcription
factors must also interact with each other through their "transactivation"
domains to exert their effects. Transactivating domains can be amphipathic
helices which were first characterised for the yeast factors GCN4 and GAL4 (La
lhange and Rigby 1988), whereas glutamine-rich regions have been described
for SP1, Oct1/2 and Pit 1 and proline-rich regions are known for AP1 and the
CTF family of transcription factors. It is thought that transcriptional activation is
mediated by the protein-protein or protein-RNA polymerase interactions through
their transactivation domains.
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The mechanism of the action of the transcription factor ATF has been
described (Horikoshi, et al., 1988; and Hai, 1988) and it was shown that ATF
association with its consensus element allows weakly bound TFIID to associate
strongly at the TATA box and the transcriptional start site. Once the increased
TFIID association occurs, the binding of RNA polymerase and other TFlls is
facilitated and transcription can occur from this stable complex.
1.6. Regulation of HLA-DRa gene expression at the molecular genetic level
1.6.1. HLA-DRa expression is under transcriptional control
The regulation of HLA-DRa.expression is controlled at the transcriptional
level (Cogswell, et al., 1991; Sullivan, et al., 1987; and Benoist and Mathis,
1990). The induction of HLA-DRa. expression by IFN-y results in the
accumulation of cytoplasmic mRNA transcripts after 4 to 8hr which reaches its
maximal level after 24hr (Collins, et al., 1984; and Rosa, et al., 1983). The cell
surface expression of HLA-DR reaches maximal levels by 48hr (Rosa, et al.,
1983).
Transcription (the synthesis of an mRNA molecule complementary to the
sequence of DNA) of eukaryotic genes is mediated by the binding of specific
DNA-binding proteins, called transcription factors, to sequences of DNA in the
region of genes upstream of the transcriptional start site - the promoter. The
transcription of most genes is mediated through the TATA box, necessary for
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the accurate positioning of the initiation site transcription, and transcriptional
initiation occurs after the association of TFslIA, 0, E and 8 and RNA
polymerase II, (la Thangue and Rigby, 1988). As described in section 1.5.,
the control of transcription is mediated by the binding of promoter-specific
transcription factors to cis-acting sequence elements upstream of the TATA box.
These transcription factors act in concert to affect the events at the TATA box.
Transcription factors may also be repressor proteins which function to regulate
transcription in a negative manner.
1.6.2. Structure of the HLA-DRa promoter
Early studies into the transcriptional regulation of HLA-DRa (and other
human and rodent class II MHC) gene expression relied on sequence data of
the region of DNA 5' to the structural gene. The available sequences for all
class II genes were compared to determine whether there were homologies
between them. It was found that the class II genes contained conserved DNA
sequence elements in their promoter regions and some of which show
homology to cis-acting sequences of other genes, including a TATA box
(TAnA) (Sullivan et al., 1987). The original "class II box" was defined by two
highly conserved 13 base pair elements, termed X and YI which are separated
by 19-20bp of DNA (Okada, et al., 1985). In HLA-DRa, the X box
(CCTAGCAACAGATG) is found between nucleotide positions -108 and -95 and
the Y (CTGATTGGCCAAAG) box occurs between nucleotides -74 and -61.
The Y box contains an inverted CCAAT box (ATTGG), a transcriptional activator
to which ubiquitous nuclear factors generally bind. Peculiar to the HLA-DRa
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promoter is an octamer motif (ATTTGCAT) at position -52 to -45. A third class II
sequence element was defined upstream of the X box, originally termed the Z
box (H or S in murine genes), the W box (TCCTGGACCCCTTTGCAAGA) is
comprised of 18 nucleotides from position -135 to -117 in the promoter of
HLA-DRa.. This element contains two so-called Servenius sequences of which
SRV1 shows an inverted homology to the X box (Cogswell, et al., 1991a). The
V box (GTTGTCCTGTTT) covers the nucleotides form -193 to -179. Figure
1.7. represents the structure of the HLA-DRa.promoter.
The promoter of the class II invariant chain has also been shown to
contain sequence elements homologous to those found in class II MHC
promoters (Brown, et al.,1991). This appears to be a consequence of the
requirement for its coordinate regulation along with class II a. and fl chain
genes.
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Figure 1.7. The structure of the HLA-DRa promoter
v w x y o T
Notes:
The proposed regulatory elements of the lll.,A-DRa promoter defined by sequence
homology with other class II MIlC genes. V, W, X and Y are all MIlC class II-specific
sequence elements. "0" represents an octamer motif and T is the TATA element. The
nucleotide ranges of each element is given respective to the cap site (start of
transcription, designated as +1).
1.6.3. Functions of cis-acting sequences
By deletional and sequence mutagenesis of the HLA-DRa promoter and
its employment in reporter gene assays, the functions of the cis-acting
elements, V, W, X and Y, were assessed in cell lines. Such assays rely on the
expression of a gene (introduced into the cell by transfection in plasmid form)
which is usually absent from the cells studied. In many cases the bacterial
gene for chloramphenicol acetyl transferase (CAT) is employed and its
expression is driven by the heterologous promoter being studied. Reporter
gene assays, therefore, allow the manipulation of a promoter such that the
functions of individual regions can be assessed in the activation of gene
expression. The following sections will describe the individual functions of the
defined cis-acting elements and then will discuss how they work in concert to
bring about tissue-specific and IFN-y-induced expression of HLA-DRa.
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i) The V box.
The V box was delineated as a weak negative regulatory element by
Cogswell, et al., (1990). This sequence displays homology with both the Wand
X boxes, the X box homology being inverted. In experiments where nuclear
factors are allowed to associate with a radiolabelled probe corresponding to a
particular DNA sequence, called bandshift, gel retardation or electromobility
shift assays, the V box has been shown to form two protein-DNA complexes.
The proteins which bind to the V box have not been identified.
ii) The Wbox
The W box has been shown to be essential for tissue-specific and
IFN-y-induced transcription of HLA-DRa (Tsang, et al., 1988; Cogswell, 1991b).
Its involvement in the IFN-y-induced expression was shown to be critical by
Basta, et al., (1988): when the region of ORa from -141 to -109 (which contains
the W box) was mutated, IFN-y-inducibility of reporter gene expression was
abolished.
In bandshift experiments the W box had been shown to bind two nuclear
factor, termed W-B1 and W-B2 (called NF-Zc and NF-Z2 by a different group)
(Tsang, et al., 1990; and Cogswell, et st. 1990a and 1990b). These factors
were also shown to be competed out by an X box oligonucleotide - a
consequence of their binding to the X box homology within the W box.
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iii) The XlX2 box
This element is also essential for tissue-specific and IFN-y-induced
HLA-DRa expression (Tsang, et al., 1990; Sherman, et el., 1987; and Sherman,
et al., 1989).
The X box can be dissected into two elements, termed X and X2, the
latter being defined after it was shown to bind a leucine zipper type of
transcriptional activator, termed human X box binding protein 1 (hXBP1) (Liou,
et al., 1990) later shown to form a heterodimer with c-fos (Ono, et al., 1991a &
b). The X2 box has homology with the AP-1 binding site and, not surprisingly,
was shown to bind the jun-fos heterodimer (Peterlin and Andersson, 1990).
The X box has been shown to bind a factor termed regulatory factor-X
(RF-X) which has been shown to be absent in the condition bare lymphocyte
syndrome (Reith, et al., 1988). However, this factor's involvement in this
disease in now in dispute (reviewed in Ting and Baldwin, 1993). An IFN-y
"enhanced" factor from murine primary astrocytes has been shown to associate
with the HLA-DRa X box (Moses, et aI, 1992), this factor has been termed
IFNEX for "IFN enhanced X" box factor.
ivY The Y box
This sequence element has also been described as being critical for
tissue-specific and IFN-y-induced HLA-DRa gene expression (Tsang, et al.,
(1990); Sherman et el., (1989». Its spacing from the X box is conserved at 18
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to 20 nucleotides, but the spacer's sequence is variable (Kelly and Trowsdale,
1985). The critical spacing was shown to enable the alignment of X and Y box
binding factors to affect transcription (Vilen, et al., 1991).
The Y element contains an inverted CCAAT box which interacts with
several DNA binding proteins, the first of these whose gene was isolated was
termed YB-1 (Didier, et al.,1988). This factor binds to the CCAAT element of
HLA-DRa.and is thought to be a negative factor since levels of its mRNA are
inversely correlated with class II expression in several cell lines (Didier, et al.,
1988).
The ORa.Y element binding protein (YEBP), also called NF-Y, has been
established as a CCAAT-element-binding protein by methylation interference
analysis (Sherman, et al., 1989). The relationship between NF-Y association
with the Y box and the upstream X1X2 element was demonstrated by Wright,
et al., (1994). By in vivo genomic footprinting, it was shown that mutation of the
CCAAT box abolished binding at the X1X2 element, whereas mutation of the
X1X2 box had no effect on CCAAT box binding. Thus binding of NF-Y at the
CCAAT box stabilises association of factors at the X box and as such is an
initial event in the association of transcription factors with the HLA-DRa.
promoter.
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v) The oetamer element
The octamer element is essential for HLA-ORa promoter function in OR+
Band T cell lines, but not in other OR+ cell lines (Tsang, et al., (1989);
Sherman, et al., 1989; and Wright and Ting, 1992). This element binds the
transcription factors OTF-1 and OTF-2.
vi) The TATA box
Although the TATA box does not have a rOle in the promoters of the
murine class II MHC promoters Ea and Aa, its function in the transcription of
HLA-ORa is now unequivocal (Matsushima, et al., 1992). Therefore, in ORa,
the TATA box serves its traditional rOle in fixing the transcriptional start site.
The transcription factors which have been shown to associate with the
cis-acting elements of the HLA-ORa promoter are portrayed graphically in
figure 1.8.
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Figure 1.8. Interaction of transcription factors with the HLA-DRa promoter
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Notes:
The binding of nuclear factors to the cis-acting elements of the lll.A-DRa promoter has
been assessed by band shift and footprinting techniques. Transcription factors shown to
associate with the promoter are given different shapes. A dotted line down the centre of
a protein suggests that the protein is composed of more than one subunit. Section 1.6.3.
discusses the individual functions of the cis-acting elements and their corresponding
trans-acting factors.
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1.6.4. IFN-y-induction of transcription
Due to the nature of the expression of class II MHC antigens and their
inducibility in a variety of non-haematopoietic tissues, the induction by IFN-y
has been extensively investigated. Unlike the promoters of class I MHC genes,
which possess a discrete, defined interferon response element, IFN-y-induction
of class II MHC requires the cooperative action of all three sequence elements
W, X and Y (Tsang, et aI, 1990; Dedrick and Jones, 1990; Tsang, et aI, 1988;
Yang, et aI, 1990; Moses, et al., 1992; and Sloan, et al., 1992). As well as the
requirement for the presence of the three sequence elements, their
stereospecific alignment within the promoter is also critical (Vilen, et al., 1991;
and Vilen, et al., 1992). The IFN-y signal was shown to involve protein kinase C
in a promonocytic cell line (Gumina, et al., 1990) in addition to Na2+ entry
(Benveniste, et al., 1991). The IFN-y-induced expression of HLA-DRa and the
other class II MHC genes has been shown to be transcriptional and dependent
on de novo protein synthesis by its inhibition in the presence of cycloheximide
(Amaldi, et al., 1989; Kerr, et al., 1990).
The IFN-y-induction of HLA-DRa gene expression, therefore, represents
a unique model of gene induction which involves a trimeric regulatory DNA
mOiety whose function is dependent on structural constraints. These
constraints most likely reflect protein-protein interactions or unique DNA
structures.
In human systems, the pursuit of an IFN-y-induced factor which binds to
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W, X or Y has been fruitless despite much research in many transformed cell
lines. Conversely, when nuclear proteins from rat primary astrocytes were
studied, a factor which was observed only in small amounts prior to
IFN-y-stimulation was very much enhanced post-stimulation (Moses, et al.,
1992). This factor, called IFNEX, was shown to associate consistently with the
X box region, but was shown not to be serologically related to RF-X.
Recent hypotheses for the IFN-y-induction of HLA-DRa transcription
have focussed on the alteration of factors which are already bound to the
promoter - IFN-y stimulation leads to enhanced interaction of factors at the X
and Y boxes. Uninducible cell lines are considered to have "open" XlX2 and Y
sites (Ting, 1993). The enhanced interaction of factors with the promoter is
considered to be due to their modification or the increased accessibility of the
promoter itself. The possibility of a promoter organising factor has been studied
intensively with respect to combined immune deficiency (CID) by Glimcher et
al., who have employed in vivo footprinting techniques to determine the
deficiency in this disease. The possibility for a class II promoter organising
factor, which affects promoter accessibility with regards to transcription factors,
is addressed in Kara and Glimcher, (1993).
A breakthrough in research into the IFN-y-induced transcription of
HLA-DRa came with the discovery of CIITA (class II transcriptional activator)
(Steimle, et al., 1994). This factor was shown here to be defective in one type
of bare lymphocyte syndrome and as such is assumed to be essential for
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constitutive MHC class II expression also. The gene for CIITA is induced by
IFN-y in a similar manner to that for the guanylate binding protein gene (GBP)
which contains the first described y-activated sequence. Induction of CIITA is
thought be caused by the binding of active p91 to its promoter. This novel gene
product appears, therefore, to be the much sought-after link between IFN-y
binding at the cell surface and the activation of class II MHC gene
expression. There is no evidence for the direct association of CIITA with the
MHC class II promoter and it is proposed that it may act as a coactivator which
affects the transcriptional activity of proteins already bound to the promoter
without binding itself. Figure 1.9. demonstrates the proposed mechanism for
the action of IFN-y in the induction of class II MHC gene expression.
Figure 1.9. Action of IFN-y in the induction of class II MHC gene expression
Jak 1 ~91 ffi1 ~j:=t.= --...~ _..,.. -+-- ....
Jak2 p91 ~ ~A I
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The induction of class II MHe genes by IFN-y involves the intermediate gene
product eIITA (class II transactivator) which is synthesised de novo following
IFN-y-stimulation of the cell. p91 is the 91kD subunit of ISGF3 which becomes
phosphorylated by Jak1 and Jakz tyrosine kinases associated with the IFN-y receptor.
eIIT A is believed to activate transcription of class II MHe genes without interacting with
the promoter DNA itself (Steimle, et al., (1994)).
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1.S.S. Inhibition of the IFN-y-induced expression of class II MHC by IFN-a~
and TGF-~
The IFN-y-induced surface expression of class II MHC antigens has been
reported to be affected by a cell's cotreatment with IFN-y and IFN-ap or IFN-y
and TGF-p (Morris and Tomkins, 1989; Darley, et al., 1993). There has been
little research in to the negative regulation of HLA-DRa. transcription by these
cytokines.
Devajyothi, et al., (1993) and Reimold, et al., (1993), simultaneously
reported that 176bp of upstream sequence of the HLA-DRa. promoter were
required for TGF-p and IFN-ap-mediated suppression of IFN-y-induced reporter
gene expression. It was also shown that IFN-y-induced reporter gene
expression from the ICAM-1 promoter was not affected by TGF-p or IFN-aP
treatment of an astrocyte cell line (Devajyothi, et et., (1993», indicating that the
signalling pathway from the IFN-y receptor to the nucleus was unaffected. No
change in the proteins binding to the HLA-DRa.promoter or in in vivo occupancy
of the promoter was reported after TGF-p treatment of a melanoma cell line
(Reimold, et et., (1993».
The influence of TGF-p on signal transduction mechanisms involved in
IFN-y-induced MHC class II gene expression was investigated in primary
astrocytes (Panek, et al., 1995). It was demonstrated that TGF-p inhibited
IFN-y-induced MHC class II surface protein, mRNA and promoter activity
without affecting JAK1/2 and STAT 1a.phosphorylation or IFNEX "induction". It
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was postulated that, in astrocytes, TGF-f3 exerts its effects by modulation of the
expression or function of constitutively expressed factors responsible for class II
MHC gene expression.
The modulation of IFN-y-induced class II gene expression by IFN-a.f3 has
not been investigated as extensively and the involvement of both IFN-a.f3 and
TGF-f3 in IFN-y-induced class II gene expression in other cell systems has
generally been reported at the level of the cell surface. The stage is therefore
set for further research into the mechanisms of cytokine-mediated suppression
of HLA-DRa induction.
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1.7. Investigation objectives
As discussed in section 1.2.2. the induced expression of HLA-DRa. by
non-haematopoietic tissues may be of relevance not only in infection and
inflammation, but also in conditions such as neoplastic disease and
autoimmunity. The primary aim of this study was to examine a panel of human
tumour cell lines which were either inducible or non-inducible for HLA-DR
surface expression by IFN-y. The study investigated the population of nuclear
factors within these cell lines to determine whether HLA-DRa.promoter-binding
proteins were different from cell line to cell line. Also investigated was the
stimulation of cells with IFN-y to determine whether treatment had any effect on
the populations of DNA binding proteins which were capable of binding to
HLA-DRa.promoter and to the individual regulatory elements.
A second aim was to study the effects of IFN-aJ3and TGF-J3upon the
IFN-y-induced expression of a reporter gene driven by HLA-DRa. promoter
sequences. The HLA-DRa. promoter contains a consensus IFN-aJ3response
element from nucleotides -593 to -565 relative to the start of transcription, its
involvement in any IFN-aJ3-mediatedsuppression of induced expression was
also to be investigated here.
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CHAPTER 2: MATERIALS AND METHODS
2.1. Cell lines
The cell lines employed in this investigation were chosen to represent a
range of MHe class " inducibility after interferon-y treatment. The most
common cell type was that which represented human colorectal epithelium, to
furnish this requirement the cell lines chosen were: colo 201 (ATee eel 224;
Semple, et al., 1978), colo 205 (ATee eel 222; Semple, et al., 1978), lS180
(ATee ci 187; Tom, et al., 1976), HT29 (ATee HTB 38; Fogh and Trempe,
1975) and caco 2 (ATee HTB 37; Fogh, 1977). All of these lines were
originally derived from human colon adenocarcinomas.
The human glioblastoma cell lines U138MG and U373MG were also
employed in certain studies due to their ease of manipulation.
The properties of these cell lines as regards expression of MHe antigens
is shown in table 2.1.
2.2. Bacterial strains
The E. coli strain Xl t-blue was used in all transformations and for the
amplification and maintenance of plasmid vectors. A description of its genotype
is given as follows: rec At, end At, gyr AOO, thi-1, hsd R17, sup E44, rei Ai,
lac, [F' pro AB' lacl9UM15, Tn 10 (tet'j]
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Table 2.1. Properties of cell lines
HLA-D HLA-D growth
cell line cell type inducibility* reduced by inhibited by
TGF-~? TGF-P?
colo 201
colo 205 colorectal positive no yes
LS180 colorectal negative - yes
caco z colorectal negative - -
HT29 colorectal positive no -
U138MG glioblastoma positive yes stimulated
U373MG glioblastoma positive yes stimulated
(astrocytoma)
* all cell lines were constitutively negative with respect to HLA-D expression. The
inducibilityof HLA-D at the cell surface refers to the expression of class II MHe after
treatment of cells in culture with recombinant human interferon-y for 48h.
The individual flow cytometric profiles for the induction of class II MHC
(HLA-DR) in the cell lines indicated are shown in figure 2.1.
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Caco-2
Figure 2.1. Induction of HLA-DR antigens by IFN-y in cell lines employed
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Cells were treated with lOOU/ml IFN-y for three days and stained for HLA-DR using
FITC-Iabelled monoclonal antibody (clone L243, Becton Dickinson, Oxford, UK). An
isotype-matched control antibody was included in all experiments (not shown) and was
always indistinguishable from untreated cells stained for HLA-DR. Dashed lines indicate
IFN-y-treated cells; solid lines indicate untreated cells. Flow cytometric analysis was
performed on a Becton Dickinson FACStar. Experiments performed by and histograms
prepared by Dr. Wendy 1. Bateman, University of Warwick.
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2.3. Growth media
2.3.1. Tissue culture media
The colorectal cell lines colo 201 and colo 205 were grown in RPM I 1640
medium (Sigma chemical Co., Poole, Dorset, UK). All other cell lines were
cultured in DMEM (Sigma). Medium was supplemented with 10% (v/v) foetal
calf serum (Gibco), 2mM L-glutamine, and antibiotics; penicillin (100 iU/ml) and
streptomycin (100 llg/ml). Medium supplemented with these additives is
referred to as "complete medium".
2.3.2. Bacterial growth media
E. coli clones were grown in 2xYT broth supplemented with 100 ~g/ml
ampicillin (Sigma) to maintain plasmid vectors.
2xYT broth: 16g tryptone
1Og yeast extract
5g NaCI
sterile distilled water to 1 litre
Medium was autoclaved prior to addition of ampicillin and growth of
bacteria.
Solid medium was obtained by the addition of 1.5% (w/v) bacto-agar
(Oifco) prior to autoclaving at 121°C @ 20 psi pressure for 15 min. Indicator
plates for the detection of lac z expression by recombinant colonies also
contained 0.5mM IPTG and 0.02% (w/v) X-gal.
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2.4. Oligonucleotides
Oligonucleotides were synthesised by the Applied Biosystems DNA
synthesiser as single stranded molecules. lyophilised oligonucleotides were
typically suspended in 500lli sterile distilled water and the concentration of DNA
calculated from measurement of 00200. Stock oligonucleotides were aliquoted
in 10111volumes and stored at -200Cto prevent repeated freeze-thawing events.
Equimolar amounts of complementary strands were annealed by.heating
oligonucleotide mixtures at 900C for 10min and allowing to cool for 3-4hr or
overnight until the temperature attained that below the melting temperature
(Tm) of each oligonucleotide. Tmwas approximated by employing the formula:
Tm = 4(G+C) + 2(T +A)
Annealed oligonucleotides were diluted to 10pmol/Ill, and stored at -200C
in 10111aliquots.
The sequences of double-stranded oligonucleotides employed in protein-
DNA binding analyses are given in table 2.2.
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Table 2.2. Oligonucleotide sequences of double stranded DNA probes
PROBE NAME RANGE IN ORa* SEQUENCE
V BOX -193 ~ -179 TGTTGTTGTTGTTGTCCTGTTTGTTTAGA
ACAACAACAACAACAGGACAAACAAATCT
WBOX -139 ~ -114 CGTGTCCTGGACCCTTTGCAAGAACCG
GCACAGGACCTGGGAAACGTTCTTGGC
X BOX -110 ~-85 CCCCTAGCAACAGATGCGTCATCTC
GGGGATCGTTGTCTACGCAGTAGAG
YBOX -84 ~-61 AAAATATTTTTCTGATTGGCCAAAG
TTTTATAAAAAGACTAACCGGTTTC
Notes:
• refers to the corresponding nucleotide positions of sequences in the promoter of
HLA-DRa..
All sequences are given 5' to 3' with the coding strand above the non-coding strand.
Bold underlined text indicates the consensus protein binding sites.
2.5. Plasmids
2.5.1. pBS (KS+) ORa 680 vectors
The HLA-DRa680 fragment
The polymerase chain reaction was employed to generate a fragment of
DNA corresponding to the region of the HLA-ORa. gene from nucleotides 511 to
1191 (the HLA-ORa.680 fragment; numbering system from the Beckman
Microgenie database and as cited in Oast et al., 1984)). This fragment spanned
the proximal promoter region and extended into the first transcribed nucleotides
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of the HLA-ORa gene such that nucleotides -540 to +40 relative to the cap site
were included. The cloning of this fragment into the phagemid pBluescript
(KS+) allowed further manipulation (by PCR and restriction endonuclease
digestion) and subcloning into other plasmid vector types. Preparation and
subsequent cloning of this fragment was performed by Mr. George Ward
(Biological Sciences, University of Warwick). The sequences of primers
employed in PCR amplification of HLA-ORa fragments are given in table 2.3.
The method by which the ORa680 fragment was amplified is outlined below in
table 2.4.
Table 2.3. Oligonucleotide primers employed in the PCR amplification of
HLA-DRa promoter fragments
PRIMER NAME SEQUENCE REGION BOUND IN
(5'~3') HLA-DRa
DR1 GGATCGAGTCAGTAGAGCTCGGGAG +22~+42
DR2 CCTGTGTTTCAAGATACAGCCGATCC -641-7-621
DR4 GGATCCTCTTTGGCCAATCA -73-7-60
The above table gives the sequences of the single stranded DNA oligonucleotide
primers (DRl, DR2 and DR4) employed in the generation of the HLA-DRa promoter
fragments DRa680 and DRaS82. Combinations of DR2 with DRl and DR4 in PCR
reactions were used to amplify 680 and 582 base pair fragments, respectively. The
regions to which the primers bind within the HLA-DRa gene are indicated in relation to
the start of transcription (cap site). Bold sequences indicate the presence of an
introduced restriction endonuclease recognition sequence.
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Table 2.4. Summary of the reaction conditions employed for the
amplification of the HLA-DRa 680 promoter fragment
COMPONENT ATIRIBUTES
target DNA (genomic) 1IJg
PCR primers, DR1 & DR2 2.5pM
deoxy nucleoside triphosphates 200j.JM
magnesium" 1.5mM
Taq DNA polymerase 2.5U
denaturation 94°C,1min } 30 cycles
annealing/elongation 72°C, 1.5 min
final elongation 72°C, 10 min
This table describes the components and conditions for the polymerase chain reaction
amplificationof the 680 base pair fragment of the HLA-DRa. promoter. The sequences
of the primers DRI and DR2 and the regions of the HLA-DRa. gene with which they
associate are defined in table 2.3.
2.5.2. Preparation of the pBluescript(KS+)DRa680 vectors
These vectors were prepared by the appropriate restriction
endonuclease digestion of the PCR-generated HLA-DRa.680 fragment and the
phagemid vector pBluescript and the subsequent enzymatic ligation of the two
moieties. Generation of cohesive ends in the HLA-DRa.680 fragment was
achieved by digestion with Bam HI - this was made possible by the introduction
of artificial restriction sites into the primers for the peR reaction. The
pBS(KS+)DRa.680 vectors were prepared by Mr. George Ward, Department of
Biological Sciences, University of Warwick.
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This cloning procedure yielded two vectors which contained the
HLA-DRa680 promoter fragment in 5'~3' or 3'~5' orientation relative to the
pBluescript(KS+) polylinker. Fragment orientation was determined by the
characteristic sizes of restriction fragments obtained by digestion of
recombinants with Xba I. These vectors were named pBS(KS+)DRa680 5'~3'
and pBS(KS+)DRa680 3'~5'. The orientation of the HLA-DRa680 promoter
fragment relative to the pBluescript polylinker in these vectors is represented
schematically in figure 2.2.
Figure 2.2. Orientations of the HLA-DRa680 promoter fragment in the
pBS(KS+)DRa680 vectors
a) pBS(KS+)DRa680 5'~3'
HincH
AccI
Sail
b) pBS(KS+)DRa680 3'~5'
AIlaI
01811 Cia I Pst I
Hlnc II EcoRI
AccI
Sail
Sac II
Notes:
Figures (a) and (b) represent the two vectors obtained from the cloning of the
peR-generated 680 base pair lILA-DRa promoter fragment into Bam HI-linearised
, pBluescript (KS). Nomenclature for the recombinants was dependent upon the
orientation of the cloned promoter fragment with respect to that of the polylinker of the
vector.
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2.5.3. Preparation of HLA-DRa CAT expression vectors
pDRa680CAT
Chloramphenicol acetyl transferase vectors were employed in a variety
of reporter gene studies devised to elucidate the possible mechanisms of
cytokine-mediated control of HLA-DRa. gene expression. Vectors were
prepared by the cloning of DNA fragments corresponding to regions of the
HLA-DRa. promoter into the multiple cloning site of the eukaryotic expression
vector pCATbasic (Promega) such that a "functional" promoter was provided for
the expression of chloramphenicol acetyl transferase from this plasmid following
transient transfection and appropriate cytokine treatment of cells. The
pCATbasic vector itself lacks eukaryotic promoter and enhancer sequences, but
provides insertion points for the cloning of promoter or enhancer elements (see
figure 2.3.). Amplification of pCATbasic (and derivatives thereof) was permitted
by the presence of a bacterial origin of replication and a p-Iactamase coding
region for selective growth in transformed E. coli in the presence of ampicillin.
All CAT plasm ids contained SV40 donor and acceptor splice sites and
polyadenylation signals form the gene encoding the small t-antigen.
The vector pDRa.680CAT contained the 680 base pair HLA-DRa.
promoter fragment upstream of the structural CAT gene of pCATbasic. Cloning
of this promoter fragment into this vector was achieved in the following
manner: pCAT basic was linearised by restriction endonuclease digestion
with Sal I and the cohesive ends blunted by the Klenow reaction. A second
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digestion with Pst I yielded a Pst I-blunt site for the ligation of a HLA-DRa680
fragment generated by the a) Acc I digestion followed by Klenow end-filling,
then b) Pst I digestion of pBS(KS+)DRa680 5'~3'. Ligation yielded a
recombinant vector in which the HLA-DRa promoter fragment had been inserted
in the correct orientation for transcription of the CAT gene. This cloning
strategy is summarised in figure 2.3.
pDRa320CAT
A deletion mutant of the HLA-DRa promoter was prepared such that the
effects of loss of the upstream region of the promoter could be assessed. This
deleted promoter fragment, termed DRa320, was again cloned into the
polylinker of pCATbasic. Preparation of the vector was achieved by its
restriction endonuclease digestion with Xba I and dephosphorylation by
treatment with calf intestine alkaline phosphatase as described. The DRa320
promoter fragment was prepared by "dropping out" the appropriate piece of
DNA from pBS(KS+)DRa680 5J~3J by its digestion with Xbal. The DRa320
fragment was purified by electrophoresis through agarose, followed by
electroelution and subsequent purification by phenollchloroformlisoamyl alcohol
extraction and ethanol precipitation (detailed in section 2.8.). Ligation was
performed "blind" such that the recombinants may have contained this promoter
fragment in either orientation with respect to the CAT structural gene. Those
recombinants with the promoter fragment in its correct orientation were
identified by restriction endonuclease digestion with Spe I and Hind III - this
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digestion released a 344bp fragment from those recombinants with the 320
bpHLA-DRa.promoter fragment in the correct orientation. The cloning strategy
employed for the preparation of pDRa.320CAT is represented schematically in
figure 2.4.
Figure 2.3. Cloning strategy for the preparation of the pDRa680CAT
expression vector
I pBS(KS)+ORu680 I
1)Acc I/Kleno~
2) Pst I _.. ,.,
Pst I DRu680 :;
1L.._-VL.Ll'i
1_'~~~--li~1I_._.J1"li~~:::& Klenow
pCAT-basic
(4364bp) EcoRI
pDRa680CAT
EcoRI
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digestion released a 344bp fragment from those recombinants with the 320
bpHLA-DRa promoter fragment in the correct orientation. The cloning strategy
employed for the preparation of pDRa320CAT is represented schematically in
figure 2.4.
Figure 2.3. Cloning strategy for the preparation of the pDRa680CAT
expression vector
1) Acc I/Kleno
2) Pst I
Pst I DRa680 =
---1'---_--J~u..I--~'-=~-..~L-J1"li~~:::& Klenow
pCAT-basic
(4364bp) EcoRI
I p8S(KS)iQRa680 I
pORa680CAT
EcoRI
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2.5.4. pSV2CAT and pOCAT
The plasmid pSV2CAT contained the SV40 late promoter to drive the
expression of the CAT gene. Plasmid pOCAT contained only the CAT reporter
gene with no promoter sequence to drive gene expression. This vector was
prepared by the removal of the SV40 late promoter sequence from pSV2CAT by
its restriction endonuclease digestion with Accl and Hind III followed by its
religation after formation of blunt ends. These plasmids were prepared by
Mr. George Ward; schematic representations are given in figures 2.5 & 2.S.
2.5.5. The ~-galactosidase expression vector
Plasmid pRSV~-gal expressed the bacterial lac z gene (~-galactosidase)
from the Rous Sarcoma virus long terminal repeat (LTR). Polyadenylation and
small t-antigen donor and acceptor splice sites for the processing of transcripts
were from SV40. This vector also contained a bacterial origin of replication and
~-Iactamase gene for propagation in transformed E.ec/i.
This vector was prepared by Dr. Simon Swingler, University of Warwick,
(PhD thesis, 1992) by the ligation of a 3736 fragment containing the lac z open
reading frame (generated by the Hind III-Bam HI restriction digestion of plasmid
pCH110 (Pharmaciaj) into Hind III-Bgl II digested RSV-33. RSV-33 is a
eukaryotic expression vector which contains the RSV LTR, SV40 processing
signals and sequences for maintenance and propagation in bacteria. A diagram
of pRSV~-gal is shown in figure 2.7.
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Figure 2.5. pSV2CAT
pSV2CAT
-4.5Kb EcoRI
late promoter
Figure 2.6. pOCAT
EcoRI
pOCAT
-4.3 Kb EcoRI
Figures 2.5& 2.6: pSV2CAT was a positive control vector for the transfection of
eukaryotic cells and transfected cells' ability to process reporter gene transcripts.
Transcription of the chloramphenicol acetyl transferase gene was directed by the SV40
late promoter. This vector also contained the gene for f3-lactamase (AmP) in addition to
SV40 polyadenylation and splice sites for the processing of CAT transcripts (not shown).
Removal of the SV40 late promoter by restriction endonuclease digestion with Hind II
and Ace I, followed by ligation of Klenow-generated blunt ends resulted in the negative
control vector pOCAT.
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Figure 2.7. pRSVp-gal
Bam HI
Bam HI/Bgl II
pRSVp-GAL
7.2Kb
,,- 'RSVLTR
The eukaryotic expression vector pRSVp-gal contained the bacterial lac z gene, which
encodes p-galactosidase, and was employed in transient transfection studies as a positive
control. It was prepared by the ligation of a 3736bp fragment containing the lac z
sequence into the Hind ITI-Bgi IT digested RSV-33 (refer to text). Expression of the
p-galactosidase gene was driven by the Rous sarcoma virus long terminal repeat
(RSV LTR). Polyadenylation and small t-antigen donor and acceptor splice sites were
included from SV40 and the vector also contained a bacterial origin of replication in
addition to the p-lactamase gene (Amp).
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2.6. Cytokines
Recombinant human interferon-y was prepared from CHO-DHFR-cells
(clone 12CMTX) transfected with an expression vector containing cDNAs for
human IFN-y and dihydrofolate reductase (Morris and Ward, 1987). Expression
of the IFN-y was amplified by growing cells in the presence of methotrexate.
Cells were grown in complete GMEM followed by maintenance in aMEM
supplemented with 1%(v/v) FCS, 0.2M hepes, 2mM L-glutamine, 0.1M
Na2HC03• 100iU/I penicillin and 100119/1 streptomycin. Maintenance medium
was harvested daily, filtered and supplemented with 0.02% sodium azide.
Interferon-y was partially purified by gel filtration through a blue sepharose
column, collected in 1ml aliquots and stored at -7CFC. The specific activity was
assessed by Semliki Forest Virus assay (performed by AGM).
Human IFN-aJ3and TGF-J31were purchased from Sigma and British
Biotechnology Products, Ltd., respectively.
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2.7. Cell culture
2.7.1. Growth of cell lines in culture
Suspension cells were grown in complete RPMI 1640 medium in tissue
culture grade plastic flasks (Costar) at 370C in a humidified atmosphere of 5%
CO2. The cells were maintained at an approximate density of 10
5 cells/ml by
dilution in fresh, prewarmed medium every 3-4 days.
Adherent cells were grown in complete OMEM in the conditions specified
and the medium changed every 2-3 days. Upon confluence, the monolayers
were washed briefly with warm PBS then incubated with 2-5ml trypsin-EDTA
solution (5mg/ml trypsin, 5mM EOTA; Gibco) at room temperature until the cells
detached from the inner surface of the flask. The cell suspension was added to
an equal volume of prewarmed complete medium and the cells pelleted by
centrifugation at 400g for 5min. The pellet was resuspended in an appropriate
volume of complete medium and the cells reseeded into fresh medium at a
dilution of 1:8 to 1:10 in a new flask.
2.7.2. Storage of cells in liquid nitrogen
Confluent monolayers were trypsinised and pelleted as described. The
cells recovered from a 25cm2 surface area were resuspended in 1ml of freezing
medium (95% FCS, 5% OMSO) and allowed to slowly freeze to -70°C for 24hr.
The cells were then transferred to liquid nitrogen for long term storage.
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2.7.3. Recovery of cells from liquid nitrogen
Vials were carefully removed from liquid nitrogen and placed in a
waterbath at 37°C to facilitate rapid thawing of the cell suspension. The cells
were carefully diluted into 10ml complete DMEM then pelleted by centrifugation
to remove DMSO. The pellet was then resuspended in 5ml complete medium
and a 25cm2 flask seeded with the cell suspension. The medium was
replenished daily until the cells reached confluence.
2.8. Routine manipulation of DNA
2.8.1. Phenol chloroform extraction
Contaminants, e.g. protein, were removed from solutions containing DNA
by adding an equal volume of phenol I chloroform I isoamyl alcohol (25:24:1)
and vortexing. The phases were separated by centrifugation at 20,OOOg for
5-10min. The aqueous (top) layer was recovered (such that precipitated protein
at the interface was not disturbed) and transferred to a fresh tube.
Occasionally, it was necessary to "back-extract" the solvent phase. This was
achieved by adding an equal volume of distilled water (or other aqueous
reaction solution) to the phenol, vortexing and centrifuging as described. The
aqueous phases (containing DNA) were combined and either extracted again
with phenol or the DNA precipitated with alcohol as described below.
Chapter2 68
2.8.2. Precipitation of DNA
The concentration of sodium acetate, pH 5.2 (or sodium chloride) in
aqueous DNA solutions was adjusted to 0.3M. Two and a half volumes of
100% ethanol, or an equal volume of isopropanol, were added and the mixture
vortexed. Precipitation was allowed to occur at -20°C overnight, -70°C for
30-60min, or in a dry ice/ethanol bath for 15-20min. Recovery of DNA was
performed by centrifugation at 20,OOOg for 10-20min. Pellets were washed
twice with 70% ethanol to remove salt and allowed to air-dry, or dried briefly
under vacuum, prior to resuspending the DNA in TE buffer (10mM Tris-HCI,
pH 7.6; 1mM EDTA) or sterile distilled water.
2.8.3. Gel electrophoresis of DNA
i) Agarose gel electrophoresis.
Routine analysis of DNA was performed by horizontal electrophoresis
through agarose gels buffered with 1xTBE (89mM Tris-Hct, pH 8.3, 89mM boric
acid, 10mM EDTA) containing 0.5Jlg/ml ethidium bromide. Electrophoresis was
performed in a Gibco-BRL model H5 horizontal gel tank and agarose gels were
poured into 11.0cmx14.0cm plastic mould. Wells were formed by using 1 or
2mm thick plastic combs of varying numbers of teeth depending on sample
volume and number of samples. Prior to loading, samples were mixed with one
fifth volume load dye (5xTBE, 30% [v/v] glycerol, 0.25% lw/v] bromophenol blue,
0.25% [w/v] xylene cyanol). Electrophoresis was performed at 60-120V at room
temperature. Size markers (Gibco-BRL 1Kb ladder with fragment sizes ranging
Chapter 2 69
from 0.1-12Kb) were also electrophoresed alongside samples to provide a
reference for identification of characteristically-sized DNA fragments within the
samples. Upon completion of electrophoresis, the DNA in the gel was
visualised under UN light and photographed using a Polaroid camera and type
55 4"x5" land film.
ii) Electro-elution of DNA from agarose gels.
Purification of electrophoresed DNA within agarose was performed by
the electra-elution method described by Sambrook et al. (1989). The piece of
agarose containing the required piece of DNA was excised from the whole gel
using a scalpel blade. The gel slice was then placed into a dialysis bag
containing 0.5ml 1xTBE and the bag sealed with a clip. This was then
submerged in the electrophoresis buffer in the gel tank and electrophoresis
performed at 100 V for 30 min. After this time, the direction of current was
reversed for 30sec to liberate any DNA from the dialysis tubing itself. The
dialysis assembly was then visualised under UN to confirm the extraction of
DNA from the gel into the buffer. The buffer containing the DNA was
transferred from the dialysis tubing to a microcentrifuge tube and the tubing
rinsed with 0.5 volumes TBE. The pooled buffer samples were extracted with
phenol/chloroform/isoamyl alcohol (25:24:1) and the DNA precipitated with
ethanol as described.
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iii) Polyacrylamide gel electrophoresis.
Non-denaturing polyacrylamide gel electrophoresis of DNA was
employed in the purification of end-labelled probes and in the separation of
nucleoprotein-DNA complexes from free probe in bandshift experiments. Five
percent (w/v) polyacrylamide gels were prepared from a 40% stock solution of
acrylamidelbis-acrylamide (29:1) and were formed in a 150x170x1.5 mm (height
x width x thickness) apparatus. Polymerisation was catalysed by the addition of
0.1% (w/v) ammonium persulphate and 0.1% (v/v) TEMED and was allowed to
proceed for 1hr before gels were used. The ionic strength of gels was modified
according to their requirements; gels being employed for preparation of
radioactively labelled probes were typically of high ionic strength and contained
1xTBE, those being used in bandshift experiments were of low ionic strength
and contained 0.2xTBE. Electrophoresis was performed in a Gibco-BRL model
V15.17 vertical gel tank at 150V in 1xTBE or 0.2xTBE for low ionic strength
gels.
iv) Extraction of DNA from polyacrylamide gels.
Radiolabelled probes were localised by autoradiography against Fuji
RX100 for 1min. The piece of gel containing the probe was excised with a
clean scalpel blade and cut into 1mm cubes. The DNA was eluted from the gel
by the "crush and soak" method (8ambrook et al., 1989): an equal volume of
elution buffer (0.5M ammonium acetate, 10mM magnesium acetate, 1mM EDTA
[pH 8.0], 0.1% (w/v) 80S) was added to the crushed gel slice in a
microcentrifuge tube and shaken overnight on a rotating platform to elute the
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DNA. The sample was vortexed, centrifuged briefly and the supernatant
centrifuged through siliconised glass wool at 500g for 5min to remove any
remaining polyacrylamide: a 1ml syringe was packed with glass wool to ~2cm
height and placed above the open neck of a 1.5ml microcentrifuge tube inserted
into a 15ml Corex tube. The supernatant, collected in the microcentrifuge tube
after the centrifugation step, was extracted twice with an equal volume of
phenol/chloroform/isoamyl alcohol and the DNA precipitated with 100% ethanol.
After washing with 70% ethanol and resuspending in TE or sterile distilled
water, the DNA was reprecipitated and washed twice further with 70% ethanol
prior to air-drying. Samples were resuspended in an appropriate volume of TE
or sterile distilled water (typically 200~1)and stored at -20°C until use.
2.8.4. Use of DNA modifying enzymes
i) Restriction endonuclease digestions.
Restriction enzymes were typically supplied by Gibco-BRL or Amersham
and were provided with manufacturers' reaction buffer; all reagents were kept
on ice during the preparation of incubations. The DNA to be cleaved was
prepared in sterile distilled water and the appropriate volume of 10 x reaction
buffer in a microcentrifuge tube. The number of units of enzyme required to
perform the digestion in the given time (1-24hr) was calculated from the
concentration of the enzyme, the frequency of cleavage of bacteriophage "-
DNA for the particular enzyme and the amount (in ~gs) of DNA to be digested.
The required amount of enzyme was added to the DNA/reaction buffer mixture
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to start the reaction and the tube incubated at the appropriate temperature for
the required length of time.
ii) Dephosphorylation of DNA.
Prior to using digested DNA in further reactions, it was often necessary
to dephosphorylate the 5' ends. This was achieved by the use of calf intestine
alkaline phosphatase (ClAP). Following restriction enzyme digestion, the DNA
was extracted with an equal volume of phenol/chloroform/isoamyl alcohol and
ethanol precipitated. The pellet was resuspended in 50JlI ClAP buffer (10mM
Tris-HCI [pHS.3], 1mM ZnCI2, 1mM MgCI2), for 5' overhanging ends, 1U
CIAP/100pmoles DNA was added, whereas for blunt ends or recessed termini,
1U/2pmoles DNA was added. Reaction mixtures were incubated at 37°C for
30min, after which time a further aliquot of ClAP was added and tubes were
incubated for a further 30min at 45°C.
iii) Blunt end reaction.
The Klenow fragment of E. coli DNA polymerase was used in the
presence of deoxynucleoside triphosphates to generate blunt-ended DNA
molecules from those possessing 5' overhangs created by restriction
endonuclease digestion. Purified restricted DNA was resuspended in buffer
(O.5M Tris-HCI [pH 7.5], O.1M MgS04, 1mM OTT, 500Jlg/ml bovine serum
albumin [fraction V]) containing 1mM dNTPs. The reaction was started by
adding 1 unit of enzyme per microgram of DNA and allowed to proceed by
incubating at room temperature for 30min. Reactions were terminated by the
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addition of 1J.1IO.SMEDTA (pH 8.0) followed by phenol chloroform extraction
and ethanol precipitation.
iv) Ligation.
The procedure for ligating blunt and cohesive ends was identical. In a
final volume of SO~lligase buffer (SOmMTris-HCI [pH 7.6], 10mM MgCI2, 1mM
ATP, 1mM OTT, S% (w/v) polyethylene glycol-8000), 1OO~g of
dephosphorylated vector DNA was mixed with an equimolar amount of insert
DNA possessing compatible termini. One unit of T4 DNA ligase was added and
the mixture incubated at 16°C for 18hr. Following ligation, samples were stored
at -20°C until use.
2.8.5. Transformation of bacteria and preparation of plasmid DNA
i) Preparation of competent bacteria.
Transformation-competent bacterial cells were prepared from the method
of Sambrook, et al., (1989). A 10ml culture of XL1-blue cells in 2xYT broth
containing 15~g/ml tetracycline was grown overnight at 370C with gentle
shaking. The next day, 1ml of the resulting cell suspension was subcultured
into 100ml 2xYT broth containing tetracycline and grown for a further 3hr until
the culture had reached OD6X)of approximately 0.3. The culture was then
cooled on ice for 15min and the cells pelleted by centrifugation at 1500g for
10min at 4OC. The cells were resuspended in 10ml of 100mM MgCI2 and
incubated on ice for 10min prior to repelleting by a further centrifugation step.
After resuspending in 5ml of 100mM CaCI2 containing 15% (v/v) glycerol, the
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cells were aliquoted into 100lli volumes and either incubated at 40C for an hour
prior to transformation or stored at -700Cuntil use.
ii) Transformation of competent bacteria with plasmid vectors.
Twenty five microlitres of a ligation reaction mixture (or 1-51l1(1-5Ilg) of
amplified plasmid DNA) were incubated in a with 100lli competent cells in a
1.5ml microcentrifuge tube for 1hr on ice. The mixture was then heated at 42°C
for 2min prior to a further incubation on ice for 30min. Antibiotic-free 2xYT broth
(9001l1)was then added and the mixture incubated at 370C for 30min. Fifty
microlitres of the cell suspension were plated out onto 2xYT agar containing
ampicillin (and IPTG & X-gal). The remaining cells were then pelleted by
centrifugation at 20,OOOg for 1min in a microcentrifuge, the supernatant was
discarded and the pellet resuspended and plated out onto a fresh 2xYT agar
plate. Plates were incubated overnight at 37°C. All vectors employed
contained the gene conferring ampicillin resistance and plasmid constructs
based on pUC and pBluescript II carried the l3-galactosidase gene whose
expression was inactivated by the presence of an insert. Recombinants were
identified by their inability to metabolise the chromogenic galactose analogue
X-gal in solid media.
iii) Small scale preparation of plasmid DNA.
The ''TENS'' buffer mini-prep method was used to isolate plasmid DNA
from bacterial colonies prior to its characterisation by restriction endonuclease
digestion.
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Single colonies were inoculated into 5-10ml 2xYT broth containing
ampicillin and grown overnight at 37°e in an orbital shaker. The following day,
1.5ml of cell suspension was transferred to a microcentrifuge tube and the cells
pelleted by centrifugation at 20,OOOg for 1min. The supernatant was decanted
off leaving 50-100J..11in the tube and the cells were resuspended by vortexing.
Three hundred microlitres of ice-cold TENS buffer (10mM Tris-Hel, [pH 8.0],
1mM EDTA, 0.1 M NaOH, 0.5M sodium dodecyl sulphate) were added and the
tubes vortexed for 2-5sec. After the addition of 150J.,l13M sodium acetate, the
tubes were vortexed again and the resultant cell debris was pelleted by
centrifugation at 20,OOOg for 2min. The supernatant was transferred to a clean
microcentrifuge tube and 900J.,l1of 100% ethanol which had been pre-cooled to
-20oe was added. Tubes were centrifuged for 5min at 20,ooOg to pellet the
precipitated plasmid DNA. Pellets were washed with 1ml 70% ethanol and
dried under vacuum. The DNA was dissolved in 40J.,l1sterile distilled water
containing 50J.,lg/mlRNase A. Five microlitres of the resulting plasmid solution
were used for restriction enzyme analysis.
Upon identifying clones of recombinant bacteria containing the desired
plasmid, glycerol stocks of cells were prepared for long term storage. This was
achieved by pelleting 1.5ml of bacterial cell suspension and resuspending the
cells in 2xYT broth containing 40% (v/v) glycerol. Glycerol stocks of bacterial
clones were stored at -20oe for up to 12 months.
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iv) Large-scale preparation of plasmid DNA.
Milligram quantities of plasmid DNA were prepared by the method of
Sambrook, et al., (1989). An overnight culture of bacteria was prepared by the
inoculation of 10ml 2xYT broth containing 0.1mg/ml ampicillin with 10J.11of cells
from a glycerol stock (or 100J.11of a 40C cell stock) and cultures were grown at
37°C with shaking. One to five millilitres of the resulting culture were used to
inoculate 500ml of 2xYT broth containing ampicillin and the cells were allowed
to grow overnight at 37°C in an orbital shaker. Pelleting of the cells was
achieved by centrifugation (Beckman J14, 7,OOOrpmfor 5min) and supernatants
were discarded. Cell pellets were resuspended in 10ml solution I (50mM
glucose, 25mM Tris-HCI [pH 8.0], 10mM EDTA), transferred to a 50ml Falcon
tube and the bacteria lysed by the addition of 20ml freshly made solution II
(0.2M NaOH, 1% [w/v] SOS): following addition of solution II, the suspension
was gently mixed by inversion and the tubes allowed to stand on ice for
5-10min. After this time, 15ml ice-cold solution III (3M potassium acetate, 3M
acetic acid) was added, the tubes mixed by inversion and allowed to stand on
ice for 10min. Bacterial cell debris and DNA was then removed by
centrifugation at 1800g for 30min at 4°C in an MSE Chilspin 2 (4,100rpm).
Supernatants were transferred to clean Falcon tubes containing 0.6 times their
volume of isopropanol and the DNA was allowed to precipitate at room
temperature for 15-20min. The precipitated DNA was pelleted by centrifugation
at 1800g for 30min, following which it was washed twice with 70% ethanol,
air-dried, then resuspended in 7.5ml TE prior to purification of the plasmid DNA
by caesium chloride density gradient.
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v) Purification of plasmid DNA through caesium chloride density gradients.
A solution of caesium chloride was prepared by dissolving 28g CsCI in
20ml TE and was transferred to a Beckman "quick-seal" centrifuge tube and
tubes were carefully balanced at this stage by the addition/removal of CsCI.
The plasmid DNA solution was mixed with O.Smlof 10mg/ml ethidium bromide
and added to the TE in the Beckman tube and the tubes were rebalanced. The
aqueous solution was overlaid with liquid paraffin and the tubes were
heat-sealed at the neck. Tubes were then transferred to a Beckman VTi 50
rotor and centrifuged at 4S,OOOrpmfor 16hr; after which time, the centrifuge was
allowed stop without brake. The bands of plasmid and genomic DNA were
visualised under UN light. The vacuum in the tube was released by piercing its
top with a syringe needle and, following this, the lower (plasmid) band was
recovered using a 10ml plastic syringe. Ethidium bromide was removed from
the plasmid solution by extracting five times with an equal volume of H20-
saturated butan-t-ol. The caesium chloride was then removed by dialysis
versus three changes of SL of TE; each dialysis step was allowed to proceed for
1h at room temperature. DNA was recovered by ethanol precipitation; after
preCipitating, washing and drying, the plasmid pellet was resuspended in O.Sml
TE or sterile distilled water and the concentration of DNA determined by
measuring 002001280 at a dilution of 1:20. At 260nm, a SOJjg/mlsolution of
dsDNA has an optical density of 1, and the purity of a DNA solution can be
assessed by the ratio of ODs at 260 and 280nm - for pure DNA, this ratio is 1.8.
In cases where this ratio was low, i.e. too much protein in the sample, the DNA
was extracted with phenol/chloroform/isoamyl alcohol and reprecipitated.
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2.9. Transfection of eukaryotic cells
2.9.1. Transfection of adherent cells.
Adherent cells were transfected with calcium phosphate I DNA
coprecipitates prepared by a method modified from Gorman, et a/., (1985) and
Chen and Okayama (1987). Twenty four hours prior to transfection, 60mm
tissue culture dishes (Costar) were seeded with a sufficient number of cells
(3.5-6.5x1()5cells/dish depending on cell type), prepared by the trypsinisation of
confluent layers, to achieve 60-80% confluence the next day. Cells were grown
in 5ml complete DMEM in an atmosphere of 5% CO2 at 370C overnight
(20-24hr). The following day, 1ml of calcium phosphate/DNA precipitate was
prepared for each pair of dishes. Forty micrograms (20~g per dish) of caesium
chloride gradient-purified plasmid DNA was mixed with 50~12.5M CaCI2 and the
volume increased to 500~1with tissue culture grade sterile distilled water. An
equal volume of 2xHBS (50mM Hepes-NaOH [pH7.12], 280mM NaCI, 10mM
KCI, 12mM glucose, 3mM Na2HP04) was then added dropwise with gentle
shaking and the mixture allowed to stand at room temperature for 10-15min.
Following this incubation, a fine coprecipitate of Ca3(P04h-DNA could be
observed. Precipitates were mixed gently by pipetting once and 500~1were
added dropwise to the medium above monolayers on duplicate dishes with
gentle swirling. Dishes were incubated at 370C for 20hr. The next day, the
medium containing the precipitates was removed and the monolayers were
washed gently with Sml of warm PBS. The cells were then glycerol shocked for
1min with 5m120% (v/v) glycerol (Sigma, tissue culture grade) in PBS, washed
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twice with PBS and incubated at 370C in Sml complete DMEM. For transient
transfection studies, the dishes were incubated until fresh medium had
equilibrated with the temperature and CO2 atmosphere (approximately 1hr)
before the dropwise addition of cytokines. Dishes were incubated in the
presence of cytokines for 24 or 48hr.
2.9.2. Transfection of cells growing in suspension
Cells growing in suspension were also transfected by a modified calcium
phosphate-DNA precipitate method. Approximately 1x107 cells were collected
by centrifugation, the supernatant medium was discarded and the cell pellet
resuspended in 1ml of the appropriate Ca3(P04h-DNA suspension (prepared in
the manner described in 2.8.1.) and incubated at room temperature for 1hr.
Following this, the volume was increased to 10ml with complete RPMI 1640
medium and the cells introduced into a 2Scm2 tissue culture flask prior to
incubation at 370C and 5% CO2 for 4.5-6hr. The cells were then pelleted by
centrifugation and the pellets washed with 5ml PBS prior to glycerol shocking
as described. After washing twice with PBS, the cells were returned to the
incubator in 10ml complete RPMI-1640. After the cells had equilibrated with
respect to temperature and CO2, they were stimulated with the appropriate
cytokines for 24 or 48hr.
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2.10. Analysis of extracts from transfected cells
2.10.1. Preparation of cytoplasmic extracts from transfected cells
Reporter gene expression was assayed in cytoplasmic extracts from
transiently transfected cells. Twenty-four or 4Shr after glycerol shock, duplicate
monolayers were washed with Sml ice-cold PBS and the cells collected into Sml
PBS using a cell scraper. Dishes were washed with another Sml PBS and this
was combined with the cell suspension from the first scraping. Transiently
transfected suspension cells were collected by centrifugation (1200g, Smin) and
washed once with Sml ice-cold PBS. The cells were collected by centrifugation
at 1200g for Smin at 4°C, supernatants discarded and pellets resuspended in
1S0~1of ice-cold CAT lysis buffer (2S0mMTris-HCI [pH 7.S], 10% [v/v] glycerol,
0.2S% [v/v) Nonidet-P40); suspensions were transferred to 1.Sml
microcentrifuge tubes and cell membranes were lysed by incubation on ice for
10min. Cell lysis was ensured by three cycles of freeze-thawing (2min dry
ice/ethanol bath, 1min 37°C) after which cell debris was removed by
centrifugation at 20,OOOg for 12min. Supernatants were transferred to fresh
microcentrifuge tubes and stored on ice prior to further analysis.
2.10.2. Protein assay
The Bio-Rad protein assay was employed to assess the protein content
of cytoplasmic extracts. Five to ten microlitres of cytoplasmic extract was
assayed in 1ml of diluted assay reagent (200~1 reagent plus SOO~Idistilled
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water) in a 1ml plastic cuvette. The protein content was estimated by
spectrophotometry at 595nm using diluted assay reagent as a blank. From the
OD5Q5.the extract concentration could be translated into "units" where 1U of
cytoplasmic extract was the volume required to produce an absorbance reading
of 1.0 at 595nm.
2.10.3. p-Galactosidase assay
Cells were transiently transfected with ~-galactosidase gene expression
vectors such that the efficiency of transfection could be assessed. The activity
of ~-galactosidase in cytoplasmic extracts was assayed by measuring
o-nitrophenol production following enzymatic cleavage of the substrate
o-nitrophenyl galactoside (ONPG). This reaction was measured colorimetrically
since its product is a vivid yellow solution of o-nitophenol,
~-Galactosidase activity was assayed in cytoplasmic extracts prepared
as described in 2.10.1.. The assay reaction mixture was prepared in a 1.5ml
microcentrifuge tube as follows: 3111100x magnesium buffer (100mM MgCI2• 5M
~-mercaptoethanol). 66111ONPG solution (4mg/ml in sodium phosphate buffer
[100ml of 0.1M Na2HP04• adjusted to pH7.3 at 370C with 0.1M NaH2PO_J)and
the final volume of 300lli (including cell extract) attained by adding an
appropriate volume of sodium phosphate buffer. Reactions were started by
adding equal unit amounts (1-5U determined by protein assay) of fresh
cytoplasmic extracts and tubes were incubated at 37oC. Samples
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were incubated until a yellow colour was evident (30-120min), at this time the
reaction was terminated by the addition of 0.5M 1M Na2C03. Incubation at.
370C often resulted in the precipitation of cellular material, this was removed by
centrifugation at 20,OOOg for 10min. The supernatants were recovered and the
absorbance measured at 495nm. Assay conditions were assessed by the
incorporation of 100ng of purified enzyme in the reaction mixture in the place of
cytoplasmic extract.
2.10.4. Chloramphenicol acetyl transferase (CAT) assay
The enzyme assay was performed on fresh cytoplasmic extracts using
the direct scintillation diffusion method of Eastman (1987). The number of units
of extract was normalised throughout the assay such that 1-5 units (see 2.10.2.)
of cytoplasmic extract was incorporated into each reaction mixture and the
amount incorporated was equal for each reaction within an assay. Duplicate
samples were normalised according to transfection efficiency as determined by
the p-galactosidase assay. Since the p-galactosidase promoter was responsive
to cytokines (Swingler, PhD thesis (1992», it was not possible to normalise,
with respect to transfection efficiency, between samples which had been
subjected to different cytokine treatments.
Extracts were heated at 65°C for 15min prior to their incorporation into
the reaction mixture. This was done to inactivate any deacetylases within the
samples - bacterial CAT is relatively heat-stable and is unaffected by such
treatment. One to five units of extract was mixed in a plastic scintillation vial
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with the following reagents: 50~15mM chloramphenicol (aq), 25~11M Tris-HCI
pH7.8, 124~1distilled water and O.1MTris-HCI pH 7.8 to give a final volume of
300~1. The substrate, rH]-acetyl coenzyme A (0.1~Ci) was then added to start
the reaction and vials were incubated at 37°C after the rapid addition of 4.5ml
Econofluor scintillation fluid.
Controls were incorporated to measure i) the passive diffusion of
rH]-acetyl coenzyme A into the solvent phase, ii) the expression of CAT in
extracts from cells transfected with the promoterless CAT vector pCATbasic and
iii) a positive 'control was included in which the purified CAT enzyme was
employed instead of cytoplasmic extract. As the reaction proceeded, the
rH]-acetylated chloramphenicol reaction product entered the scintillant phase
and thus was able to be measured by liquid scintillation counting. Vials were
counted for 10s every 30min over a 2hr period. The enzyme reaction was linear
over this period of time as shown in figure 2.8.
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Figure 2.8. Time-course of enzymatic conversion of chloramphenicol to
the fH]-acetate during the chloramphenicol acetyl transferase assay
CPM
100,000,------------------, pCATbasic
80,000
pDRa680CAT--
pDRa680CAT
+IFN-y
-.-
o 30 60 90 120
Time (minutes)
Notes:
This time-course plot of a typical CAT assay demonstrates the linearity of substrate
conversion over the period of the enzyme reaction. This particular assay displays good
linear conversion into radioactive product despite the high level of output .
•
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2.11. Analysis of DNA binding proteins
2.11.1. Preparation of nuclear protein extracts
i) Cytokine treatment, harvesting and storage of cells.
Adherent cells were grown to confluence in roller bottles in 100ml
complete DMEMwhich had been pregassed with a 12-15s pulse of CO2 to yield
an atmosphere of approximately 5% CO2, Suspension cells were also grown in
roller bottles in 100ml RPMI-1640 until a density of 2.5x106 cells/ml had been
attained. Three or four roller bottles of cells were prepared for each cytokine
treatment. Immediately prior to addition of cytokines, the medium on adherent
cells was changed and the rollers regassed. Cells were treated with 1()3 U/ml
IFN-y, 200U/ml IFN-a or 10U/ml IFN-y & 200U/ml IFN-a for 2, 6 or 24hr.
Adherent cells were washed with 10ml PBS then harvested by trypsinisation
before being stored in 30% (v/v) glycerol in DMEM at -700C. Suspension cells
were harvested by centrifugation, resuspended in 30% (v/v) glycerol in RPMI
and stored at -70°C. Frozen cells were stored for upto 6 months prior to
preparation of nuclear proteins.
ii) Preparation of nuclear proteins.
Proteins were extracted from nuclei by a method based on that described
by Hennighausen and Lubon (1987). All solutions and apparatus were
prechilled and homogenisers were autoclaved or baked prior to use.
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Frozen preparations of cells were thawed at 37°C then pelleted by
centrifugation at 1800rpm (MSE Chilspin) for 10min at 4°C. Pellets (1-1.Sml in
volume) were washed with Sml ice-cold PBS before repelleting then
resuspending in 3 pellet volumes of ice-cold buffer A (10mM Hepes-KOH
[pH7.9], 10mM KCI, 1.SmMMgCI2, 0.1mM EGTA, 0.32M sucrose, O.SmMOTT,
O.SmMPMSF and 211g/mleach of antipain, leupeptin and pepstatin A). Cells
were transferred to a Oounce homogeniser and fully resuspended using 10-12
strokes of aB-pestle. Nonidet-P40 was added to give a final concentration of
0.1% (v/v) and the cell membranes lysed with 4 strokes of the B-pestle. Nuclei
were pelleted by centrifugation at 1200g for 10min at 4°C and washed twice
with three pellet volumes of buffer A (without Nonidet). Lysis was confirmed by
visualising nuclei under phase contrast microscopy. The nuclear pellet was
resuspended in 0.S-1ml of buffer B (400mM NaCl, 10mM Hepes-KOH [pH 7.9],
1.SmMMgCI2, 0.1mM EGTA, S% [v/v] glycerol, O.SmMOTT, O.SmMPMSF) and
transferred to a sterile glass bijou. The suspension was stirred gently at 4°C for
30min to elute the proteins from the nuclei. Nuclear debris was removed by
centrifugation at 100,OOOg for 1hr. Supernatants were dialysed against 100
volumes of buffer C (20mM Hepes-KOH [pH 7.9], 7SmM NaCl, 0.1mM EOTA,
20% [v/v] glycerol, O.SmMOTT, O.SmMPMSF) for 1.S-3hr at 4°C. Precipitated
material was removed by centrifugation (2S,OOOgfor 1Smin) and the
supernatants assayed for protein concentration by the Bio-Rad protein assay
(see section 2.9.2.). Nuclear proteins were aliquoted in volumes of 20-S00119
and stored for up to six months at -70°C until use.
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2.11.2. Preparation of radio-labelled DNA probes
DNA probes for use in bandshift and footprinting assays were prepared
from either double-stranded oligonucleotides or from larger fragments of DNA
excised from plasmid vectors. Techniques were employed such that the DNA
was radialabelied at one end to high specific activity using t- or
a-[32P]-nucleosidetriphosphates. Polynucleotide kinase from T4 bacteriophage
was used with [y.32P]-ATPto phosphorylate 51-hydroxyl groups whereas the 31
end was labelled by end-filling with reverse transcriptase and one or two
[a.32P]-dNTPs. A schedule for the radiolabelling of all probes used in bandshift
and footprinting analysis is given in figure 2.9.
i) Preparation of plasmid DNA for labelling.
The promoter sequences studied were cloned into the plasmid vector
pBluescript II KS+. Restriction endonucleases were chosen such that a
fragment of the promoter of convenient size could be excised from the vector
and radiolabelled at a site which was a suitable distance from the DNA binding
protein consensus sequences within the promoter. In order that the DNA was
radiolabelled at one end, the two restriction enzymes selected were different.
DNA was prepared according to the method described by Goodwin
(1990). Fifty micrograms of the plasmid DNA was digested with the first
restriction enzyme in 100111of buffer (see 2.8.4.[i]). Twenty units of ClAP was
then added and the mixture incubated at 37°C for 30min before the reaction
was terminated by the addition of 1011100mM EDTA and 101110% (w/v) SOS.
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The DNA was extracted twice with phenol/chloroform/isoamyl alcohol then
ethanol precipitated. After washing and air-drying, the pellet was resuspended
in 10111TE or sterile distilled water (containing 50llg/ml RNase A) and stored at
-20°C.
ii) T4 Polynucleotide kinase reaction.
Two microlitres of cut, dephosphorylated plasmid DNA or annealed
oligonucleotide (20pmol) were incubated at 370C for 45min with 10111
[y..32P]-ATP(100IlCi; 5000Ci/mmol) and 1111(10U) T4 PNK in a 50111reaction
volume containing 50mM Tris-HCI (pH7.6), 10mM MgCI2, 5mM on, 0.1mM
spermidine, 0.1mM EDTA. The reaction was terminated by the addition of
EDTA and SOS and the mixture phenol/chloroform extracted and ethanol
precipitated. The pellet was resuspended 20111TE or water and 3M sodium
acetate added to give a final concentration of 0.3M. The DNA was then
reprecipitated with 100% ethanol, washed twice with 70% ethanol, air-dried and
resuspended in 10111TE before digesting with the second restriction enzyme in
a final buffer volume of 50lli. The reaction was terminated by the method
described, 12111of formamide load dye (80% [v/v] deionised formamide, 10mM
NaOH, 1mM EDTA, 0.1% lw/v] xylene cyanol, 0.1% lw/v] bromophenol blue)
was added and the tube vortexed. The labelled DNA fragment was separated
from the vector by polyacrylamide gel electrophoresis through a 5% (50-500bp)
or 10% (20-30bp) gel in 1xTBE (see section 2.8.3.[iii]). After separation, the
labelled DNA fragments were identified by autoradiography and the desired
fragment recovered from the polyacrylamide gel by the "crush and soak"
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method (section 2.8.3.[iv]). The addition of 51lg of carrier tRNA enabled the
efficient precipitation of oligonucleotide probes. DNA was precipitated with
100% ethanol, washed with 70% ethanol and air-dried as described. Probes
were resuspended in 200lli TE or water to give a specific activity of
50,OOO-150,OOOCpmllll(3.5x107-1x1Q8cpmlllg)and stored at -20°C for upto 10
days.
iii) End-filling with reverse transcriptase.
Two microlitres (~1Ollg) of cut, dephosphorylated plasmid DNA was
incubated at 370C for 1hr with 100ilCi (10IlI) [a.-32Pl-dCTP, 100J.lCi (10J.l1)
[a..32Pl-dATP(each at 6000Ci/mmol) and 40U (2J.l1)AMV reverse transcriptase
in 50111of buffer containing 10mM Tris-HCI (pH 8.3), 80mM KCI, 10mM MgCI2
and 12mM J3-mercaptoethanol.The reaction mixture was then purified, digested
with the second restriction enzyme and separated from the vector by
electrophoresis in the same manner as that described in section 2.11.2.(ii)
(above). DNA was eluted from the polyacrylamide gel into 2.5ml low salt (LS)
buffer (0.2M NaCl, 20mM Tris-HCI [pH 7.6], 1mM EDTA) by shaking overnight
at 37°C. Centrifugation at 2000g for 10min was performed such that the solid
acrylamide could be removed. The supernatant was then collected; a further
1ml LS buffer added to the acrylamide and the tube was vortexed before
centrifuging again. The supernatants were combined and pipetted onto an
equilibrated Schleicher and Schuell Elutip D column. After washing the column
with 5ml LS buffer, the radio labelled DNA was eluted into OAml high salt (HS)
buffer (1.0M LiCI, 20mM Tris-HCI [pH7.61, 1mM EDTA). The DNA was
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precipitated with 100% ethanol at -700Cfor 1hr, collected by centrifugation and
washed twice with 70% ethanol prior to air-drying and resuspending in 200111
TE or sterile distilled water to give a specific activity of 70,OOO-150,OOOCpm/lll
(2.3 to 4.9x107cpml1l9). Probes were stored at -20°C for upto 10 days before
use.
2.11.3. Bandshift assay
In this type of experiment (also referred to as gel retardation,
electromobility shift assay etc) nuclear proteins were incubated with
radiolabelled probes corresponding various parts of the promoter of interest or
a larger promoter fragment probe. During polyacrylamide gel electrophoresis,
the labelled probe to which protein, ie transcription factors, is bound has its
progress through the gel hindered by the presence of bound proteins and so
does not travel as far as unbound probe. The binding of transcription factors to
the labelled probe is observed after autoradiography as a novel band/s above
the free probe.
The specificity of the binding of such complexes to the probe could be
assessed by the incorporation of excess unlabelled (cold) DNA of exactly the
same sequence as the probe into the binding reaction mixture. Such
sequestration of complexes by the unlabelled competitor DNA results in the
disappearance of bands or reduction in band intensity upon autoradiography.
Use and variation of this technique facilitated the study of ubiquitous and
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cytokine-inducible DNA binding factors in the cell lines under investigation with
a view to assessing whether differences in HLA-DR expression observed at the
cell surface could be reflected at the level of protein-DNA interactions.
Crude nuclear extracts (5-20ll9) were preincubated for 20min at room
temperature with 1-8ll9 poly (dl-dC):poly (dl-dC) (from 4ll9/lll stock dissolved in
poly dl-dC buffer [50mM NaCl, 10mM Tris-Hel (pH 7.6), 1mM EDTA]) and 1119
pUC13 plasmid DNA in "gel retardation buffer" (20mM Hepes-NaOH [pH7.61,
4% Ficoll, SmM MgCI2, 40mM NaCl, 0.1mM EDTA, O.SmM OTT) in a final
volume (including probe) of 20lli. One microlitre (20,OOOcpm)of probe solution
was then added and the mixture incubated for a further 45-60min on ice.
Samples were then loaded into the wells of a pre-run (150V, 20min) 5% (w/v)
polyacrylamide gel containing 0.2xTBE and electrophoresed at 150V for 3-6hr
depending on the size (in base pairs: 2-3hr for oligonucleotides; 4-6hr for DNA
fragments) of the probe employed (see section 2.S.3[iii]). Formamide load dye
was also electrophoresed in order to assess the progress of separation. After
completion of electrophoresis, gels were soaked in 10% (v/v) glycerol for 30min
prior to drying under vacuum at SOOC for 1hr. Dried gels were autradiographed
against Fuji RX 100 X-ray film at -7CPC for 12hr to 3days. After developing and
fixing the film, dark bands corresponding to free probe and probe to which
protein complexes were bound could be visualised. The specificity of the
binding of protein complexes to radiolabelJed probes was determined by
performing competition bandshift assays. This variety of experiment was
performed in the same manner as the standard assay except "competitor" DNA
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in varying molar excesses to the amount of probe DNA was incorporated into
the pre-incubation mixture. Competitor DNA was defined as an unlabelled
piece of DNA whose sequence was the same as the probe or a piece of
unlabelled DNAwhose sequence was related to that of the probe's.
Competition of binding was defined as the disappearance of a band or
the significant reduction in intensity of a band upon incorporation of competitor
DNA in the incubation mixture.
2.11.4. Maxam and Gilbert sequencing of fragment probes
End-labelled fragment probes labelled on one strand were sequenced
chemically to provide a reference for footprinting reactions. DNA for
sequencing was prepared in the following manner: a volume of end-labelled
probe sufficient to yield 60,OOOcpmdefined by Cerenkov counting, was
increased to 20J.l1with sterile distilled water and 2J.l13M sodium acetate added.
The DNAwas precipitated with an equal volume of isopropanol prior to washing
with 70% ethanol and drying briefly under vacuum. Pellets were resuspended
in 40J.l1sterile distilled water and the probe distributed between the four
chemical cleavage reactions as shown in table 2.5. The chemical cleavage
reactions were performed as described in table 2.5. Following the final
evaporation step, the cleaved DNAwas resuspended in 5J.l1formamide load dye
and stored at -200c prior to electrophoresis through sequencing gels. The
compositions of solutions employed throughout the sequencing procedure are
given below.
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Composition of Maxam & Gilbert sequencing buffers:
OMS reaction buffer
50mM sodium cacodylate, pH 8.0
1M ~-mercaptoethanol
100llg/ml tRNA
OMS stop buffer
1.5M sodium acetate
1mM EOTA, pH 7.0
100llg/mi tRNA (after filter-
sterilising)
Hydrazine stop buffer
0.3M sodium acetate, pH 7.0
0.1mM EOTA
251lg/ml tRNA (after filter sterilising)
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Table 2.5. Outline of Maxam and Gilbert chemical sequencing reactions
Seecificit~ of DNA cleavage
Component G G+A T+C C
DNA, III 58 10b 10b 58
OMS reaction buffer, III 200
Water, III 5 10 10
5M NaCl, III 5
Base-specific modification reactions
OMS, III 1
Formic acid, III 25
Hydrazine, III 30 30
Reaction time (min) 4 10 15 8
Reaction stopped rapidly by dilution with stop buffer and -200C ethanol
and immersing in dry ice/ethanol bath for 10min
OMS stop buffer, III 50
Hydrazine stop buffer, III 200 200 200
100% ethanol, III 750 750 750 750
DNA collected by centrifugation at 20,OOOg for 15min, washed twice with Iml 70%
ethanol and air-dried.
Remaining reagents removed by re-precipitation (as above)
Water,lll
3M sodium acetate, III
100% ethanol, III
200 200
20 20
500 500
200 200
20 20
500 500
Strand scission reaction at modified bases by incubation at SOOCfor 30min
in 10% (v/v) piperidine
10% (v/v) piperidine, III 70 70
70 III water added after incubation, vortexed and evaporated.
70 70
All traces of piperidine removed by evaporation twice from water
sterile water, III
sterile water, III
60 60
50 50
60 60
50 50
-10,000, b20,OOOC6renkov cpm
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2.11.5. DNase I footprinting
The method employed was based on that described by Goodwin (1990).
Probes employed were fragments of DNA derived from the HLA-DRa.promoter.
End-labelled probes were partially digested with DNase I (bovine pancreatic) in
the presence of bound nuclear proteins. Crude nuclear extract (0-200~g) was
incubated with 4~g poly (dl-dC):poly (dl-dC) and 2-Sfinol of end-labelled DNA
fragment (2x104cpm) in 100~1 buffer containing 20mM Hepes-KOH, pH 7.S,
40mM NaCl, 2mM CaCI2, SmM MgCI2, 1mM OTT, O.SmM ZnCI2, 10% (v/v)
glycerol. This was incubated on ice for SOminthen digested with 1U DNase I
for 1min at room temperature. The reaction was terminated by the rapid
addition of 100~I DNase stop buffer (2% [v/v] SOS, 10mM EDTA [pH 8.0],
0.1mg/ml tRNA) followed by 200~I phenol/chloroform/isoamyl alcohol (2S:24:1)
and mixed by vortexing. The phases were separated by centrifugation at
20,OOOg for 10min and the upper phase collected. The solvent phase was
back-extracted with 1OO~Istop buffer followed by vortexing and centrifugation.
The aqueous phases were pooled and re-extracted with 300~1
phenol/chloroform/isoamyl alcohol as above. The fragmented DNA was ethanol
precipitated then collected by centrifugation at 20,000g for 1Smin. DNA pellets
were washed twice with 70% ethanol and dried briefly under vacuum prior to
resuspending in S~I formamide load dye. The DNA was then denatured by
heating at 900 C for 10min followed by snap-freezing in dry ice/ethanol.
Samples were thawed on ice before being loaded into the wells of an 8%
sequencing gel which had been pre-electrophoresed at 1S00V (8SW, SOmA).
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2.11.6. Preparation of sequencing gels
DNase I digested DNA form footprinting reactions and DNA cleaved by
the Maxam and Gilbert sequencing method was resolved by electrophoresis
through 8% (w/v) acrylamide (19:1 acrylamide:bis-acrylamide) 8M urea gels.
Gels containing 1xTBE were prepared, filtered, then poured between
31.0x38.5cm glass plates separated by 0.4-1.2mm wedged spacers.
Polymerisation was catalysed by the addition of 850~.d10% (w/v) ammonium
persulphate and 85~1TEMED (per 1SOmiliquid gel mixture) prior to pouring the
gel. Gels were electrophoresed in a Gibco-BRl model S2 sequencing tank at
8SW (approximately 1500V, 80mA) in 1xTBE for 40-60min to pre-run and warm
the gel. The samples from footprinting and sequencing were heated to 950C for
3min then snap-frozen in a dry ice/ethanol bath prior to thawing on ice and
loading into the wells of the pre-run gel. Samples were electrophoresed at the
same settings for 4-Shr until the required degree of separation was achieved.
Following electrophoresis, one glass plate was removed and the gel transferred
to a sheet of double-thickness 3M paper. The gel was covered with cellophane
and dried under vacuum at 80° C for 3hr. Dried gels were autoradiographed
against Fuji RX film with an intensifying screen for 3-7days at -7rPC.
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Figure 2.9. Strategy for labelling fragment probes used in bandshift and
footprinting analyses
+1
Kpn I
pBS(KS+) -640
polylinker
Bam HI
Notes:
Fragment probes were prepared from the 680bp fragment of the HLA-DRc:x.promoter
cloned into the Bam HI site of the polylinker of the phagemid pBluescript (II) KS+.
Fragments were generated by restriction endonuclease digestion according to the method
of Goodwin (1990) [section 2.11.2. (i) & (ii)].
The restriction enzymes employed to generate the sites for end-filling are shown.
** indicates the incorporation of two [c:x.-32P]-labellednucleoside phosphates by reverse
transcriptase-catalysed end-filling (section 2.11.2 [iii]).
indicates the direction of transcription from the start site.
r indicates the start of transcription.
The lengths of probes and the strand labelled are indicated by number and C or NC (for
coding and non-coding, respectively). The name DRc:x.-uCindicates that this probe covers
the upstream extreme of the promoter region.
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Table 2.6. Radioactive labelling of oligonucleotides and DNA fragments
employed in bandshift and footprinting analyses
PROBE PROBE TYPE LABELLING FIRST SECOND
NAME TECHNIQUE ENZYME ENZYME
V box ds oligo [y..32P]& PNK NA NA
Wbox ds oligo [y..32P]& PNK NA NA
X box ds oligo [y_32P]& PNK NA NA
Ybox ds oligo [y..32P]& PNK NA NA
DRa470C fragment DNA [a-32P]& end filling Spel Nco I
DRa470NC fragment DNA [a..32P]& end filling Nco I Spe I
IBam HI
DRa220uC fragment DNA [a-32P]& end filling Nco I Bam HI
Notes:
The sequences of the double stranded oligonucleotides are given in table 2.2.
The methods for radiolabelling by polynucleotide kinase and reverse transcriptase
end-filling are given in sections 2.11.2. (ii) & (iii), respectively.
NA=not applicable.
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CHAPTER 3: ANALYSIS OF NUCLEAR DNA BINDING PROTEINS
INVOLVED IN THE INTERFERON1-INDUCED EXPRESSION OF HLA-DRa
3.1. Introduction
The nature of transcription factors which bound to the HLA-DRa.
promoter was investigated. Since the expression of this gene is tightly
controlled by cytokines and in a tissue-specific manner, cell lines were treated
with a variety of cytokines prior to their being harvested and nuclear proteins
being extracted by the described method.
In non-haematopoietic cells, surface expression of HLA-DR and other
class II MHC genes can only be observed after exposure to interferon-y. The
human tumour cell lines under investigation here responded variably to IFN-y
treatment in this respect: using flow cytometric analyses, the cell lines colo 201
colo 205 and U373MG showed good induction of class II MHC after IFN-y
treatment, whereas the cell lines caco 2 and LS180 could not be induced to
express HLA-DR under the same conditions (Darley, et al (1993». It was this
difference in ability for IFN-y-induced class II expression which was the prime
target for investigation here. Experimentation followed the hypothesis that
those cell lines which were unable to be induced for class II MHC expression
were lacking in components of the transcription factors required for activation of
expression.
The first part of the study was to assess the populations of HLA-DRa.
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promoter binding proteins before and after IFN-y-treatment of the cell lines
employed. This was achieved by performing bandshift assays with
radiolabelled probes which corresponded to the Wand X boxes of the
HLA-DRa.. These elements were chosen due to their reported importance in
the IFN-y-induced expression of class II MHC. The W box had been implicated
in IFN-y-induced transcription when its mutation in reporter gene assays
reduced expression levels to basal (Basta, et a/ 1988). Also, the X box had
been shown to bind IFNEX in response to IFN-y-treatment of cells. Although
absolutely necessary for the transcription of HLA-DRa, the Y box's involvement
was considered more as a general one (e.g. for the binding of CAAT
transcription factor) and as such it was not investigated in this respect.
3.1.1. Cell lines
The cell lines employed initially in this study were those which were
derived from human tumours as described in section 2.1.; these being colo 201,
colo 205, U373MG, LS180 and caco 2. None of these cell lines displayed
constitutive surface expression of class II MHC and each showed a distinct
response to IFN-y-treatment as regards surface expression of class II MHC
antigens (see table 2.1). The objective of these initial experiments was to
assess whether the differences in surface expression of HLA-DR was reflected
in differences in the populations of specific transcription factors which bind to
discrete regions of the HLA-DRa promoter. To facilitate this, double stranded
oligonucleotide probes corresponding to the individual cis-acting elements of
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the promoter were employed as radiolabelled probes (prepared by T4
polynucleotide kinase labelling) in bandshift assays. Crude nuclear extracts
from the cell lines employed were prepared before or after IFN-y-stimulation by
the method described. The bandshift assay was performed in each case by the
method of Goodwin (1990) described in section 2.11.3.
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3.2. Analysis of nuclear proteins binding to the HLA-DRa W (Z) box
The individual cis-acting sequences which are conserved within all class
II MHC promoters, ie W, X and Y boxes, have been studied extensively since
they were identified by sequence homology. Their cooperation in activation of
constitutive and cytokine induced transcription of HLA-DRa.and their individual
roles in promoter activity have been somewhat elucidated. Deletion or mutation
of just one of the elements abolishes the ability of the HLA-DRa. to direct
constitutive and IFN-y-induced transcription. One study (Basta, et al., 1988)
employing reporter gene analysis showed that deletion or mutation of just the W
(Z) box was sufficient to reduce transcriptional activity of the promoter to its
basal level. Because of this, initial bandshift studies focussed on the binding of
proteins from nuclear extracts to the W box.
A double stranded DNA oligonuceotide whose sequence incorporated
the HLA-DRa W box consensus was synthesised. The sequence of this
oligonucleotide is as follows:
5'-CGTGTCCTGGACCCTTTGCAAGAACCG-3'
3'-GCACAGGACCTGGGAAACGTTCTTGGC-5'
The part of the oligonucleotide shown in bold type indicates the
consensus W box element which is considered to be the transcription factor
binding sequence.
Chapter3 104
This was radiolabelled using T4 bacteriophage polynucleotide kinase
and employed in bandshift experiments using nuclear protein extracts from
IFN-y-treated and untreated tumour cell lines. Assays were performed at least
in duplicate with nuclear protein extracts from three independent cell
preparations. The cells were grown to high density and treated with 1000U/ml
IFN-y for 6 or 24hr prior to harvesting and extraction of nuclear proteins. This
concentration of IFN-y was used to induce the maximal response. The time
points chosen were intended to "capture" any changes in the populations of
DNA binding proteins and were selected from published observations of
HLA-DRa mRNA levels and surface expression (refer to section 1.6.).
3.2.1. Constitutive binding of protein complexes to the HLA-DRa W-box
probe
Colo 201, colo 205, LS180 and caco 2
In a series of experiments, nuclear extracts were used from the cell lines
colo 201, colo 205, LS180 and caco 2. The constitutive binding of nuclear
factors to the HLA-DRa W box probe in shown in figure 3.1.
The free probe is visualised as the dense band at the bottom of the
autoradiograph, ie, the fastest migrating band. The next fastest migrating band
(labelled NS) is a non-specific protein-DNA complex, this being confirmed in
competition bandshift experiments (see section 3.4.).
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Figure 3.1. Constitutive binding of nuclear factors to the HLA-DRa. W box
probe
4
3
2
1
NS
NP 1 3 42
F
Bandshift experiment employing nuclear extracts from unstimulated colorectal tumour
cell lines colo 201, colo 205, LS180 and caco 2 (lanes 1 to 4, repsective1y) and a
radiolabelled double stranded oligonucleotide probe corresponding to the ID...A-DRa W
box. Ten micrograms of nuclear extracts were incubated with 20,000 cpm of probe for
60min on ice prior to electrophoresis through a 5% (w/v) non-denaturing polyacrylamide
gel at 150V for 3hr (see section 2.11.3. for method). The free probe is indicated by "F";
NS=non-specific complex; NP=no protein control. Those binding complexes shown to
be specifically bound are numbered according to their respective mobilities.
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Band 1was the first of the specific protein-DNA complexes. Its presence
was ubiquitous amongst all cell lines investigated and was independent of
cytokine treatment of cells. In colo 201 and colo 205 nuclear extracts this
complex appeared to be less evident than in the LS180 and caco 2 where the
band was of much greater intensity.. This effect was likely to be due to this
complex being the most abundant in uninduced caco 2 and LS180 whereas it
was a minor complex in nuclear extracts of colo 201 and colo 205.
Band 2 was observed in colo 201, colo 205 and, to a lesser extent,
LS180, yet was absent from caco 2 extracts.
Band 3 represented the most abundant complex binding to the W box
probe in extracts from untreated colo 201 and colo 205 yet was absent in LS180
extracts and was only present in small amounts in extracts from caco 2.
Uninduced LS180 and caco 2 extracts also contained a low mobility
complex (band 4) which was absent in uninduced colo 201 and colo 205. This
complex was of equal intensity to band 1 in LS180 and it was assumed that it
was of equal abundance in this cell line. In contrast, it was of less intensity
than band 1 in caco 2 and was, therefore, less copious.
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U373MG
Nuclear extracts from U373MGwere not assessed in the same assays as
the colorectal tumour cell lines and the results cannot be compared. Bandshift
experiments with the same W box oligonucleotide probe revealed the
association of four complexes from uninduced cells (see figure 3.2). This figure
also shows the formation of binding complexes observed with nuclear proteins
from IFN-y-stimulated U373MG.
Constitutive binding of U373MG nuclear factors:
Unstimulated U373MG contained four factors which bound to the W box
probe, these are labelled as bands 1, 3 and 4 in figure 3.2. Of these
complexes, the band which is represented as "3" in the figure was observed as
a doublet. The proteins which caused the formation of these complexes and
thaVthose whose binding resulted in band 1were observed as the being equally
abundant.
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Figure 3.2. Binding of nuclear factors from unstimulated and
IFN-y-stimulatedU373MG to the HLA-DRa W box probe
NP 1 2 3
o 6 24 ¢:: IFN-y(hrs)
F
5
4
3
2
1
Bandshift experiment employingnuclear extracts from unstimulated and IFN-y-stimulated
U373MG astrocytoma cell line; cells were treated for 0,6 or 24 hr with 1000U/ml IFN-y
(lanes 1 to 3, respectively). A radiolabelled double stranded oligonucleotide probe
corresponding to the HLA-DRa. W box was employed. Ten micrograms of nuclear
extracts were incubated with 20,000 cpm of probe for 60min on ice prior to
electrophoresis through a 5% (w/v) non-denaturing polyacrylamide gel at 150V for 3hr
(see section 2.11.3. for method). The free probe is indicated by "F"; NP=no protein
control. Those binding complexes shown to be specifically bound are numbered
according to their respective mobilities.
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IFN-y-induced U373MG factor binding
The treatment of U373MG with 1000U/ml IFN-y for 6 and 24hr prior to
preparation of nuclear proteins led to increased association of factors with this
probe. Novel binding complexes are represented as bands 2 and 5 in figure
3.2. The binding of the factor resulting in band 4 was increased after 6hr IFN-y
treatment and band 5 was observed after 24 hr stimulation as a complex which
migrated with retarded mobility to band 4. The association of factors resulting
in band 3 also appeared to increase after 24hr IFN-y stimulation of cells.
3.2.2. Binding of IFN-y-induced factors to the W box
In the same series of experiments as discussed above, bandshifts were
performed employing nuclear extracts from IFN-y-treated cells alongside the
unstimulated cell nuclear extracts. Figure 3.3. shows the result of one
bandshift experiment in this series.
Nuclear extracts prepared from colo 201 and colo 205 and contained
novel W box binding factors upon stimulation with IFN-y. Colo 201 treated with
IFN-y for 6 or 24hr and colo 205 treated for 24hr possessed a factor which
migrated more slowly than the most retarded complex in the uninduced cells
(figure 3.3., band 4). This complex migrated with marginally greater mobility
than the least mobile complexes of LS180 and caco 2 (band 5).
The appearance of this complex in stimulated colo 201 and colo 205
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coincided with the diminution in intensity of band 2 compared to the untreated.
In colo 205, this complex disappeared after treatment of the cells with IFN-y, yet
it was observed to reassociate after 24hr stimulation of colo 201. It was
postulated that the complex resulting in the appearance of band 4 was a
derivative of that complex which formed band 2.
No differences in the binding of nuclear factors from LS180 and caco 2
were observed after treatment of these cells with IFN-y
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Fig. 3.3. Binding of nuclear factors to the HLA-DRa W box probe after
treatment of cells with IFN-y
1
NS
col0201 col0205 LS180 caco2
NP 1 2 3 4 5 6 7 8 9 10 11 12
5
4
3
2
F
Bandshift experiment employing nuclear extracts from unstimulated and IFN-y-stimulated
colorectal tumour cell lines colo 201, colo 205, LSI80 and caco 2 (as indicated above
lane markers) and a radio labelled double stranded oligonucleotide probe corresponding to
the HLA-DRa. W box. Ten micrograms of nuclear extracts were incubated with 20,000
cpm of probe for 60min on ice prior to electrophoresis through a 5% (w/v) non-
denaturing polyacrylamide gel at I50V for 3hr (see section 2.11.3. for method). Lanes I,
4, 7 and 10: extracts from unstimulated cells. Lanes 2, 5, 8, and 11: cells treated with
IOOOU/ml IFN-y for 6hr. Lanes 3, 6, 9 and 12: cells treated with IOOOU/ml IFN-y for
24hr. The free probe is indicated by "F"~ NS=non-specific complex; NP=no protein
control. Those binding complexes shown to be specifically bound are numbered
according to their respective mobilities.
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3.2.3. Summary of results
The binding of nuclear proteins to a probe corresponding to the
HLA-DRa W revealed differences in the transcription factor population of a
panel of human tumour cell lines. These differences were noted particularly
between inducible and non-inducible colorectal tumour cell lines.
Prior to IFN-y-stimulation of the colorectal tumour cell lines, the inducible
cell lines colo 201 and colo 205 contained nuclear proteins which formed three
major binding complexes. The uniducible lines, LS180 and caco 2 contained
two and three binding complexes, respectively and of these one was common to
all cell lines (the fastest migrating specific complex termed band 1), whereas an
intermediate migratory complex in caco 2 appeared to have the same mobility
as the most retarded band in colo 201/205 extracts (band 3). The least mobile
complex in LS180 and caco 2 was absent in nuclear extracts from colo 201 and
colo 205.
It was not possible to compare the W box binding complexes form
uniduced U373MGwith these colorectal tumour cell lines, in this situation the W
box probe bound four nuclear factors (bands 1, 3 and 4 in figure 3.2).
After stimulation of cells with IFN-y, no differences in the binding of
factors was observed with LS180 and caco 2. However, colo 201 and colo 205
both exhibited the binding of a novel complex (band 4 in figure 3.3.), migrating
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with slower mobility than those observed prior to stimulation. Its appearance
was noted after 6hr IFN-y treatment of colo 201 and 24hr stimulation of colo
205. This complex migrated with marginally greater mobility than the slowest
migrating band observed with unstimulated and IFN-y-treated LS180 and caco
2. The complex which gave rise to band 2 in unstimulated colo 201 and colo
205 was greatly diminished upon IFN-y treatment although its reappearance
was noted after 24hr IFN-y stimulation of colo 201.
A novel retarded complex from U373MG was also noted to bind to the W
box probe after 24hr IFN-y stimulation of this cell line. In contrast with the
inducible colorectal tumour cell lines, this appearance was not coincident with
the reduced binding of any complex observed prior to IFN-y stimulation.
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3.3. Analysis of nuclear proteins binding to the HLA-DRa X box
The study into X box binding factors was undertaken in order to
determine whether any novel factors were observed upon IFN-y treatment of the
colorectal tumour cell lines under investigation here. The experimentation was
performed in the same manner as that described for the W box study. The
sequence of the double stranded oligonucleotide probe employed in bandshift
experiments is given below:
5'-CCCCTAGCAACAGATGCGTCATCTC-3'
3'-GGGGATCGTTGTCTACGCAGTAGAG-5'
<------x------><-X2->
The consensus X box and adjoining X2 box are indicated by bold print.
Probes were radiolabelled using [y..32P]ATP and polynucleotide kinase
as described. Cells were grown and treated with IFN-y for 6 or 24hr or
untreated prior to harvesting and extraction of nuclear proteins. Figure 3.4.
shows the result of one bandshift experiment in which nuclear extracts from
untreated cells were incubated with the labelled X box probe.
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Fig. 3.4. Interaction of DNA binding proteins from unstimulated colorectal
tumour cell lines with the HLA-DRa X box probe
3
2
1
NS
NP 1 3 42
4
F
Bandshift experiment employing nuclear extracts from unstimulated colorectal tumour
cell lines colo 201, colo 205, LS180 and caco 2 (lanes 1 to 4, respectively) and a
radiolabelled double stranded oligonucleotide probe corresponding to the HLA-DRa. X
box. Ten micrograms of nuclear extracts were incubated with 20,000 cpm of probe for
60min on ice prior to electrophoresis through a 5% (w/v) non-denaturing polyacrylamide
gel at 150V for 3hr (see section 2.11.3. for method). The free probe is indicated by "F";
NS=non-specific complex; NP=no protein control. Those binding complexes shown to
be specifically bound are numbered according to their respective mobilities.
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3.3.1. Constitutive binding of proteins to the HLA-DRa X box
Colo 201, colo 205, LS 180 and caco 2
Constitutive binding was represented by that which is observed from the
untreated cells (see figure 3.4.) A number of complexes were observed in the
nuclear extracts from the cell lines under investigation. The free probe was the
fastest migrating band at the bottom of the autoradiograph and was the densest
of the bands observed - confirming that it was present in each incubation in
excess of the nuclear proteins. The next fastest migrating band (termed NS)
was identified as being due to non-specific binding.
The bands above were specifically bound to the probe. The first of
these, termed band 1, was present in the nuclear extracts of all the untreated
cells although it appeared as a marginally faster migrating, more diffuse band in
the extracts from caco 2. The next most retarded band (band 2) was present in
copious amounts in nuclear extracts form colo 205 and LS180 and in lesser
amounts in those from unstimulated caco 2, whereas it was absent from the
nuclear extracts of colo 201.
In the extracts from unstimulated colo 205 there was a very intense band
(band 3) which was unique to this cell line under these conditions. There was a
faint band (band 4) which was present solely in extracts from untreated LS180.
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U373MG
As was the case with the study into the W box, nuclear extracts from
U373MG were not assayed in the same experiments as those from colorectal
tumour cell lines. Bandshifts with the X box revealed the association of four
nuclear protein complexes (shown in figure 3.5.). Comparisons could not be
made between these factors and those observed from the colorectal cell lines.
Of the four complexes observed binding to this probe, two (bands 2 and 4) were
the most abundant. The appearance of bands 1 and 3 was very faint,
presumably due to their relatively low concentrations in this population of X box
binding proteins.
There was no difference in the association of factors to the X box probe
after treatment of U373MG with IFN-y (figure 3.5).
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Figure 3.5. Binding of U373MG nuclear proteins to the HLA-ORa X box
probe
NP 1 2 3
o 6 24 *= IFN-y(hrs)
F
4
3
2
1
Bandshift experiment employingnuclear extracts from unstimulated and IFN-y-stimulated
U373MG astrocytoma cell line; cellswere treated for 0,6 or 24 hr with 1000U/ml IFN-y
(lanes 1 to 3, respectively). A radiolabelled double stranded oligonucleotide probe
corresponding to the Ill-A-DRa X box was employed. Ten micrograms of nuclear
extracts were incubated with 20,000 cpm of probe for 60min on ice prior to
electrophoresis through a 5% (w/v) non-denaturing polyacrylamide gel at 150V for 3hr
(see section 2.11.3. for method). The free probe is indicated by "F". Those binding
complexes shown to be specifically bound are numbered according to their respective
mobilities.
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3.3.2. Binding of factors to the HLA-DRa X box probe after stimulation of
cells with IFN""l
In nuclear extracts from colo 201 which had been treated which
1000U/ml IFN-y for Sand 24hr a difference in binding to the X box probe was
observed compared to the unstimulated extract (figure 3.6.). This was
manifested in the appearance in two novel bands (termed A and 8) which
migrated much slower than the single band ("band 1") observed with the
unstimulated extracts. The most retarded of the novel bands migrated with the
same mobility as "band 5" which was observed with extracts from LS180 and
caco 2 before and after IFN-y stimulation.
The faster migrating of the two novel bands (band A) did not have the
same mobility as any band which was observed with the extracts from the other
cell lines studied. The intensity of this band was greater at 24hr IFN-y
stimulation than at Shr and this increase in intensity coincided with the reduced
intensity of band 1 although the initial appearance of band A did not result in
such a reduction in intensity of band 1. This suggested that the complex
resulting in the appearance of band A was not formed by the acquisition of that
protein(s) which caused the appearance of band 1.
Nuclear extracts from IFN-y-treated colo 205 also contained "novel" X
box-binding factors compared to the unstimulated control. The most prominent
difference observed was the appearance of a band (band B) which had the
same mobility as "band 5" (also present after IFN-y treatment of colo 201). This
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was coincident with the diminution of band 3 in extracts from cells treated for
both 6 and 24hr. Treatment of colo 205 with IFN-y also resulted in the
disappearance of the complex which gave rise to band 2 in the unstimulated
controls.
No differences were observed in the binding of nuclear proteins to the X
box probe after IFN-y-treatment of LS180, caco 2. The apparent appearance of
the retarded complex 6 in caco 2 nuclear extracts is an artefact of the
photographic procedure employed. This complex was observed in extracts from
this cell line before and after IFN-y stimulation although it is not clearly visible in
figures 3.4 and 3.6.
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Figure 3.6. Binding of nuclear factors to the HLA-DRa X box probe after
treatment of cells with IFN-y
~ 4
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col0201 col0205 LS180 cac02
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Bandshift experiment employing nuclear extracts from unstimulated and IFN-y-stimulated
colorectal tumour cell lines colo 201, colo 205, LS180 and caco 2 (as indicated above
lane markers) and a radiolabelled double stranded oligonucleotide probe corresponding to
the HLA-DRa. X box. Ten micrograms of nuclear extracts were incubated with 20,000
cpm of probe for 60min on ice prior to electrophoresis through a 5% (w/v) non-
denaturing polyacrylamide gel at 150V for 3hr (see section 2.11.3. for method). Lanes 1,
4, 7 and 10: extracts from unstimulated cells. Lanes 2, 5, 8, and 11: cells treated with
1000U/ml IFN-y for 6hr. Lanes 3, 6, 9 and 12: cells treated with 1000U/ml IFN-y for
24hr. The free probe is indicated by "F"; NS=non-specific complex; NP=no protein
control. Those binding complexes shown to be specifically bound are numbered
according to their respective mobilities, bands ~ and ~ are induced in colo 201 after IFN-y
treatment.
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3.3.3. Summary of results
The HLA-DRa X box probe was employed in a series of bandshift
assays. As with the investigation into the binding of factors to the W box, the
cell lines employed displayed differences in their populations of X box-binding
nuclear proteins.
Prior to stimulation of cells with IFN-y, the colorectal tumour cell lines
shared a common, rapidly migrating complex (band 1 in figures 3.4 and 3.6.) -
this formed the major complex in colo 201. In colo 205, LS180 and caco 2 a
second protein complex, which migrated with marginally retarded mobility to the
ubiquitous rapidly migrating complex, was shared. The next band (band 3 in
figure 3.4.) was unique to uninduced colo 205, whereas a complex which
migrated with slower mobility was observed only in LS180 and to a lesser
extent in caco 2 nuclear extracts. A very retarded complex was observed only
in nuclear extracts from caco 2 (band 6 in figure 3.6.).
The astrocytoma cell line U373MG contained four X box-binding
complexes, two of which were the most abundant in this population.
No differences were observed in the binding of nuclear factors to the X
box probe when LS180, caco 2 and U373MG had been treated with IFN-y for 6
or 24hr. This observation was in contrast to those seen for IFN-y-stimulated
colo 201 and colo 205.
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Interferon-y-stimulated colo 201 contained two novel X box-binding
complexes, the most retarded of which (band 8) migrated with the same mobility
as band 5 observed in uniduced and IFN-y-stimulated LS180 and caco 2. The
faster migrating of the two IFN-y-induced complexes (band A) was not observed
in nuclear extracts from any other cell line.
The stimulation of colo 205 by IFN-y resulted in the loss of binding of the
complexes which formed bands 2 and 3 in the uninduced state. Concurrent
with this was the novel binding of a complex which migrated with the same
mobility as band 5, again termed band 8 in figure 3.6.
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3.4. Displacement of factors bound to the W box probe with unlabelled W
and X box oligonucleotides
Competition bandshift assays were performed for two principal reasons.
Firstly, the specificity of binding of the observed complexes was determined by
"competing out" the binding with increasing molar excesses of unlabelled W box
oligonucleotide in the bandshift reaction mixture. Secondly, the cross-reactivity
of the complexes which bound to the W box could be assessed as regards their
binding to the X box. The second use of competition bandshift assays came
about from the observation that certain complexes which bound to the W box
oligonucleotide probe migrated with similar if not the same mobility as factors
which bound to the X box probe. Also, the sequence homology between the W
and X boxes led to the possibility that certain proteins would have the ability to
associate with either sequence element. By incorporating varying molar
excesses of unlabelled X box oligonucleotide into the binding reaction prior to
the addition of the radiolabelled W box probe, it was possible to determine
whether any of the complexes which were observed bound to the W box could
also bind to the X box; i.e. were factors "shared" by the two consensus
elements?
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3.4.1. Specificity of binding of complexes to the W box probe
Since most of the complexes which were observed bound to the W box
were only present in nuclear extracts from cells treated for 24hr with IFN-y,
competition bandshift assays were performed which employed such "24hr"
extracts.
Nuclear proteins were preincubated at room temperature for 20min with
carrier DNA, poly dl-dC:poly dl-dC and increasing amounts of unlabelled
"competitor" oligonucleotide in molar excess from 1 to 500 times that of the
probe. After addition of the probe, the reaction was incubated for a further
40-60min at room temperature prior to electrophoresis through a
non-denaturing ployacrylamide gel by the described method (see section
2.11.3).
The results of a series of assays employing nuclear extracts from treated
and untreated cells are shown in figures 3.7. to 3.8. These results show that
displacement of bound complexes started to occur with as little as an equal
amount of unlabelled W box oligonucleotide, this was seen as the reduction in
intensity of band 5 compared to the no competitor control with nuclear extracts
from all four cell lines. All complexes corresponding to bands 2 to 5 were nearly
fully competed out by SOXexcess competitor. Such a competition pattern was
indicative that these complexes were specifically bound to the W box probe.
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Figure 3.7. Competition of HLA-DRa W box-bound factors from
IFN-y-induced cells by the W box and X box oligonucleotides
competitor: 0
NP 1
colo 201
W X 0
2345678
colo 205
W X---- ..
9 10 11 12 13 14
A)
A) Bandshift with nuclear extracts form IFN-y-stimulated colo 201 and colo 205 and the
W box probe. Binding offactors has been competed out by the incorporation of IX, lOX
or 50X molar excess of unlabelled oligonucleotides corresponding to the Wand X boxes
(arrows indicate increasing competitor oligonucleotide concentration). Nuclear extracts
(luug), competitor and probe were incubated as described and DNA-binding moieties
separated by electrophoresis through a 5% (w/v) polyacrylamide gel at l50V for 3hr.
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Figure 3.7. (contd.)
competitor: 0
NP 1
LS180
W X 0
2345678
~~
W X----+
9 10 11 12 13 14
B)
B) Bandshift with nuclear extracts form IFN-y-stimulated LS180 and caco 2 and the W
box probe. Binding of factors has been competed out by the incorporation of 1X, lOX or
50X molar excess of unlabelled oligonucleotides corresponding to the Wand X boxes
(arrows indicate increasing competitor oligonucleotide concentration). Nuclear extracts
(lOJ.lg), competitor and probe were incubated as described and DNA-binding moieties
separated by electrophoresis through a 5% (w/v) polyacrylamide gel at 150V for 3hr.
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Figure 3.8. Competition of HLA-DRa W box-bound factors from uninduced
colo 201 by the Wand X box oligonucleotides
competitoree
IFN-y~ NP 0 6 24
o W x
Bandshift employing nuclear extracts from colo 20I binding to the HLA-DRa. W box
probe. 0,6 and 24 indicate that cellswere treated with (IOOOU/ml)IFN-y for these times
(in hours) prior to preparation of nuclear extracts. The binding of proteins from
untreated cells to this probe was competed out by increasing concentrations (indicated by
the horizontal arrow) of unlabelled Wand X box oligonucleotides. The relative
competitor oligonucleotide concentrations were: lane A: Ox;lanes Band E: Ix; lanes C
and F: 1Ox; lanes D and G: 50x molar excess of the labelled W box probe.
Nucleoprotein-DNA complexes were separated from the free probe by electrophoresis
through a 5% (w/v) non-denaturing polyacrylamidegel for 3hr as described.
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3.4.2. "Cross-reactivity" of W box-binding factors with the X box
Competition bandshift assays were performed in order to determine
whether those factors which were bound to the Wand X boxes (giving rise to
complexes with similar mobility) had the ability to cross-react with the two
consensus oligonucleotides. Assays were performed in which the binding of
nuclear factors to the radialabelied W box probe was competed out by the
presence of unlabelled X box oligonucleotide in the preincubation mixture as
described. The result of such an assay employing nuclear extracts from cells
which had been treated with IFN-y for 24hr is shown in figure 3.7•.
The factor(s) bound to the W box which gave rise to the least mobile
constitutively bound complex in LS180 and caco 2 and the IFN-y-induced
complex in colo 201 and colo 205 was partially competed out by the presence
of a 50X molar excess of unlabelled X box oligonucleotide. This implied a
degree of cross reactivity for this factor although it was not competed out with
the same readiness that was observed when the W box was used as competitor
versus the W box probe; in that case a 10X molar excess of unlabelled
oligonucleotide was sufficient for near total ablation of binding.
The same results were obtained for those factors from uninduced cells
which bound to the W box probe. Figure 3.8. displays how those factors from
uninduced colo 201 were competed out by both Wand X box oligonucleotides.
Most complexes were competed out by upto 50X molar excess of W box
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oligonucleotide, yet only the most retarded band showed any degree of
association with the X box.
None of the other factors which bound to the W box either before or after
IFN-y-stimulation of cells were competed out by the presence of excess X box
oligonucleotide.
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3.4.3. Discussion
Competition bandshift assays were used to show which complexes
bound to the HLA-DRa.W box probe were specific for that consensus element.
It was determined that 4 out of the 5 observed bands were due to the binding of
complexes specific for the W box.
The cross reactivity of binding of W box-binding factors to the X box
oligonucleotide was also studied. It was shown that although certain factors
which bound to the W box might also be bound to the X box (through similarities
in their migratory properties), only one W-binding factor had the ability to be
partially sequestered by an unlabelled X box oligonucelotide. One W
box-binding protein, termed W-B1 has also been shown to bind to the sequence
within the W box corresponding to the most 5' part of this element (Tsang, et al.,
1990; Cogswell, et al., 1990) which shows a strong inverted homology to the X
box:
Homology between HLA-DRa W box and X box
SRV1f\N2 SRV2f\N
s'ATCTTGTGTCCTGGACCCT3'
3,TAGAACACAGGACCTGGGAs,
III IIII I: II
X: TAG *ACAC * GATCC
3' A 5'
Notes:
The W element is shown as dissected into two Servenius-like sequences, SRVI and
SRV2. The homologous X-box sequence is aligned beneath the W box. Solid lines
between bases represent identical base pairs while dotted lines indicate a conserved base
change.
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3.5. Displacement of factors bound to the X box probe by unlabelled X and
W box oligonucleotides
Similar competition bandshift experiments to those described for
determining W box-binding specificity and cross reactivity were performed
employing the X box probe. As with the W box, the reasons for such
experiments were to determine whether those factors observed binding to the X
box were speciflc for that element and to identify any factors which might also
have the ability to interact with the W box.
3.5.1. Specificity of binding of factors associated with the X box probe
Competition assays were performed in the same manner as that
described for the W box. An example of one such assay employing nuclear
extracts from cells treated for 24hr with IFN-y is shown in figure 3.9. This
shows that most of the factors bound to X box were competed out by a 500X
molar excess of unlabelled X box oligonucleotide. The only band which could
not be competed out was band 1 and it was determined that this band was due
to non-specific binding.
The concentration of competitor required for dissociation of bound
factors was much higher than that required for the dissociation of factors from
the W box probe when competed out by excess W box oligonucleotide: 500X
molar excess X box compared to 10-50X molar excess of the W box (see
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section 3.4.1.). Such an effect was most likely to be due to the strong
association of factors to this probe rather than the binding of factors being
non-specific since the complexes were displaced by excess competitor
eventually.
3.5.2. Cross-reactivity of X box-binding factors with the W box
Cross-competition assays were also performed in which an attempt was
made to compete out X box binding factors with varying molar excesses of the
W box oligonucleotide. The protocol was followed as described employing
nuclear extracts from cells treated with IFN-y for 24hr and W box
oligonucleotide was used in 10-500X molar excess of the X box probe. No
cross-competition was observed under these circumstances. This result
suggested that no factors which bound to the X box could bind to the W box.
However, due to the high affinity with which factors were bound to the X box (as
determined through competition assays), the inability of the W box to displace X
box-binding factors was not unexpected.
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Figure 3.9. Displacement of factors bound to the HLA-DRa X box probe by
the X box oligonucleotide
NP 1
colo 201
2 3 4 5
colo 205
6 7 8 9 10 11 12
A)
A) Bandshift employing nuclear protein extracts from colo 201 and colo 205 which had
been untreated prior to nuclear protein preparation. Ten micrograms of nuclear extracts
were incubated with radiolabelled X box probe and increasing molar excesses of
unlabelled X box oligonucleotide. The relative concentration of competitor employed
was: Lanes 1& 7: Ox; lanes 2 & 8: Ix; lanes 3 & 9: IOx; lanes 4 & 10: SOx; lanes S & 11:
100x; lanes 6 & 12: SOOxmolar excess of the probe. Protein-DNA complexes were
separated from the free probe as described.
Chapter 3 135
Figure 3.9. (contd.)
B) LS180 caco2
NP 1 2 3 4 5 6 7 8 9 10 11 12
B) Bandshift employing nuclear protein extracts from LS] 80 and caco 2 which had been
untreated prior to nuclear protein preparation. Ten micrograms of nuclear extracts were
incubated with radiolabelled X box probe and increasing molar excesses of unlabelled X
box oligonucleotide. The relative concentration of competitor employed was: Lanes 1 &
7: Ox; lanes 2 & 8: Ix; lanes 3 & 9: IOx; lanes 4 & 10: SOx; lanes S & 11: 10Ox; lanes 6 &
12: 500x molar excess of the probe. Protein-DNA complexes were separated from the
free probe as described.
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3.6. Discussion
Experimental limitations
8andshift assays, also known as gel retardation and electromobility shift
assays, proved useful in the detection of DNA binding proteins derived from the
nuclei of human tumour cell lines. This type of technique is best employed for
the detection of DNA binding factors specific for a particular sequence of DNA
where the exact sequence of DNA to which binding occurs is not required.
Detection of binding factors relies on the retarded electrophoretic progress of a
radiolabelled probe through a non-denaturing polyacrylamide gel when
nucleoprotein-DNA complexes are formed during the initial binding reaction.
The binding of proteins with different individual electrophoretic properties
results in a number of bands being retarded compared to the progress of the
free probe. Since non-denaturing polyacrylamide gels are employed to
maintain the nucleoprotein-DNA complexes, proteins are separated according
to their charge and mass. Hence it is inappropriate to assume that more
retarded complexes contain "bigger" protein moieties compared to those
complexes which migrate more freely.
This technique does not distinguish whether retarded bands are due to
the binding of single or multiple protein factors to a particular probe molecule.
As a consequence, it is not valid to assume that complexes with the same
electrophoretic mobility represent the same nucleoprotein-DNA complexes. If it
Chapter3 137
could be assumed that complexes which have the same migratory properties
are due to a single protein, the crudity of the technique could not determine the
exact binding site.
With all of these considerations taken into account, when employed to its
full potential, this type of technique affords a valuable means of analysing the
populations of DNA binding proteins specific for a particular sequence of DNA
under varying conditions. Indeed, for this part of the present investigation,
these techniques, and variations thereof, proved ideal for the assessment of
populations of HLA-DRa Wand X box binding proteins in the cell lines studied.
Association of nuclear factors with the HLA-DRu Wand X boxes.
The HLA-DRa Wand X boxes were studied individually in order to
correlate differences in surface expression of class II MHC antigen with
differences in the binding of nuclear factors from unstimulated and IFN-y treated
cell lines to these consensus sequences. Indeed, specific for both of these
cis-acting regulatory elements, the cell lines studied contained different
populations of nuclear DNA binding proteins. Differences were also observed
in the binding of nuclear factors to the W box probe after treatment of the
HLA-DRa-inducible cell lines colo 201, colo 205 and U373MG with IFN-y.
Similarly for the X box, IFN-y treatment of colo 201 and colo 205 led to changes
in the array of nuclear-localised factors which associated with this probe.
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Other researchers employing similar techniques with lymphoid cell lines
such as Raji and Jurkat, and the epithelial cell line HeLa have described Wand
X box binding complexes. The identities of the factors which were shown to
bind to these probes in the current investigation could not be determined and
these binding activities could not be correlated with previously identified factors.
Chapter 8 discusses the putative roles for the Wand X box-binding factors
described in this study and how these may relate to those transcription factors
already known to associate with the cis-acting sequences in other cell lines.
CHAPTER4
CHAPTER 4: INVESTIGATION OF THE INTERACTION OF NUCLEAR
DNA-BINDING PROTEINS TO THE HLA-DRa PROXIMAL PROMOTER
4.1. Introduction
The HLA-DRcx.proximal promoter region, defined as the 300 to 400 base
pairs immediately prior to the transcriptional start site, was studied in order that
the interaction of DNA-binding proteins with the promoter and with other such
factors could be assessed. An attempt was made to translate the effects
observed regarding the binding of nuclear proteins to the consensus Wand X
box probes (see chapter 3) to the whole promoter region scenario. The
employment of promoter fragments as radiolabelled probes was intended to
enable the "footprinting" of the region described in order that binding sites of
individual transcription factors could be determined (described in chapter 5).
However, such footprinting probes proved to be of greater use in the bandshift
experiments documented in the current chapter.
The primary objective of the experimentation described here was to show
that the "induced" binding of novel factors to the Wand X boxes upon
interferon-y treatment of cells was also reflected at the level of the whole
promoter. The cooperation of factors towards their interaction with the promoter
was assessed by adapting the competition bandshift assay techniques
described in chapter 3.
Chapter" 141
4.1.1. Experimental considerations
Radiolabelled double-stranded DNA fragment probes corresponding to
regions of the proximal promoter were employed in bandshift assays with
nuclear extracts from the cell lines under investigation. The DNA fragments
used for the preparation of probes were derived from a larger 680bp HLA-DRa.
promoter fragment which had been cloned into the Bam HI restriction site in
+
polylinker of the phagemid pBluescript (KS). The probes employed in the
majority of experiments described in this chapter contained the consensus
upstream sequences V, W, X, Y and the TAATA box; the exception being the
DRa.370 probe which lacked the TAATA element. They were end-labelled on
one strand by end-filling the 3' recesses created by restriction endonuclease
digestion with [a._32p] dNTPs in reactions catalysed by AMV reverse
transcriptase as described in section 2.11.2.
Due to the increased lengths of probes compared to the oligonucleotides
employed in other assays, non-specific binding of proteins to the probes was
much greater. This was counteracted by the addition of greater concentrations
of poly (dl-dC):poly (dl-dC) to the incubation mixtures as determined in
preliminary titration experiments. The amount of nuclear extract incorporated
into the binding reactions was also titrated for each probe employed such that
non-specific binding was minimised.
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4.1.2. The HLA-DRa 470 probes
The probe which was most commonly employed for use in this type of
bandshift assay was one which covered 470bp of sequence corresponding to
the proximal promoter and a portion of the 5' untranslated region of the
HLA-DRa gene. The sequence spanned the region of the promoter from
nucleotides -423 to +47 relative to the start of transcription (cap site). Within
this region, the defined consensus upstream sequences of the promoter were
present in their native locations as described (see figure 4.1 below). This
fragment was generated by restriction endonuclease digestion of the larger
HLA-DRa 680 fragment which had been amplified by peR and cloned into the
polylinker of pBS (KSt, Excision of the fragment was always performed in
preparation for and during the radiolabelling of probes as described in section
2.11.2. The order in which the restriction enzymes (Nco I and Spe I) were
employed was dependent on whether the resultant probe was to be labelled on
the coding or non-coding strand.
Figure 4.1. The HLA-DRa 470 fragment
-423
5'LWOGjg
Nco I
•• IN I:~lm ~5'
v w xx, Y T
Notes:
The figure is a schematic representation of the HLA-DRa 470 base pair promoter
fragment employed in bandshift and footprinting assays following radioactive labelling
with [a._uP] nucleoside triphosphates. The consensus upstream sequences of the
promoter are indicated by shaded boxes, their respective names are indicated beneath; the
TAATA box is referred to by "T". The scale is shown by numbered nucleotides. The
restriction endonucleases employed to generate this fragment and the nucleotide
sequences of the respective recognition sites are shown. The site of the start of
transcription is shown by an arrow.
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4.1.3. The HLA-DRcx 370 probe
Occasionally, a truncated promoter fragment probe was employed in
bandshift assays. This probe, termed HLA-DRa 370, was derived from the
plasmid pBS (KStDRa582 and was the same as the HLA-DRa 470 probe
except that the 3' most 100 base pairs had been removed by peR prior to its
cloning into the vector. The resulting fragment probe corresponded to the
region of the promoter from bases -423 to -53 (relative to the cap site) and
contained all the upstream consensus elements of the HLA-DRa promoter
except the TATA box. The use of this probe in assays was intended to aid the
clarification of any bandshifts where there may have been confusion due the
presence of TATA box-binding factors. A schematic representation of the
HLA-DRa 370 probe is shown in figure 4.2.
Figure 4.2. The HLA-DRa 370 fragment
-423
5'~g
Nco I
-200 -so
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•• lllil~5'
v w x x, y
Notes:
The figure is a schematic representation of the truncated HLA-DRa 370 base pair
promoter fragment employed in band shift and footprinting assays following radioactive
labelling with [a_31P] nucleoside triphosphates. The consensus upstream sequences of the
promoter are indicated by shaded boxes, their respective names are indicated beneath ..
The scale is shown by numbered nucleotides. The restriction endonucleases employed to
generate this fragment and the nucleotide sequences of the respective recognition sites are
shown.
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4.2. Binding of nuclear factors to the HLA-DRa 470 probe
4.2.1. Constitutive binding of nuclear proteins
The presence of constitutive HLA-ORa promoter-binding factors in the
nuclear extracts of the colorectal cell lines colo 205, LS180 and caco 2 was
assessed by bandshift assay employing the 470bp probe. The number of cell
lines chosen was restricted because of the intensive and time consuming nature
of this experimentation. The colorectal tumour cell line colo 201 was excluded
due to its similar properties to colo 205. U373MG were excluded due to the
repeated low concentrations of nuclear extracts obtained during protein
preparations.
The constitutive binding of factors to this promoter fragment was defined
as that which was observed with nuclear extracts from cells which had been
untreated with cytokines. Figure 4.3. shows the result of a bandshift
experiment where nuclear extracts from unstimulated cells were incubated with
the radiolabelled ORa 470 probe.
The binding of factors to individual upstream consensus elements was
competed out by the incorporation of excesses of oligonucleotides
corresponding to the W, X and Y boxes in a "pair-wise" manner such that Y & X,
W & Y, and X & W box binding factors were competed out sequentially. In such
a system, addition of excesses of both X and Y box oligonucleotides to the
binding reaction mixture would not permit association of X or Y box-specific
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factors to the probe, but binding of proteins to the W box (and other promoter
elements) could occur. By employing all combinations of competitor
oligonucleotides, complexes observed binding to the promoter probe could be
attributed sequentially to the individual sequence elements.
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i) Binding of nuclear factors from untreated colo 205
Nuclear extracts from unstimulated colo 205s provided three major
complexes which bound to this probe (see figure 4.3.). In the absence of
competitor oligonucleotides, the majority of binding was observed as two
retarded complexes which migrated with slow mobility compared to the free
probe.
The complex which gave rise to the most retarded band was effectively
competed out by the presence of excess X box oligonucleotide. When the W
and Y box oligonucleotides were present in excess, this band was present with
the same intensity as observed where no competitor was present. Such
evidence was indicative that this factor was bound specifically to the X box.
When the binding of complexes to this probe was competed out by the
combined excess of X and Y box oligonucleotides, the most retarded band
observed in the absence of competitor was resolved as being attributed to the
binding of more than one protein factor. This was manifested as the resolution
of a W box binding factor which was obscured prior to the removal of other
complexes by competition with X and Y box oligonucleotides.
The band described as band 2 was present regardless of incorporation
of competitor, however, its appearance was most abundant where the Wand Y
box oligonucleotides had been included in the binding reaction mixture. The
least retarded band which was attributed to the binding of a nuclear protein(s)
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(band 1) was not competed out by any of the combinations of oligonucleotides
employed in this assay. It was also observed with the same intensity regardless
of this treatment. Such a result led to the assumption that this band was not
caused by the binding of a protein(s) to the probe in the location of the W, X or
Y boxes or a consensus element with sequence homology to these sequences.
ii) Binding of nuclear factors from untreated LS180
With nuclear extracts from unstimulated LS180, the binding of factors to
this probe was different to that observed with the colo 205 extracts. Figure 4.4.
shows the result of one such bandshift. Firstly, the most retarded band
observed with the colo 205 nuclear proteins was only faintly visible in this case
and here it was resolved into its two components. Also, the least retarded band
(band 1) was similarly only faintly present in this situation. A novel binding
factor was also observed with these nuclear extracts. This gave rise to a faint
band which migrated slightly faster than "band 2" in colo 205.
Upon the incorporation of the combined competitors into the binding
reaction mixture, band 1 was observed with greater intensity. The binding of
other complexes from the LS180 extracts to this probe was unaltered by the
presence of competitor oligonucleotides.
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iii) Binding of nuclear factors from untreated caco 2
Nuclear extracts from unstimulated caco 2 contained HLA-DRa.
promoter-binding proteins which resulted in the observation of three gel
retardation complexes with the 470bp probe (refer to fig. 4.5.). The complexes
observed were the same as the three most retarded complexes binding to this
probe from unstimulated colo 205. However, association of proteins in the
formation of the slowest migrating complex was much less than observed with
colo 205 nuclear extracts and its presence was as a minor complex. This was
the opposite to with colo 205 where this protein's rOle in the in the formation of
nucleoprotein complexes with the HLA-DRa.470 probe was a major one.
The slowest migrating band was effectively competed out by the addition
of excess W, X and Y box oligonucleotide indicating either a weak or
non-specific association of this factor with the probe. The corresponding band
observed with colo 205 nuclear extracts was shown to be due to the specific
interaction of a factor(s) with the X box region of the promoter. It was therefore
unlikely that the same band observed with caco 2 extracts was due to the
non-specific association of a factor with the promoter, rather, its binding was
specific to the X box region but the association was a weak one which allowed
its displacement from the probe by X box-related sequences.
Another difference observed between the binding of nuclear proteins
from caco 2 and those from other cell lines was the absence of the fast
migrating complex termed "band 1"with colo 205 and LS180. This complex was
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not observed in extracts from unstimulated caco 2 and its presence was not
altered by the incorporation of competitor oligonucleotides - a phenomenon
encountered when nuclear extracts from LS180were employed under the same
circumstances.
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Figure 4.3. Binding of unstimulated colo 205 nuclear proteins to the
HLA-DRa 470 probe
ccmpetltoree o x+yw+xw+y
NP 1 2 3 4
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2
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Bandshift employing nuclear extracts from unstimulated colo 205 and the ID..,A-DRa.470
probe. Ten micrograms of nuclear extract were incubated with probe (and competitor
oligonucleotides) for 1hr on ice before electrophoresis through 5% (w/v) non-denaturing
polyacrylamide for Shr. Competitor oligonucleotides were those corresponding to the
ID..,A-DRa. W, X and Y boxes, they were added in a pair-wise manner such that their
incorporation would reveal the net binding of proteins at one site (for example, W + Y
box competition would reveal the net binding at the X box, refer to text).
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Figure 4.4. Binding of unstimulated L5180 nuclear proteins to the
HLA-DRa 470 probe
competitoree o x+yw+xw+y
4
,3
2
1
F
Bandshift employing nuclear extracts from unstimulated LSl80 and the HLA-DRa.470
probe. Ten micrograms of nuclear extract were incubated with probe (and competitor
oligonucleotides) for lhr on ice before electrophoresis through 5% (w/v) non-denaturing
polyacrylamide for 5hr. Competitor oligonucleotides were those corresponding to the
HLA-DRa. W, X and Y boxes, they were added in a pair-wise manner such that their
incorporation would reveal the net binding of proteins at one site (for example, W + Y
box competition would reveal the net binding at the X box, refer to text).
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Figure 4.5. Binding of unstimulated and IFN-y-stimulated caco 2 nuclear
proteins to the HLA-DRa 470 probe
competitor=>
1 2 3 4
o x+y w+x w+y 0 x+y w+x w+y
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Bandshift employing nuclear extracts from unstimulated and IFN-y-stimulated caco 2 and
the HLA-DRa470 probe. Ten micrograms of nuclear extract were incubated with probe
(and competitor oligonucleotides) for lhr on ice before electrophoresis through 5% (w/v)
non-denaturing polyacrylamide for Shr. Competitor oligonucleotides were those
corresponding to the HLA-DRa W, X and Y boxes, they were added in a pair-wise
manner such that their incorporation would reveal the net binding of proteins at one site
(for example, W + Y box competition would reveal the net binding at the X box, refer to
text). Lanes 1-4: untreated nuclear extracts; lanes 5-8: lanes from caco 2 treated with
IFN-y (1000U/ml) for 24hr.
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4.2.2. Binding of nuclear factors to the HLA-DRa 470 probe after
interferon-y-treatment of cells
Cells were treated with 1000U/ml recombinant human IFN-y for 6 and
24hr and nuclear extracts prepared as described. Seven to fifteen micrograms
of extract was employed in each bandshift assay. In the same manner to that
described for the constitutive binding of factors to the HLA-DRa 470 probe,
competitor oligonucleotides corresponding to the consensus upstream
sequences W, X and Y were incorporated in a pair-wise manner into selected
reactions. The binding reactions for untreated and IFN-y stimulated nuclear
extracts were performed at the same time with the aliquots of extracts prepared
from cells grown and harvested Simultaneously in order that differences and
similarities in binding could be assessed. The result of assays employing
nuclear extracts from IFN-y-treated cells is shown in Figures 4.6.-4.7.
i) Binding of nuclear factors from IFN-"ttreated colo 205
Treatment of this cell line with 1OOOU/ml IFN-y for 6hr prior to harvesting
and extraction of nuclear proteins revealed the increased overall binding of
protein factor(s) to this probe (see figure 4.6a). This was manifested in the
reduced mobility of the slowest migrating complex observed prior to IFN-y
treatment. In the study of constitutively bound HLA-DRa promoter binding
factors, it was determined, by competition studies, that this band was due to the
binding of ubiquitous complexes to the Wand X boxes. It was therefore
determined that the increased binding observed after 6hr IFN-y treatment was
due to increased interaction at the WIX box domain of the promoter or with
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other proteins already associated with the promoter at these sites. It was
concluded that the reduced mobility IFN-y-induced binding moiety was due to
increased association with factors already bound at these locations due to the
reduced intensity of the WIX band in proportion to the appearance of the novel
band.
The treatment of colo 205 cells with 1000U/m11FN-yfor 24hr prior to their
harvesting and extraction of nuclear proteins led to a different pattern of binding
of complexes to the HLA-DRa.470 probe compared to the unstimulated controls
with the result that net binding of proteins was reduced (see figure 4.6.b). This
was manifested in the association of complexes with the probe resulting in one
major band corresponding to the second most retarded band observed with
extracts from unstimulated colo 205s. A diffuse band which migrated marginally
faster than this band was also observed.
Stimulation of cells with IFN-y for 24hr also resulted in the loss of binding
of the factor contained in colo 205 extracts which migrated with fastest mobility.
No differences were observed upon incorporation of competitor
oligonucleotides into the binding reaction mixtures although the intensity of the
most retarded band was increased upon competing out Wand Y box-binding
factors.
Chapter" 155
ii) Binding of nuclear factors from IFN-r-treated LS180.
Prior to the incorporation of competitor oligonucleotides into the reaction
mixture, the nuclear extracts from IFN-y-stimulated LS180 contained factors
which bound to the HLA-DRa. 470 probe resulting in the appearance of one
major band (refer to figure 4.7.). This band had the same mobility as that band
which was observed after binding of IFN-y-stimulated colo 205 nuclear extracts.
When the W, X and Y box-binding factors were competed-out in the
pair-wise manner described, the fastest migrating band which was observed
with extracts from unstimulated colo 205 and LS180 (but not with
IFN-y-stimulated colo 205) also became apparent. This band was as abundant
as the slower migrating complex observed prior to competitor incorporation and
did not appear to be due to the specific association of a protein factor with any
of the consensus elements W, X or Y. Such a conclusion was made due to the
fact that band intensity did not change with the addition of any combination of
competitor oligonucleotides.
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iii) Binding of nuclear factors from IFN-y-treated caco 2
There was no net difference in binding observed when caco 2 were
treated with IFN-y. Complexes bound to the probe to yield two major bands
which corresponded to bands 1 and 2 in figure 4.5. When the competitor
oligonucleotides were added as described, the result was the near total
disappearance of band 1 and a high degree of dissociation of factors causing
the observed band 2 {see figure 4.5.}.
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Figure 4.6. Binding of IFN-y-stimulated colo 205 nuclear factors to the
HLA-DRa 470 probe
A)
IFN~
NP 1 2 3 4 5 6
+
F
Bandshift with increasing concentrations of colo 205 nuclear extracts binding to the
lll.A-DRa470 probe. Five to fifteen micrograms of nuclear extract was incubated with
probe on ice and nucleoprotein-DNA complexes separated from free probe by
electrophoresis as described. Lanes 1 & 4: 5!lg; lanes 2 & 5: lOug; lanes 3 & 6: l Sug
nuclear protein extracts. Nuclear proteins used in lanes 4 to 6 were prepared from cells
which had been treated with IFN-y (IOOOU/ml)for 6hr.
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Figure 4.6. (contd.)
B) cornpetltoree o x+y w+x w+y 0 x+y w+x w+y
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B) Bandshift employing nuclear extracts from unstimulated and IFN-y-stimulated
colo 205 and the :m..,A-DRa470 probe. Ten micrograms of nuclear extract were
incubated with probe (and competitor oligonucleotides) for 1hr on ice before
electrophoresis through 5% (w/v) non-denaturing polyacrylamide for Shr. Competitor
oligonucleotides were those corresponding to the :m..,A-DRa W, X and Y boxes, they
were added in a pair-wise manner such that their incorporation would reveal the net
binding of proteins at one site (for example, W + Y box competition would reveal the net
binding at the X box, refer to text). Lanes 1-4: untreated nuclear extracts; lanes 5-8:
nuclear extracts from cells treated with IFN-y (1000U/ml) for 24hr.
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Figure 4.7. Binding of IFN-y-stimulatedL5180 nuclear factors to the
HLA-DRa 470 probe
competitoree o x+y w+x w+y 0 x+y w+x w+y
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Bandshift employing nuclear extracts from unstimulated and IFN-y-stimulated LS180 and
the HLA-DRa.470 probe. Ten micrograms of nuclear extract were incubated with probe
(and competitor oligonucleotides) for lhr on ice before electrophoresis through 5% (w/v)
non-denaturing polyacrylamide for 5hr. Competitor oligonucleotides were those
corresponding to the lll.,A-DRa W, X and Y boxes, they were added in a pair-wise
manner such that their incorporation would reveal the net binding of proteins at one site
(for example, W + Y box competition would reveal the net binding at the X box, refer to
text). Lanes 1-4: untreated nuclear extracts; lanes 5-8: nuclear extracts from cells treated
with IFN-y (lOOOU/rnl) for 24hr.
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4.2.3. Binding of nuclear factors from untreated and IFN-y-stimulated
colo 205 to the truncated HLA-DRa 370 promoter probe
A study of the binding of nuclear factors from untreated and
IFN-y-stimulated colo 205 to the 3'-truncated HLA-DRa 370 probe was
performed in an attempt to clarify those data obtained with the HLA-DRa 470
probe. It was possible that the bandshifts obtained using the 470 base pair
promoter fragment probe showed the binding of factors to the TAATA box
region of the probe and that these complexes were complicating the
interpretation of the data. The removal of the TAATA box region of the probe
was devised to determine if any of those anon-specific" factors bound to the 470
base pair probe were TAATA-associated.
Since those factors which bound to the HLA-DRa 470 probe - but not
competed out by the consensus W, X and Y oligonucleotides - were ubiquitous
between the cell lines studied, the HLA-DRa 370 probe was only studied with
nuclear extracts from colo 205. It was assumed that the results of such
experiments would be mirrored with nuclear proteins from the other cell lines so
that repeated experiments employing limited stocks of these nuclear extracts
were avoided.
The result of a bandshift employing this probe and untreatedllFN-y
stimulated colo 205 nuclear extracts is shown in figure 4.8. This result is the
same as those others observed under the same conditions with the longer
probe. This confirmed that the "non-specific" factors which bound to the
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HLA-DRa. 470 promoter probe were not associated with the region downstream
from the Y box.
Figure 4.8. Binding of nuclear factors from unstimulated and IFN-y-treated
colo 205 to the HLA-DRa 370 probe
competitor=> o x+y w+x w+y 0 x+y w+x w+y
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Bandshift employing nuclear extracts from unstimulated and IFN-y-stimulated colo 205
and the IllA-DRa.370 probe. Ten micrograms of nuclear extract were incubated with
probe (and competitor oligonucleotides) for 1hr on ice before electrophoresis through 5%
(w/v) non-denaturing polyacrylamide for 5hr. Competitor oligonucleotides were those
corresponding to the IllA-DRa. W, X and Y boxes, they were added in a pair-wise
manner such that their incorporation would reveal the net binding of proteins at one site
(for example, W + Y box competition would reveal the net binding at the X box, refer to
text). Lanes 1-4: untreated nuclear extracts; lanes 5-8: nuclear extracts from cells treated
with IFN-y (lOOOU/ml) for 24hr.
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4.3. Discussion
The bandshift experiments described in this chapter were of use in
furthering the understanding of the interaction of DNA binding proteins with the
HLA-DRa promoter.
As discussed in chapter 3, there were limitations with this technique
which meant that a clear and definitive picture of the association of nuclear
factors with the promoter fragment probes employed was not attainable. That is
to say, the actual nucleotides with which binding factors were associated could
not be identified with this type of assay. However, it was possible to determine
whether each of the cell lines employed possessed nuclear factors which had
the capability of binding to the HLA-DRa proximal promoter. The use of the
promoter fragment probe also gave an indication of the dependency of
factor-binding upon the presence of other cis-acting elements and the proteins
which they bound.
It was noted that the results obtained from bandshift assays with the
HLA-DRa promoter fragment probe indicated a somewhat simplified association
of transcription factors compared to what might have been expected from those
assays employing oliqonuclsotide probes. If the binding patterns from
oligonucleotides were simply additive when resolved in the whole promoter
situation, then it might be expected that twelve or more bands would appear
with a promoter fragment probe. This was not the observation and it was
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perhaps the case that the bands obtained with the promoter fragment probe
were due to series of alternative binding "combinations" of those factors which
associated with the probe. For example, slowly migrating complexes could
have been due three or more proteins being bound, and high-mobility bands
could have been attributed to single proteins associating with the probe. Such
speculation cannot explain fully why the bandshifts discussed in this chapter
seemed simple.
The putative roles for the interaction of DNA binding proteins with the
HLA-DRa.promoter probes are discussed in Chapter 8.
CHAPTERS
CHAPTER 5: LOCALISATION OF BINDING SITES OF TRANSCRIPTION
FACTORS BY DNASE I FOOTPRINTING OF THE HLA-DRa 470 PROBE
5.1. Introduction
5.1.1. General comments
The clarification of the data obtained from the bandshift assays. such that
individual binding sites of HLA-DRa. promoter-binding proteins could be
determined. formed the next part of these investigations. DNase I footprinting
was employed in a variety of assays in an endeavour to furnish this
requirement.
The cell lines discussed previously were employed in this investigation.
Again. prior to harvesting of cells and extraction of nuclear proteins. they were
treated with IFN-y. or IFN-y and IFN-a.J3concurrently for 24hr. or remained
unstimulated. Costimulation with IFN-a.J3was performed in order to determine
the effects. if any. of this cytokine upon the binding of nuclear proteins to the
HLA-DRa.promoter probe.
5.1.2. Protocol requirements and assay optimisation
The requirements for footprinting were similar to those for bandshift
assays employing fragment DNA probes. but the reactions were "scaled-up"
such that all the probe molecules were "covered" with protein. One hundred to
250~g of concentrated nuclear extracts (approximately 10~g~r1)were incubated
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with fmol amounts of high specific activity radioactive probes to achieve this.
The binding reaction mixture was also optimised in order to allow
maximal binding of the majority of factors which are present in the crude nuclear
protein extracts. The concentrations of divalent metal ions and salt were
altered in accordance with optimal binding activity, The concentration of
DNase I and the digestion conditions were optimised such that, on average, one
incision was made per probe molecule. The most commonly used footprinting
parameters employed in this study are detailed in section 2.11.5.
Important in the interpretation of footprints were the inclusion of controls.
Firstly, "no protein" controls were incorporated into each procedure such that
comparisons could be made between those footprints obtained from the binding
of proteins to the probe with the naked "DNA ladder" obtained from the partial
digestion of probe alone.
In order that any areas of protection observed from the footprints could
be localised within the probe, the chemically sequenced DNA ladder was also
electrophoresed alongside the footprinting reactions. Maxam and Gilbert
sequencing was employed since this method did not require "priming" of the
probe and hence, the probe's length was not altered by the sequencing
procedure. When the sequencing fragments were electrophoresed alongside
those probe fragments obtained from DNase I digestion, the sequence of any
region of the DNase I footprint could be deduced from the associated sequence.
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5.2. DNase I footprinting of the HLA-DRa 470 probe in the presence of
nuclear factors from unstimulated and IFN'"l and IFN'"l + IFN-aP- treated
colo 205, LS180 and caco2
Data from bandshift assays of this probe and the individual consensus
upstream sequences Wand X had revealed a number of differences in the
apparent array of HLA-DRa promoter binding proteins contained within these
cell lines under the stimulus of IFN-y and with the untreated cells. These
differences were obvious between the cell lines, but a marked difference in the
binding (to the oligonucleotide probes Wand X) of nuclear proteins from colo
205 nuclei was also observed after treatment of these cells with IFN-y. The
main objective of this part of the investigation was to determine whether the
location of contact-points of these observed binding moieties were the same for
each of those observed for the individual cell lines. It was also of interest to
determine whether the "footprints" for those binding activities which appeared to
be shared between cell lines and consensus upstream sequences were the
same - indicating that the protein was the same.
It had been argued that the protein(s) giving rise to a binding activity of
the same or similar migratory properties might be active in one cell line yet of no
transcriptional potential in another - differences in the footprint of the
transcription factor might have resulted from this and the hypothesis been
verified.
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The appearance of novel Wand X box-binding activities in the nuclear
extracts from IFN-y treated colo 205 (and colo 201) compared to those cells
which had been untreated, led to the question of whether this/these "induced"
complexes were due to: a) the binding of a novel factor to these sequence
elements; b) the binding of an IFN-y-induced protein 'cofactor' to one or more of
those proteins already bound to the cis-element (without itself associating with
the DNA); c) the modification of a constitutively-bound factor(s) upon stimulation
of the cells with IFN-y. Footprinting techniques may have allowed the
interpretation of the corresponding bandshift data in this respect.
Concurrent with this was the study into the effects of simultaneous
treatment of cells with IFN-y and IFN-a.~. The physiological effects of such
treatment upon the stimulation of MHC class II surface expression is discussed
in Chapters 6 and 7. However, this study was undertaken as a "prequel" and as
a complement to that which is described later.
The result of a footprint assay employing the HLA-DRa 470 probe
(labelled on the coding strand) and nuclear protein extracts from the respective
cell lines before and after cytokine treatment is shown in figure 5.1.
Figure 5.1. The HLA-DRa470 probe labelled on the coding strand was digested by 1U
(Iul) of .bovine pancreas DNase I for 2min at room temperature. Lanes labelled ''NP''
indicate that the probe was digested in the absence of nuclear proteins. Other lanes (a-h):
the probe was digested under the same conditions, but after incubation with 1OOllg of
nuclear protein extracts from the cell lines indicated above the lanes. Cells were
untreated (lanes a, d and f) or treated with 200U/ml IFN-y (lanes b, e and h) or 200U/ml
IFN-y + 500U/ml IFN-af3 (lanes c and g). Regions of protection are indicated at the left
hand side of the figure. Protected regions 1, 2 and 3 were observed constitutively.
whereas that region labelled "IFN-ab" was observed only after the concurrent treatment
of cells with IFN-y and IFN-af3. The sequences of the protected regions were
determined from the Maxam & Gilbert sequence of the same probe and these are
indicated in table 5.1.
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Figure 5.1. DNase I footprint of the HLA-DRa 470 probe in the presence of
nuclear proteins from unstimulated, and IFN-y and IFN-y + IFN-ap treated
colo 205, LS180 and caco 2
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5.2.1. Constitutive and IFN-y-inducedprotection of the HLA-DRa 470 probe
This footprint indicated the binding of complexes to the coding strand of
this probe in the regions of the TAATA box, and the W, X and Yelements. This
binding was not clear and was only evident from the compression of bands
either side of these binding sites. The sequences of these binding sites were
determined from the appropriate Maxam and Gilbert sequence.
Although the locations and nucleotide sequences of these protected
regions were not easily resolved, the results from numerous such footprinting
analyses indicated that binding to this promoter was consistent between the
nuclear extracts of cell lines studied. This indicated that each of the cell lines
studied contained similar populations of ORa promoter-binding proteins prior to
treatment with stimulating cytokines. No clear differences in the binding of
nuclear factors were observed after IFN-y treatment of the cells. The protected
sequences and their respective approximate nucleotide ranges within the
HLA-ORa promoter are shown in table 5.1.
5.2.2. Protection of the HLA-DRa 470 probe by IFN-y + IFN-a~-treated
nuclear extracts
The treatment of cells with IFN-aJ3 for 24hr concurrent with IFN-y
stimulation (both at 200U/ml) resulted in a novel protected region of the coding
strand-labelled HLA-ORa 470 probe (figure 5.1.). This protection was not
observed with unstimulated extracts or with those from cells treated with IFN-y
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alone. No differences in the association of nuclear factors with the HLA-DRa.
470 probe were observed from IFN-a{3-treated cells when the parallel bandshift
assay was performed.
The IFN-a{3-"induced" protected region was of greater size than any
observed with other stimuli and, from sequence data, it spanned the nucleotides
including the X box and those upstream of this towards the W box. Those
sequences protected by proteins in the unstimulated and IFN-y-stimulated
nuclear extracts were also protected by factors within extracts from the
IFN-y+IFN-a{3 costimulated cells. The sequence of nucleotides protected and
their range in the HLA-DRa. promoter is given table 5.1.
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Table 5.1. Summary of complexes observed binding to the coding
strand-labelled HLA-DRa 470 probe
complex 1 complex 2 complex 3 IFN-ap- "induced"
Maxam &
Gilbert GGCGTAC AGCGGTT GTATGTGGGAC AGACCACCCACAGGCGGTT
sequence
nucleotide
range -103- -97 -118--112 -140- -129 -129--112
(approx.)
correspond
-ing GCGTCAT AGATGCGT TGTGTCCTGGACCC AAGAACCCTCCCCTAAGCAGAT
sequence
in ORa
element ID X2 box X box Wbox pyrimidine tract-X box
The sequences of the protein binding sites within the HLA-DRa promoter (determined by
Maxam & Gilbert sequencing of the radiolabelled probe) were compared with the actual
sequence of the promoter. Complexes 1 to 3 were observed in all nuclear extracts
whereas the IFN-a.~-induced factor was only observed when cells had been treated
concurrently with IFN-y and IFN-a~. Difficulties in reading the sequences were taken
into consideration when comparing the experimental data with the published sequences.
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5.3.Discussion
5.3.1. Technical considerations
Footprinting techniques rely on the premise that a protein factor which is
associated with a specific binding site on a length of DNAwill inhibit or alter the
access of reagents to the bases or sugar phosphate backbone of that sequence
(Goodwin, 1990). DNase I fooprinting, therefore, employs an enzymatic
reaction and it is the reaction of DNase I (from bovine pancreas) upon the piece
of DNA of interest which is inhibited sterically by the presence of bound
proteins.
The basis of all footprinting techniques is to generate a nested series of
DNA fragments from an end-labelled probe which is labelled on one strand.
Where proteins have been bound and the fragmentation is inhibited, the area of
protection is translated into a "gap" when the DNA fragments are separated by
electrophoresis and the pattern of resolved bands is visualised. The "gap" is
the footprint. Compression of bands in a footprinting "ladder" is also indicative
of the presence of bound factors.
5.3.2. Practical problems and difficulties with footprint interpretation
Results from several footprinting assays performed under a variety of
assay conditions were disappointing in that protected areas in footprints were
not clearly defined and this led to difficult interpretation of data.
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In many cases, an effect was encountered which led to low molecular
weight probe fragments being lost from footprinting samples prior to their being
separated by polyacrylamide gel electrophoresis. This loss of low molecular
weight probe fragments was a consequence of the purification procedure after
the probe had been digested by DNase. It appeared that such low molecular
weight fragments were harder to release from the phenol-chloroform/aqueous
phase interface in situations where relatively large concentrations of nuclear
extracts had been used. It was assumed that this was the reason for the low
intensity of those fragments towards the lower end of gels rather than
insufficient digestion of probes.
Another complication was encountered in the reading of Maxam and
Gilbert sequences in many of the assays performed; one of the reasons for this
being a different, more efficient recovery system for the chemically fragmented
probe sequences compared to the phenol-chloroform extraction and ethanol
precipitation procedures for those probe fragments produced by enzymatic
digestion. This resulted in greater, more uniform band intensity for the
sequencing reactions which were revealed by autoradiography at a much faster
rate than the low molecular weight footprinting probe fragments.
The relative distances of the binding sites from the labelled end of the
probes employed were also cause for difficulties in the interpretation of
footprinting data. Regions for the binding of nuclear factors were situated from
72 to 220 bp from the labelled end of the "codingDstrand probe. This resulted in
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the majority of binding sites for nuclear factors being in the least resolving part
of the sequencing gel after over Shr electrophoresis under the defined
conditions. Increased lengths of time for electrophoresis were impractical and
did not produce a clearer footprint.
5.3.3. Interpretation and conclusions drawn from footprinting data.
Enzymatic footprinting of the HLA-ORa 470C (coding strand) probe
revealed protected regions corresponding to the X2, X and W boxes when
nuclear extracts from unstimulated and IFN-y-stimulated colo 205 and LS180.
The sequences of the protected regions given in table 5.1. were determined
from Maxam and Gilbert sequences and, for the reasons given in section
5.3.2., were not exact matches with those published. However, it was
determined that the experimental sequences obtained were sufficiently
consistent with published data to allow the identification of the protected
sequences as those declared in table 5.1.
Footprinting data produced no conclusive evidence for the presence of
differences in nuclear factor populations between the inducible and
non-inducible colorectal tumour cell lines. Nor was there any indication that
IFN-y treatment of the cells prior to their harvesting and extraction of nuclear
proteins produced a change in the existing populations of these ORa
promoter-binding proteins.
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These data were in contradiction somewhat to those obtained during the
study of transcription factor-DNA binding interactions through the less fastidious
bandshift assay analyses (see section 4.2.). It was concluded that the
limitations of the footprinting technique employed in this study, and the relative
lack of success therein, led to the revelation of no detectable differences in the
binding of nuclear proteins, derived from the cell lines studied, to the part of the
HLA-DRa promoter of interest here.
The results from footprinting assays may, however, be interpreted in
another manner. It was possible that the patterns of binding revealed in
bandshift studies were the results of protein "cofactors" binding to those
transcription factors ubiquitously associated with the consensus upstream
elements of the HLA-DRa. promoter. Each cell line was hypothesised as
having a different population of these cofactors whose association with
transcription factors would not have been detectable by footprinting. The
models for such hypotheses are discussed in Chapter 8.
In contrast, in the colorectal tumour cell lines colo 205 and LS180
displayed novel protection of the HLA-DRa 470C probe after treatment with
IFN-ap concurrent with IFN-y stimulation. This "induced" factor spanned
approximately 17 base pairs of the promoter (nucleotides -129 to -112)
including the X box and extended to the boundary of the W box.
When the corresponding bandshift assay was performed, no such
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phenomenon was observed and IFN-ap treatment of cells did not result in a
difference in the binding of nuclear proteins. It was possible that the increased
footprint observed was due to the association of factors already bound altering
their contact nucleotides in response to the IFN-aJ3signal.
CHAPTERS
CHAPTER 6: AN INVESTIGATION INTO THE INHIBITORY EFFECTS OF THE
CYTOKINES INTERFERON-aJ\ AND TRANSFORMING GROWTH FACTOR-J\
ON IFN-y-INDUCED REPORTER GENE ACTIVITY DIRECTED BY A
680 BASE PAIR HLA-DRa PROXIMAL PROMOTER FRAGMENT
6.1. Introduction
Reporter gene assays have been used extensively to delineate those
regions of the HLA-DRa promoter which required for tissue specific and/or
cytokine induced class II MHC expression in vitro. Such studies had shown that
IFN-y-induced and tissue-specific HLA-DRa expression required all three of the
upstream consensus sequences W, X and Y - deletion or mutation of anyone
would obliterate the ability of cells to drive transcription from the altered
promoter. However, no study has established an IFN-y response element within
this promoter either through reporter gene assays or DNA binding protein
analyses.
The inhibitory effects of the cytokines interferon-af3 (IFN-af3; type I
interferon) (Morris & Tomkins, 1989) and transforming growth factor-f3 (TGF-f3)
(Czarniecki, et al., 1988; Epstein, et al., 1991 & Darley, et al., 1993) on the
IFN-y-induced expression of class II MHC molecules have been reported. The
effects of these inhibitory cytokines on the binding of transcription/repressor
factors to regions of class II promoters and the cis-acting sequences or specific
regions of the promoters to which they might bind have not been identified. A
candidate promoter element for being the mediator of IFN-af3 action was
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identified as being a consensus IFN-af3 response element, identified by
sequence homology, at the distal end of the cloned 680 base pair HLA-DRa
promoter fragment occupying the nucleotides -593 to -565.
In the colorectal carcinoma situation, these two cytokines were of
particular importance because of the evidence for high levels of TGF-f3
production and secretion within tumours. In conjunction with the presence of
tumour infiltrating lymphocytes, the secretion of TGF-f3by tumour cells could not
only down-regulate IFN-y-induced HLA-DRa expression by the tumour cells, but
also suppress the activity of the infiltrating lymphocytes 'Nhose presence might
otherwise allow recognition and removal of the tumour cells.
The objectives of this section of the study into the cytokine-mediated
expression of HLA-DRa were to: a) show that there was an inhibitory effect on
the IFN-y-induced expression by IFN-af3 and/or TGF-f3; b) to attempt to
delineate any sequence element 'Nhich was responsible for such
down-regulation of IFN-y-induced expression.
6.1.1. Objectives, background and experimental considerations
The primary objective was to establish a model for the IFN-y-induced
transcription of HLA-DRa, and from this to determine the effects of IFN-af3and
TGF-f3 upon such induced transcription. To furnish this requirement, reporter
gene assays were employed in which the 680 base pair HLA-DRa proximal
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promoter fragment was used to drive the transcription of the prokaryotic gene
chloramphenicol acetyl transferase (CAT).
The basis of reporter gene assays is the expression of a gene which is
not present normally in the cells of interest whose transcription is modulated by
a heterologous promoter - the promoter being studied. Transcription from
heterologous promoters is detected by an enzymatic reaction which is
indicative of the presence of the reporter gene, in this case CAT. This is a
bacterial enzyme which catalyses the transfer of an acetyl group from acetyl-
coenzyme A to the 3'-hydroxy position of the antibiotic chloramphenicol. The
bonding of the acetyl group to chloramphenicol allows its transport into a
hydrophobic phase.
This reaction system allowed the "direct scintillation" method (Eastman,
1987) for measuring the conversion of chloramphenicol to the acetate. In this
method, the acetyl group of acetyl-CoA is tritiated so that its transfer to the
chloramphenicol would be detected as it entered the solvent phase of a
biphasic reaction consisting of aqueous reactants and scintillation fluid-
containing products.
Such a system affords the means to quantitatively assess the efficiency
of the heterologous promoter when the promoter and reporter genes are
introduced into a cell in the form of an plasmid expression vector. Expression
of the enzyme required for conversion of chloramphenicol to the solvent-phased
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acetate is dependent on promoter efficiency, hence the more "active" a
promoter, the greater the output of radioactive product. Thus, 'Nhere the
promoter structure is altered, or an environmental pressure is introduced (for
example cytokine treatment of cells) such that gene expression is altered, these
changes can be detected by changes in the concentration of the reporter gene
product. Therefore, the supposition employed in all reporter gene assays of the
type described here is the greater the radioactive output, the greater the
promoter activity.
Experimental strategy
The experimental strategy for this study was designed to provide a model
for the inhibitory effects of IFN-a~ and TGF-f3 on the IFN-y-induced transcription
of class II MHC genes in non-lymphoid cells. To enable this, the assay
constituents had to satisfy certain criteria. One of the most critical stages of the
assay was the transfection of the cells with the expression vector:
transfectability of the cells employed and sterile plasmid preparations were
essential for this. The transfection status of each "batch" of cells in an assay
was assessed by their cotransfection with an expression vector for
~-galactosidase, pRSV~gal (see section 2.9). Here, the expression of the
f3-galactosidase gene resulted in the appearance of the functional enzyme in
cytoplasmic preparations of the transfected cells, and the degree of transfection
was indicated by this enzyme's ability to catalyse the chromogenic conversion
of o-nitrophenyl galactoside (o-NPG) to o-nitrophenol (section 2.10.3.). The
inclusion of the f3-galactosidase expression vector into the transfection reaction
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provided an internal control for the transfection procedure as well as providing a
means for the normalisation of assay replicates.
Another criterion which had to be met in the establishment for a model for
the cytokine effects investigated was the chosen cell line's ability to be induced
for the expression of class II MHC (HLA-DRa) and for this expression to be
down-regulated by the actions of IFN-ap and/or TGF-p. The cell lines of choice
were those colorectal tumour cell lines which had been investigated with regard
to their repertoire of HLA-DRa promoter binding proteins described in chapters
3 to 5. Initial experiments with these cell lines proved unsuccessful and it was
decided that the technique should be established with a cell line which was
known to be easily transfectible and which would show an IFN-y-induced
response when transfected with the pDRa680CAT vector. The cell line chosen
was selected by its ability to furnish these requirements on the basis of the
surface HLA-DRa expression determined by fluorescence-activated cell sorting
(FACS) analysis (Darley, et a/., 1993) and its ease of handling during standard
cell culture and calcium phosphate/DNA precipitate transfection.
The cell line selected for the establishment of the reporter gene assay for
cytokine-regulated HLA-DRa expression was the human multiform glioblastoma
cell line U138MG. In previous studies, this cell line had been shown to be class
II MHC negative, yet was inducible for HLA-DRa surface expression by
treatment for 24-48hr with IFN-y. This effect had also been shown to be
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abrogated by the concomitant treatment with IFN-afl or TGF-fl whereas these
effects were not observed with the colorectal tumour cell lines (Darley, et al.,
1993). The employment of this cell line in previous reporter gene assays of this
nature had proved it to be easily manipulated and transfectable with similar
expression vectors (Swingler, PhD thesis, 1992).
Initial CAT assay experiments were directed to the establishment of
optimal conditions for the transfection and subsequent cytokine treatment of the
cell line U138MG.
6.2. Assay optimisation
6.2.1. Conditions and controls for the transfection of cells
The individual criteria responsible for successful cell growth, transfection,
cytokine response and reporter gene output were determined over a series of
CAT assays employing U138MG cells and the vector pDRa680CAT. The
optimised protocol for the transfection of this cell line is detailed in section 2.9.
and cells were prepared for transfection by the method described therein.
Baseline CAT expression from the vector was estimated by the
transfection of one set of replicates within each assay with the promoterless
expression vector pCATbasic while a positive control for CAT expression was
achieved by the transfection of another duplicate culture with the vector
pSV2CAT where expression of the CAT gene was driven by the SV40 late
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promoter. Each set of duplicate cell cultures were transfected with 20~g of the
relevant CAT vector.
They were also each transfected with 1O~gof the vector pRSVtlgal such
that the efficiencies of transfection could be assessed and the amounts of
cytoplasmic extract for each duplicate employed in the final CAT enzyme assay
could be normalised to compensate for differences in this transfection efficiency
should they have been significant.
As described in section 2.9., maximal transfection efficiency was
achieved when cell monolayers were transfected with calcium phosphate/DNA
coprecipitates for 20-24hr at 37°C, although incubation of monolayers with
precipitates for 6hr under the same conditions proved sufficient for efficient
transfection.
6.2.2. Cytokine concentrations and treatment periods
Once the conditions for transfection had been optimised, the transfected
cells could be treated with the cytokines of interest and the effects of such
treatment assessed by the CAT assay. The following data are expressed as
"fold augmentations" where stimulated CAT expression is compared to that from
unstimulated controls. In the first instance, where the optimum stimulating
concentration of IFN-y was determined, the data are expressed after
normalising for the number of cytoplasmic extract "units" and transfection
efficiency in each assay.
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6.2.2.1. Treatment of transfected cells with IFN--y
Initial experiments were designed to establish which concentration of
IFN--y, and the period of treatment, would be sufficient to yield maximal
expression of CAT when activated by the HLA-DRa promoter fragment; i.e. the
saturating dose of IFN-y was established. Since the time period for maximum
surface expression of HLA-D antigens had been established as being 48hr
(Darley, et al., 1993), this stimulation period was employed for treatment with
IFN-y here.
Although it was important to use a concentration of IFN-y which would
stimulate the cells sufficiently, it was of greater priority to establish a stimulating
concentration of IFN-y which was not saturating since this would have affected
the ability of IFN-ap and TGF-p to inhibit (if any inhibition was to be shown) the
induced expression. Therefore, when the optimal concentration of stimulating
IFN-y was established, it was done so in the presence of a range of
concentrations of IFN-ap and TGF-p which showed increasing degrees of
inhibition of the detected CAT expression.
Concentrations of IFN-y from 1-200U/ml were employed to determine the
saturating dose for expression of CAT directed by the HLA-DRa 680 base pair
promoter fragment. Figure 6.1. shows the effects of the treatment of
pDRa680CAT-transfected U138MG with a range of concentrations of IFN-y.
Expression of CAT was determined by the direct scintillation method as
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described and is expressed as fold conversion of chloramphenicol to
chloramphenicol eH]-acetate when the output from IFN-y-treated cytoplasmic
extracts were compared to those of untreated transfected cells. The results,
displayed graphically in figure 6.1., indicated that the stimulating IFN-y
concentration became saturating at 1DU/mldue to the "plateauing" of this curve
at this point.
Figure 6.1. Relative stimulation of DRa680 promoter-driven CAT reporter
gene expression by increasing concentrations of IFN-y in U138MG cells
fold augmentation §
o 0 1 10 100 200
IFN-y concentration (U/ml)
Notes:
Results were obtained from a series of experiments in which U138MG cells were
transfected for 20-24hr with a chloramphenicol acetyl transferase expression vector in
which gene expression was dependent upon the heterologous lfl.,A-DRa.680 promoter
fragment. After transfection, cells were treated for 48hr with the concentrations of
recombinant human IFN-y specified. Cytoplasmic extracts from transfected cells were
assayed for CAT enzyme activity and expression of the CAT gene is expressed above (§)
as the ratio of radioactive counts obtained from IFN-y-treated transfected cells to those
obtained form untreated cells which had been transfected with the same expression
vector. This "fold" increase in expression was normalised depending on the number of
extract "units" per assay.
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6.2.2.2. Treatment of pDRa680CAT-transfected cells with IFN-aJ3
As described in section 6.2.2.1. (above) the concentration of IFN-aJ3
selected to produce a significant inhibition of the IFN-y-induced CAT expression
was done so empirically and was dependent upon the stimulating concentration
of IFN-y.
Initial experiments were conducted to show inhibition of the
IFN-y-stimulated CAT expression where the cells which had been transfected
with pDRa680CAT and stimulated with up to 200U/ml IFN-y. Here "equal"
concentrations, Le. 100-200U/ml, of IFN-a~ 'Here added to the medium above
the monolayers at the same time as IFN-y.
Although slight inhibition of CAT expression by IFN-a~ was observed
under such conditions the level of inhibition was deemed not to be significant
(the mean fold induction fell within 2 SEM of that observed when transfected
cells 'Here treated with IFN-y alone). When expressed as percent augmentation
(mean ± SEM) compared with that for IFN-y stimulation alone, CAT expression
was 86±9% for 10U/mIIFN-y + 100 U/mIIFN-aJ3(n=3) and 90±4% for 100 U/ml
IFN-y + 100 U/ml IFN-aJ3(n=2). These results led to conclusion that although
the same "unit" concentrations of IFN-y and IFN-aJ3were being employed, these
'Here not equimolar amounts and the amount of IFN-y would have been in a
great excess of IFN-aJ3 in molecular terms. This was due to the assay
employed to determine the "bioactive" concentration of the cytokines. The
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Semliki Forest Virus assay was employed as a standard assay to determine the
antiviral potency of interferon preparations. Since IFN-y has poor antiviral
properties compared to IFN-a.P, it was most likely that greater molar
quantities of this cytokine were required to achieve the same degree of antiviral
activity as IFN-y in this assay system. When the two types of interferon
preparations were compared out of the antiviral context, Le. in the regulation of
gene transcription as was the situation here, their potencies were more
comparable and the relative amounts used could not be determined by their
antiviral property-derived specific activity.
Because of the problems in determining the appropriate relative amounts
of IFN-y and IFN-ap for the detection of the latter cytokine's inhibition of the
IFN-y-stimulated CAT expression, it was necessary to "titrate" the cytokines
against each other.
The saturating dose of IFN-y for the expression of CAT driven by the 680
base pair HLA-DRa upstream promoter fragment had been shown to be 10U/ml
for 48hr. At this concentration of stimulating IFN-y, the inhibition exhibited by
the concomitant treatment with 100U/ml IFN-a.pwas evident but not significant.
When stimulation of CAT expression was induced by 1U/ml IFN-y for 48hr and
cells were simultaneously treated with 100U/ml IFN-aP, the observed inhibition
of transcription was greater. Here, the fold increase in CAT expression
observed with 1U/mIIFN-y- and 1OOU/mIIFN-ap-treated transfected cells was
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between 26% and 79% (mean±SEM=47±11%; trimmed mean±SEM=32±2.2%,
n=5) of that observed with 1U/ml IFN.-yalone.
The inhibition observed by the addition of IFN-aJl to the IFN-y-treated
transfected cultures showed an inverse correlation to the degree of
augmentation of CAT expression by treatment of the transfected cells with IFN-y
alone. It appeared therefore, that although a greater degree of IFN-aJl-induced
inhibition was observed when stimulation of CAT expression was achieved with
1U/ml IFN.-y treatment, such a stimulating IFN-y concentration was still
saturating in a number of these assays.
Thus, the results of numerous CAT assays employing the pDRa680CAT
vector in which a range of concentrations of IFN-y were employed to induce
expression of the reporter gene from this promoter showed that IFN-aJ3could be
employed to antagonise this induction. Although the degree of inhibition varied
according to the stimulating concentration of IFN-y, it was found that
augmentation of CAT expression was reduced by the presence of 100U/ml
IFN-aJ3to a mean of 47% of that observed when the pDRa680CAT-transfected
cells were treated with 1U/mIIFN-y alone. The results of these experiments are
shown graphically in figure 6.2.
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6.2.2.3. Treatment of pDRaCAT680-transfected cells with TGF-P
A similar experimental strategy was employed for the study of the effect
of transforming growth factor f3 (TGF-f3)on the expression of CAT directed by
this 680 base fragment of the HLA-DRa proximal promoter. In this part of the
investigation, the transfected cells were treated with a range of concentrations
of IFN-y from 1-100U/ml and treated simultaneously with 10U/ml recombinant
human TGF-f31 (British Biotechnologies) in accordance with the protocol
described for the investigation of inhibition of surface expression of HLA-D
antigens (Darley, et a/; 1993). The augmentation of CAT expression was
compared to that achieved by the treatment of transfected cells with IFN-y
alone.
Inhibition of the augmentation of CAT expression was observed for all
stimulating IFN-y concentrations. When 1U/ml IFN-ywas used to stimulate CAT
expression and the transfected cells were treated simultaneously with 10U/ml
TGF-f3, the mean fold increase in CAT expression over pCATbasic was
1.94±O.33(mean ± SEM; n=3) compared to 7.7±2.92 in the absence of TGF-f3.
The percentage augmentation of CAT activity ranged from 19 to 37% (27±S.2%,
n=3) of that observed when transfected cells were treated with 1U/ml IFN-y
alone. Upon treatment of the transfected cells concomitantly with 10U/mIIFN-y
and 10U/ml TGF-f3, the mean fold increase in CAT expression was 10.68±3.3
compared to 13.S7±3.1 when the transfected cells were treated with 10U/ml
IFN-yalone. It appeared, therefore, that although inhibition of CAT expression
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was observed under these conditions (percentage augmentations ranging from
70% to 86%), such inhibition was not significant. The results of these assays
are portrayed graphically in figure 6.3.
Figure 6.2. Relative augmentation of CAT activity by IFN-y in the presence
of IFN-aJl
mean fold augmentation (%) §
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Notes:
The CAT reporter gene system was employed to assess the ability of the HLA-DRa 680
base pair promoter fragment to drive expression of chloramphenicol acetyl transferase in
the glioblastoma ceU line U138MG.
§: Augmentation of CAT expression is expressed as the mean number of radioactive
counts obtained from cytokine-induced CAT enzyme activity divided by the mean
radioactive counts due to basal expression of the enzyme from the transfected plasmid
pDRa680CAT. Gene expression was augmented by 1, 10 and 100U/ml IFN-y and was
inhibited by the simultaneous treatment ofpDRa680CAT-transfected ceUs with 100U/ml
IFN-afl· Although the absolute values for the fold increase in CAT expression were
different for each stimulating IFN-y concentration, that observed with IFN-y alone was
expressed as 100% in each case (empty). The mean (± SEM) "fold" augmentation for
costimulation of cells with IFN-y and IFN-afl is expressed as a percentage of that
observed with the appropriate IFN-y treatment alone (filled).
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Figure 6.3. Relative augmentation of CAT activity by IFN-y in the presence
ofTGF-~
mean fold augmentation (%) §
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Notes:
The CAT reporter gene system was employed to assess the ability of the fll..A-DRa 680
base pair promoter fragment to drive expression of chloramphenicol acetyl transferase in
the glioblastoma cell line U138MG.
§: Augmentation of CAT expression is expressed as the mean number of radioactive
counts obtained from cytokine-induced CAT enzyme activity divided by the mean
radioactive counts due to basal expression of the enzyme. Gene expression was
augmented by 1 or 10U/ml IFN-y and was inhibited by the simultaneous treatment of
pDRaCAT-transfected cells with 10U/ml TGF-~ - concentrations of the cytokines
employed in each treatment are indicated in brackets. The mean (±SEM) ''fold''
augmentation for each of the respective cytokine treatments is indicated as a percentage
within the histogram (stimulation with IFN-y alone is shown as 100% regardless of
concentration).
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6.3. Reporter gene assays with pDRa680CAT
in colorectal tumour cell lines
6.3.1. Introduction
The establishment of the CAT assay technique in the glioblastoma cell
line U138MG led to the progression of the study in the colorectal tumour cell
lines which had been investigated previously. Here, the binding of nuclear
proteins from untreated or IFN-y-stimulated cells were employed in
electrophoretic binding assays and differences in the binding of nuclear factors
from different cell lines under different stimuli were related to their ability to be
induced for class II MHG expression at their surface. The reporter gene assays
described below were devised to relate such transcription factor binding to
transcriptional function of the HLA-DRa. promoter in the human colorectal cell
lines studied.
6.3.1.1. Effects of interferon-y treatment upon cell surface expression of class II
MHC in human colorectal tumour cell lines
The colorectal tumour cell lines investigated in this study had been
selected from a larger panel of candidate cell lines because of differences in
their abilities to respond to IFN-y with respect to surface expression of MHG
class II antigens. The use of fluorescence activated cell sorting (FAGS)
techniques in which the surfaces of cells were stained with specific fluorescent
antibodies to HLA-D allowed this identification (Darley, et aI, (1993». Of the
colorectal cell lines already studied two, LS180 and caco 2, had been selected
because of their inability to express class II MHC antigens after treatment with
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IFN-y, while colo 205 had been used for the converse reason. None of these
cell lines expressed class II MHC antigens constitutively. Due to its relative
ease of handling and its inducibility for class II MHC, a fourth colorectal cell line,
HT29, was introduced for this investigation. In the investigation described by
Darley, et ai, (1993), this cell line was also shown to display no constitutive
class II MHC surface antigens, but were strongly induced by treatment with
IFN-y. In contrast to colo 205, however, HT29 is a cell line which grows as a
monolayer and this proved desirable for the type of experimentation undertaken
here.
6.3.1.2. The effects of IFN-ap and TGF-p on IFN-y-induced expression of class
II MHC antigens by colorectal tumour cell lines.
The analysis of the colorectal cell lines employed in this study as regards
their expression of class II MHC antigens at the cell surface in response to
IFN-y also established their respective responses to TGF-p. Darley, et et,
(1993) described the growth-inhibitory and MHC class II down-regulatory
properties of TGF-p in a panel of cell lines and these data were of use when the
cell lines to be employed in this investigation were chosen. It was shown that
none of the colorectal cell lines displayed TGF-p-related inhibition of
IFN-y-induced MHC class II antigen expression and colo 205 and LS180 were
growth-inhibited by TGFp while HT29 showed no response in this regard. On
the other hand, U138MG, the glioblastoma cell line employed in initial parts of
reporter gene studies, had its growth stimulated by treatment with TGF-p and
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IFN-y-induced surface expression of class II MHC antigens was also
down-regulated. Hence, it was not expected that reporter gene assays
employing pDRa680CAT-transfected colorectal tumour cells would show any
response to TGF-p treatment and only colo 205 and HT29 were expected to
display induction of IFN-y-induced CAT expression.
No data for the inhibitory effects of IFN-aP on IFN-y-induced HLA-DR
antigen expression were provided by the study mentioned above, however, this
cytokine's inhibitory properties upon the expression of class II MHC expression
have been well documented (Morris, and Tomkins, 1989; Ling, et et.
1985). Since IFN-ap had already been shown to antagonise the IFN-y-induced
expression of pDRa.680CAT in U138MG, it was assumed that the same
methodology could reveal any similar effects, should they occur. in the
colorectal cell lines chosen. The same reasoning was true for the potential
effects of TGF-p treatment of cells concurrent with IFN-ystimulation.
6.3.1.3. Other considerations with the employment of non-inducible cell lines
The inability of cells to be induced for class II MHC expression has been
the subject of many studies into the transcriptional aspects of regulation of class
II genes. A number of these studies. particularly in the case of class II-deficient
combined immunodeficiency (CID) have concentrated on the accessibility of
class II promoters to transcription factors and have postulated that cell types
which should be able to be induced by IFN-y for class II MHC expression are
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unable to because of this. This "inaccessibility" of promoters within this MHC
locus may be due to promoter configuration (perhaps due to chromatin
structure) and is secondary to a defective class II promoter factor whose role it
is to organise these promoters into an accessible configuration (Kara and
Glimcher, 1993). In the situation of some of the colorectal tumour cell lines
studied here, it was possible that class II uninducibility was a result of a similar
defect in promoter accessibility rather than a deficiency in a transcription factor
responsible for IFN-y-induced HLA-DRa expression. Because of this, it was a
possibility that a deficiency in a class II promoter organising factor would be
indicated by IFN-y-induced expression of CAT directed by the "naked" HLA-DRa
promoter fragment in this in vitro system.
Hence, the investigation here would provide information regarding the
uninducibility of the cell lines caco 2 and LS180 to express class II MHC in
response to IFN-y stimulation as well as determining whether TGF-JJand IFN-aJJ
could inhibit the IFN-y-induced expression of CAT in the inducible cell lines
col0205 and HT29.
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6.3.2. Interferon-y-induced expression of chloramphenicol acetyl
transferase by pDRa680CAT-transfected colorectal tumour cell lines
A number of CAT assays were performed with each of the colorectal
tumour cell lines in an attempt to establish whether there would be a response
to IFN-y in the context of the reporter gene assay. The results of these
are summarised in figure 6.4. As indicated by this graphic, the effects of IFN-y
treatment on pORa,680CAT-transfected colorectal tumour cells were minimal
compared to those results observed with U138MG although a slight, yet
insignificant increase in CAT expression by the inducible cell lines colo 205 and
HT29. The lack of IFN-y-induction of CAT expression of all colorectal cell lines
was irrespective of transfection efficiency. as assessed directly by
p-galactosidase assay from the transfected vector pRSVp-gal and indirectly by
CAT expression by pSV2CAT-transfected cells. Although the transfection
efficiency of these cells was not as great as that obtained with U138MG,
ranging from 20 to 50% of the transfection levels obtained with the glioblastoma
cell line, CAT expression due to pSV2CAT was seen to be at the same level as
observed in U138MG. These results are incorporated into figure 6.4.
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Figure 6.4. The response of pDRa680CAT-transfected colorectal tumour
cell lines to IFN-y
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Notes:
The human colorectal tumour cell lines LS180, caco 2, colo 205 and HT29 were
employed in a series of CAT assays in which each was transfected with the expression
vector pDRa680CAT or pSV2CAT. Presence of chloramphenicol acetyl transferase in
cytoplasmic extracts was dependent upon promoter activity: "augmentation" of
pDRa680CAT was attempted with up to 100U/ml IFN-y while expression of CAT driven
by the SV40 late promoter was constitutively high and acted as a positive control. In the
histogram, ''DRa'' refers to cells which had been transfected with pDRa680CAT and
treated with 100U/ml IFN-y for 48hr prior to preparation of cytoplasmic extracts and
chloramphenicol acetyl transferase assay; "SV2" refers to cells (within the same assay)
which had been transfected with pSV2CAT and assayed for CAT enzyme activity without
cytokine treatment. "Fold augmentation" was measured by comparing the radioactive
counts from IFN-y-treated pDRa680CAT transfected cells with those which remained
untreated, whereas that for pSV2CAT -transfected cells was measured by comparison of
counts with those cells transfected with the comparable pOCAT vector.
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6.4. Discussion
Reporter gene assays were employed to assess the ability of the 680
base pair HLA-DRa proximal promoter fragment to drive transcription of the
bacterial gene chloramphenicol acetyl transferase (CAT) in a variety of cell
lines.
Reporter gene studies relied on the introduction of plasmid constructs,
based on CAT, into the cells where they were expressed transiently in episomes
(Alam and Cook, 1990), and the resultant mRNA processed and translated into
enzyme product. Cytoplasmic extracts were prepared in which functional
enzyme product was determine. Thus, reporter gene assays do not provide a
direct assessment of transcription from the heterologous promoter, rather a
measurement of gene expression. Although the level of enzyme activity is likely
to be related to steady-state mRNA levels and frequency of transcription
initiation at the promoter, RNA stability post-transcription should be taken into
account. The same is also true for translational efficiency where although the
transcription was efficient, translation into the functional enzyme product did not
occur. These considerations were taken into account when interpreting data
obtained from CAT assays.
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6.4.1. The U138MG human glioblastoma cell line displayed IFN-y-induced
CAT expression driven by the 680 base pair HLA-DRa promoter fragment
6.4.1.1. Summary of results
The results from the CAT assays employing the multiform glioblastoma
cell line U138MG provided a model for roles of the cytokines IFN--y.IFN-aP and
TGF-p in the control of the transcription of class II MHC genes. Over a series of
assays it was shown that IFN--ycould induce the expression of the enzyme
chloramphenicol acetyl transferase when the reporter gene was cloned
downstream of the 680 base pair HLA-DRa proximal promoter fragment in the
expression vector pDRa680CAT. This induced transcription. defined by the
activity of the CAT enzyme product and normalised for transfection efficiencies
and units of cytoplasmic extract employed per assay. ranged from 7.7 to 15.5
fold the basal transcription of the gene when transfected cells were treated with
between 1 and 200U/ml IFN-yfor 48hr (see figure 6.1.).
The stimulating concentration of IFN--yat which augmentation of CAT
expression was maximal was found to be 10U/ml. At this stimulating
concentration of IFN--y.the antagonistic effect of IFN-ap treatment upon CAT
expression was not significant and augmentation of CAT activity was 85% of
that observed with IFN--yalone. However. when stimulation of CAT expression
by transfected U138MG was augmented by 1U/ml IFN--yfor 48hr and the cells
were also treated with 100U/ml IFN-ap. the induction of CAT expression was
reduced to 47%. on average. of that displayed by cells stimulated with IFN--y
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alone (see section 6.2.2.2, and figure 6.2.).
When TGF-p was used in an attempt to antagonise the IFN-y-induced
augmentation of CAT expression, strong inhibition was observed with 10U/ml
TGF-p when 1Ulml IFN-y was used as the stimulating concentration. Under
these conditions the augmentation of CAT expression was reduced to 27% of
that observed with IFN-y alone (see section 6.2.2.3.). When the stimulating
concentration of IFN-y was increased to 1CU/mland TGF-p was also employed
at 10U/ml, the augmentation of CAT expression was 78% of the maximum,
indicating that this IFN-y concentration was saturating. The combined results of
these experiments are shown in table 6.1.
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Table 6.1. Effects of cytokines on chloramphenicol acetyl transferase
augmentation by U138MG transfected with pDRa680CAT
stimulating IFN-y Percentage Augmentation··
concentration" (mean±SD)
IFN-aP, 100U/ml TGF-p,10U/ml
1U/ml 47±28% (32±8%)1 27±9%
10U/ml 86% 78±8%
100U/ml 90% NO
Results were obtained from U138MG cells following transfection with the CAT
expression vector pDRa,680CAT and stimulation with the concentrations of the cytokines
specified. **Percentage augmentation refers to the mean fold increase in radioactive
counts due to chloramphenicol acetyl transferase activity expressed as a percentage of
that which was observed with transfected cells treated with IFN-y alone. *Stimulating
IFN-y concentration refers to the concentration of IFN-y employed to induce CAT
activity in pDRa680CAT-transfected cells. In all cases, cytokine treatment was for 48hr
prior preparation of cytoplasmic extracts and CAT assay. t is the trimmed mean for this
data set. N.D. = not determined
6.4.1.2. Conclusions drawn from CAT assays with U138MG and pORa680CAT
Thus, the results obtained from reporter gene assays employing
pDRa,680CAT-transfectedU138MG glioblastoma cells provided a model for the
inhibition of IFN-y-induced HLA-ORa expression by IFN-a~ and TGF-~. It was
shown that this inhibition was possible with a 680 base pair HLA-DRa promoter
fragment which spanned the nucleotides -640 to +40, relative to the start of
transcription. The assumptions made with reporter gene assays led to the
assumption that observed inhibition was transcriptional. This has been
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supported by other studies with primary astrocytes which have shown that
TGF-rl exhibits an inhibitory effect upon the IFN-y induction of class II MHC
mRNA and surface protein as well as affecting promoter activity (Panek, et al.,
1995).
Other evidence in support of the observations encountered here was
provided in independent studies, both employing the CAT assay reporter gene
system, in Reimold, et al., (1993) and Oevajyothi et al., (1993). The former
investigation studied the inhibition of IFN-y-induced CAT activity by TGF-rl in a
melanoma cell line (Hs294T9(c)) and concluded that this inhibition was exerted
through the W-X1 region of the promoter although there was no evidence for the
interaction of TGF-rl-induced transcription factors within this region. Oevajyothi
et al., (1993) employed CAT reporter gene assays in the astrocytoma cell line
CRT in which a nested series of 5' deletion mutants of the HLA-ORa promoter
from -2.2 kilo bases to -267 bases was cloned into CAT expression vectors.
Again, it was shown that 267 base pairs of upstream sequence was required for
IFN-a.rl and TGF-rl to elicit their inhibitory effects upon IFN-y-induced CAT
activity in this cell line. This study was of particular interest since it was
performed in a cell line of neural origin and the data obtained were considered
to reflect somewhat those obtained here with U138MG. The astrocytoma
cells displayed similar levels of IFN-y-induced augmentation of CAT expression
to U138MG and the inhibition, expressed as a percentage, was 76% for IFN-a.rl
and 60% for TGF-p. These levels of inhibition were greater than those seen in
the present investigation, yet different concentrations and preparations of the
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respective cytokines were employed. Hence, a qualitative parallel was
observed between these two related cell lines.
6.4.2. Reporter gene assays in human colorectal tumour cell lines
Reporter gene assays employing the four human colorectal tumour cell
lines and the vector pDRa680CAT proved to be "unsuccessful" in increasing the
understanding of cytokine-induced HLA-DRa. promoter-driven reporter gene
expression which had been gained by the use of U138MG. Although a number
of assays were performed for each of the cell lines, none displayed any
IFN-r-induced CAT activity when transfected with the pDRa.680CATvector and
treated with a range of IFN-r concentrations for 48hr. This was not unexpected
for the non-inducible cell lines caco 2 and LS180, yet was completely
unexpected for the "inducible" colo 205 and HT29 colorectal tumour cell lines.
The potential for these data to have been erroneous were addressed by
repeated experimentation with several preparations of solutions employed
during transfection and CAT assay as well as with different batches of plasmids.
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6.4.2.1. Transfection efficiencies of colorectal tumour cell lines
It could have been argued that the human calorectal tumour cell lines
employed did not show any CAT activity from the plasmid pDRa680CAT
because they were not transfected efficiently, however evidence obtained from
controls showed that this was not the case here. Internal controls incorporated
into each assay indicated that, although transfection rates were decreased
compared to those observed with U138MG, the cells had been successfully
transfected with pRSVp-gal. The assumption adhered to when employing such
cotransfection protocols was that p-galactosidase activity in cytoplasmic
extracts of cells which had also been transfected with another plasmid (in this
case, pDRa680CAT) would reflect the "transfection status" of those cells for all
the vectors involved. That is to say, the greater the p-galactosidase activity, the
greater the transfection efficiency for that event. It was therefore assumed that
the cell lines employed here had been transfected efficiently with all plasmids
when the p-galactosidase Iisignal"was seen to be significant.
Another piece of evidence to support the efficient transfection of the cells
was the constitutively high expression of chloramphenicol acetyl transferase
due to transfection with pSV2CAT. This was also significant in that it showed
that all of these cell lines had the ability to process CAT transcripts efficiently
and produce the final enzyme product. Thus, the apparent lack of induction of
CAT from the pDRa680CAT vector was unlikely to be due a defect in the cell
lines' transcription/translation machinery with regards to this gene product.
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One other possibility for these cell lines' inability to show induction of
CAT expression from the pDRa680CAT vector was that the vector itself was
damaged or that a poor plasmid preparation was employed for these particular
assays. Each plasmid preparation was assessed for purity by
spectrophotometry at 260 and 280nm and their integrities were assessed by
electrophoresis through 1% agarose (see section 2.8.3.). Also, in many of the
assays employing colorectal tumour cell lines, assays employing U138MG cells,
in which CAT activity from this plasmid was augmented as described, were
performed simultaneously.
Hence, it was assumed that since transfection was efficient, the
colorectal cell lines were able express CAT from the SV40 late promoter and
U138MG were inducible for DRa680-driven CAT expression when transfected
simultaneously, the colorectal tumour cell lines employed here were unable to
exhibit IFN-y-induced CAT expression from pDRa680CAT for reason/s other
than those experimental considerations addressed above.
Although not tested experimentally, the inability of the human colorectal
tumour cell lines to be induced for HLA-DRa680 CAT expression by IFN-y was
most probably explained by the promoter fragment itself. That is to say that the
680 base pair promoter fragment employed in these assays either contained a
tissue-specific repressor or lacked a tissue-specific enhancer element.
Although no published data were available to support this conclusion the
presence of the octamer element within the HLA-DRa promoter, involved in
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B-cell-specific expression, demonstrates that tissue specific enhancer elements
do have a role in the control of this gene's expression.
Because of their inability to display IFN-y-induced CAT expression when
transfected with pDRa680CAT, the colorectal tumour cell lines could not be
assessed for the effects of IFN-a.~ and TGF-~ treatment in this regard.
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CHAPTER 7: AN INVESTIGATION INTO THE INHIBITORY EFFECTS OF THE
CYTOKINES INTERFERON-aP AND TRANSFORMING GROWTH FACTOR-P
ON IFN-y-lNDUCED REPORTER GENE ACTIVITY DIRECTED BY A
320 BASE PAIR HLA-DRa PROXIMAL PROMOTER FRAGMENT
7.1. Introduction
As discussed previously, reporter gene assays have been used to
demonstrate the importance of the consensus upstream sequences in the
control of HLA-DRa expression in a variety of cell types. Chapter 6
demonstrated the ability of a 680 base pair proximal promoter fragment to
mediate the augmentation of CAT expression in human glioblastoma cells
(U138MG) transfected with a CAT plasmid whose expression was driven by this
heterologous promoter after the cells' treatment with IFN-y.
This HLA-DRa promoter fragment was also shown to have the ability to
mediate the IFN-a~ and TGF-~ suppression of IFN-y-induced CAT expression in
this cell line. Although no consensus sequence for the binding of a
TGF-~-induced "repressor" factor was present in the HLA-DRa promoter, a
consensus IFN-ap response element had been identified in the region of the
promoter between the nucleotides -593 to -565 relative to the start of
transcription.
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The following chapter describes how a 5' deletion of the DRa680
fragment was employed to determine whether this sequence was alone
responsible for the antagonistic effects of IFN-a.(3 treatment upon the
IFN-y-induced expression of chloramphenicol acetyl transferase in the
appropriately transfected cells.
7.1.1. The pDRa320CAT expression vector
This reporter gene vector was prepared by the restriction endonuclease
digestion of the plasmids pCAT-basic and pBS(KStDRa680 5'~3' with Xba I.
The resultant DRa320 fragment and the recipient pCAT-basic plasmid were
ligated as described in chapter 2. The 5' deletion of the 680 base pair
HLA-DRa promoter fragment resulted in the excision of the putative IFN-a.p
regulatory element. Transfection of the appropriate cell line with this vector and
subsequent treatment with IFN-y in the presence or absence of IFN-a.(3was
expected to reveal whether the deleted consensus IFN-a.(3 element was
responsible for the IFN-a.p-mediated suppression of IFN-y-induced CAT
expression observed with the vector pDRa680CAT in U138MG cells.
7.1.2. Cell lines and experimental strategy
The cell lines of choice were those derived from human colorectal
tumours such that the binding of nuclear proteins to the HLA-DRa promoter and
to individual sequence elements could be related to transcriptional function.
For the reasons given in chapter 6 regarding the relative technical difficulties in
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handling these cell lines, it was again decided to optimise the assay in a
"proven" cell line.
The human glioblastoma cell line U138MG was again used to establish
the optimal conditions for the study cytokine regulation of HLA-DRa expression
in reporter gene assays. This cell line had proved to be easy to manipulate and
was readily transfectable with plasmid vectors.
The investigation to delineate the regions of the HLA-DRa promoter
responsible for the observed IFN-a13and TGF-13suppression of IFN-y-induced
expression was continued with this cell line in further experiments employing
the deleted HLA-DRa promoter fragment-containing vector pDRa320CAT. Here
the strategy for experimentation was the same as that described for the
pDRa680CAT vector. Initial experiments determined the response of
pDRa320CAT-transfected U138MG to varying concentrations of IFN-y such that
the saturating dose could be determined. Following this titration of IFN-y and
optimisation of transfection, incubation and assay conditions, it was possible to
assess the transfected cells' response to IFN-a13and TGF-13.
The study was then continued in the human colorectal tumour cell lines
colo 205, HT29, LS180 and caco 2. The responsiveness of these cell lines to
the cytokines IFN-y, IFN-n13and TGF-13as regards surface expression of class II
MHC antigens has been described previously (summarised in table 2.1.).
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This investigation was undertaken despite the apparent uninducibility of
these cell lines for CAT expression from the vector pDRa680CAT. It was of
interest to confirm the results obtained here since such data would have
indicated a general inability of these cell lines to express this type of reporter
gene vector. The continued inability to express CAT when driven by the
truncated promoter would have been indicative that a tissue-specific enhancer
)
element was absent. However, had pDR320CAT-transfected colorectal tumour
cell lines expressed CAT, it would be assumed that removal of the 360 base
pair upstream promoter sequence released the cells from a tissue-specific
repressor.
Again, the control vectors pRSV~-gal and pSV2CAT were employed to
assess these cell lines' ability to be transfected and to transcribe and process
CATmRNA.
7.2. Reporter gene assays with U138MG and pDRa320CAT
7.2.1. Conditions for cell culture and transfection
The cell line U138MG was cultured in vitro in complete DMEM under the
conditions described in materials and methods (chapter 2). Passage of the
cultures was performed such that weekly preparations of confluent cells were
available for employment in CAT assays as described in section 2.9.1. Calcium
phosphate-mediated transfection of cell lines with expression and control
vectors was performed as described previously.
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7.2.2. Augmentation of DRa320-mediated CAT expression by IFN-y
The same strategy for the IFN-y-stimulation of pDRa320CAT-transfected
U138MG was employed as that described for those cells transfected with
pDRa680CAT. Cells were stimulated with a range of IFN-y concentrations from
1 to 100U/ml for 48hr post glycerol shock. The response of
pDRa320CAT-transfected U138MG to IFN-y ranged from 4.2 to 6 fold the CAT
expression seen with untreated transfected cells. These responses were
normalised for the number of units of cytoplasmic extracts employed within each
assay. Figure 7.1. is a graphical representation of the IFN-y-induced CAT
expression by pDRa320CAT-transfected U138MG cells.
7.2.2.1 Comparison of IFN-y responses with pDRa320CAT and pDRa680CAT
On average, the IFN-y-stimulation of pDRa320CAT-transfected U138MG
cells yielded a greater expression of CAT than the same treatment of those cells
transiently transfected with pDRa680CAT. This was based on the comparison
of the mean fold increase in CAT expression per unit of cytoplasmic extract for
each of the concentrations of IFN-y stimulation. Although the results did not
appear to be significantly different (the respective mean values fell within 2
SEM of each other), a trend was observed for all of the IFN-y stimulations. For
example, the mean fold increase in CAT expression stimulated by 1U/ml
IFN-y was 4.18±1.44 (mean±SEM) for pDRa320CAT (n=3) compared to
3.2S±O.83for pDRa680CAT (n=4).
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Although these observations were not statistically proven, it appeared
that removal of the upstream-most 360 base pairs of the promoter released
some repression which might have been imposed by this region. This gave a
primary indication that this upstream region of the promoter did indeed contain a
sequence or sequences involved in the down-regulation of HLA-DRa.
expression in this cell line. This comparison between the CAT expression
observed for the two vectors is shown graphically in figure 7.1.
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Figure 7.1. Augmentation of CAT expression by IFN-y in
pDRa320CAT-transfected U138MG cells
fold augmentation
6
7 ,--------------, pDRa320CAT...
pDRa680CAT
-+-
OU----~---~---~o 1 10 100
IFN-'Y concentration (U/ml)
Notes:
CAT assays were employed to assess the IFN-y-mediated gene expression through the
HLA-DRcx. 320 base pair promoter fragment in the U138MG human glioblastoma cell
line. Cells were transfected transiently with the vector pDRcx.320CAT then treated for
48hr with varying concentrations of IFN-y. Gene expression was measured as a function
of CAT enzyme activity in the cytoplasmic extracts of transfected cells. Fold
augmentation was calculated by dividing those radioactive counts obtained from
IFN-y-induced CAT enzyme activity by those obtained untreated transfected cells this
was then normalised to take into account the number of "units" of cytoplasmic extract
used. Fold augmentations for individual IFN-y stimulating concentrations were also
normalised for transfection efficiency from the expression of p-galactosidase.
The comparable data for the IFN-y-stimulated augmentation of CAT expression
from U138MG transfected with pDRcx.680CAT are also shown.
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7.2.3. Suppression of IFN-y-induced CAT expression by IFN~~
The removal of the putative IFN-a.~ consensus element from the
HLA-DRa.promoter in the generation of the pDRa.320CATvector was intended
to determine whether this was the region of the promoter responsible for the
IFN-a.~-mediated suppression of IFN-y-induced HLA-DRa. and pDRa680CAT
expression. A similar strategy as that employed for the investigation of IFN-a.~
suppression of IFN-y-induced CAT expression from pDRa.680CAT was
employed for this study.
This study involved the treatment of transiently transfected U138MG with
IFN-y concurrent with IFN-a.~; results from the study with cells transfected with
pDRa680CAT were utilised to determine initial conditions for this treatment of
the cells with cytokines. The cytokine treatment of U138MG which had been
transfected with pDRa320CAT was performed with 1U/ml IFN-y concurrent with
1OOU/mIIFN-a.~for 48hr post glycerol shock. This treatment achieved a level of
CAT expression whose mean was 84±6% (mean±SEM; n=3) of that observed
with 1U/mIIFN-'}' alone.
It appeared, therefore, that the deletion of the HLA-DRa.promoter in the
construction of this expression vector had resulted in the reduced potency of
IFN-a.~ in the suppression of IFN-y-induced CAT expression. The same
cytokine treatment of pDRa.680CAT transfected U138MG cells resulted CAT
expression being reduced to a mean of 47% of that observed with IFN-y
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treatment alone (see section 6.2.2.2.).
When the pDRa320CAT-transfected cells were stimulated with 1U/ml
IFN-y concurrent with 1000U/ml IFN-a(3,CAT enzyme activity was reduced to
26±10% (mean±SEM; n=3) of that observed in cells stimulated with IFN-y
alone. This result indicated that the removal of the putative IFN-a(3consensus
element was not sufficient to render the promoter completely unresponsive to
the inhibitory effects of this cytokine. The responses of pDRa320CAT-
transfected U138MG to IFN-y and IFN-a(3are represented graphically in figure
7.2.
Figure 7.2. Relative suppression of IFN-y-induced CAT expression by
IFN-a~
relative CAT expression (%)
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Notes:
U138MG cells were transiently transfected with pDRa320CAT and treated with lU/ml
IFN-y alone or with IFN-y (lU/ml) concurrent with IFN-a.(3at 100 or 1000U/ml. CAT
expression is represented as a percentage where the augmentation observed with IFN-y
alone is given as 100% and the CAT expression observed when cells were treated
concurrentlywith IFN-a(3 is expressed as a percentage of this.
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7.2.4. Suppression of 1FN-'Y'"induced CAT expression by TGF-p
As with the investigation into IFN-aP suppression of IFN-y-induced CAT
expression in pDRu320CAT -transfected U138MG, the same strategy for study
of TGF-p-mediated inhibition of expression was employed as with
pDRu680CAT transfected cells. The cytokine concentrations employed for the
stimulation of CAT expression with IFN-y and the consequent inhibition by
TGF-p were 1U/ml and 100U/ml, respectively. Such treatment with TGF-p
resulted in an average augmentation of CAT expression of 55±12%
(mean±SEM) of that observed with IFN-y alone. This level of CAT expression
was approximately double that observed when pDRu680CAT-transfected cells,
where CAT expression was observed at 27±9% (mean±SEM) of the
IFN-y-induced controls (see section 6.2.2.3). The results for this suppression of
IFN-y-induced CAT expression by TGF-p are represented graphically in figure
7.3.
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Figure 7.3. Relative inhibition of IFN-y-inducedCAT expression by TGF-~
relative CAT expression (%)
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Notes:
U138MG cells were transiently transfected with pDRa.320CAT and treated with 1U/ml
IFN-y alone or with IFN-y (lU/ml) concurrent with 100U/ml TGF-f3. CAT expressionis
representedas a percentagewhere the augmentation observedwith IFN-y alone is given
as 100% and the CAT expression observedwhen cells were treated concurrently with
TGF-f3 is expressedasa percentageof this.
7.2.5. Comparison of CAT expression in U138MG transfected with
pDRa320CAT and pDRa680CAT
The human glioblastoma cell line U138MG was employed to assess the
function of the upstream 340 base pair region of the HLA-DRa. promoter with
respect to IFN-a.f3 and TGF-f3-mediated suppression of IFN-y-induced CAT
expression. This region contained a putative IFN-a.f3 response element and its
deletion in the construction of pDRa.320CAT was intended to verify or discount
this element's involvement in IFN-a.f3-mediated down-regulation of
IFN-y-induced expression from the HLA-DRa. promoter. Deletion of this portion
of the upstream promoter was also intended to determine whether any distal
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elements were responsible for cytokine-mediated or constitutive repression of
expression.
Interferon-y-induced CAT expression in U138MG transiently transfected
with pDRa320CAT tended to be greater than that from cells transfected with
pDRa680CAT and treated with the same concentration of IFN-y (see section
8.2.2.1). Although this increase in CAT expression was not statistically proven
(the increase in expression was not significantly different), it was a trend which
was observed for all concentrations of IFN-y stimulation. These results
indicated that removal of the 360 base pair upstream region of the HLA-DRa
promoter also released an inherent repressive cis-acting element which acted
within the upstream part of the promoter.
Concurrent treatment of pDRa320CAT-transfected U138MG cells with
IFN-y and IFN-aJ3at the concentrations of 1U/ml and 100U/ml, respectively was
insufficient to show the inhibition of CAT expression observed previously for
these cytokine concentrations in pDRa680CAT-transfected cells. Under these
conditions, CAT expression was observed at a mean of 84% of that observed
when pDRa320CAT-transfected cells were treated with 1U/ml IFN-y alone,
compared to 47% in cells transfected with pDRa680CAT. It appeared,
therefore, that the putative IFN-aJ3 response element was effective in this
cytokine's involvement in the suppression of gene expression from the
HLA-DRa promoter. The suppression could be reinstated by increasing the
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concentration of IFN-afl to 1000U/ml and under these conditions the CAT
expression was observed to be 26% of that with 1U/ml IFN-y alone. Although,
the upstream promoter region appeared to be involved in the IFN-afl-mediated
suppression of IFN-y-induced gene expression, this suppression was not solely
mediated through this region. Whether the removal of suppression was due to
a specific IFN-afl response element or whether removal of a more general
cis-acting repressor element was responsible could not be determined,
however, the trend towards increased IFN-y-induced CAT expression from the
320 base pair promoter fragment indicated that the latter may be true.
Treatment of pDRa320CAT-transfected U138MG with 1U/ml IFN-y
concurrent with 100U/ml TGF-fl resulted in CAT expression being 55% of that
observed when cells were treated with 1U/ml IFN-y alone. As with the other
cytokine treatments of cells transfected with this vector, this level of CAT
expression was greater than when the same cell line was transfected with
pDRa680CAT and treated with the same cytokines (here the CAT expression
was 27% of maximal). Again, levels of CAT expression were greater with
pDRa320CAT-transfected cells than with cells transiently transfected with
pORa680CAT. This indicated that a general repressor was present in the 360
base pair fragment of the HLA-DRa promoter deleted in the construction of
pDRa320CAT.
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In conclusion, deletion of the 360 base pair upstream promoter region
from pDRa.680CAT in the construction of pDRa320CAT resulted in a CAT
expression vector which was more effective in expression of the reporter gene
CAT after induction of transiently transfected cells with IFN-y. Although the
suppression of CAT expression with 100U/mIIFN-afl appeared to be abolished
- CAT expression was restored to near maximal - when the concentration of
IFN-afl was increased to 1000U/ml, the inhibition was restored. Suppression of
CAT expression by TGF-fl was also reduced with this plasmid. It appeared,
therefore, that removal of the upstream region of the HLA-DRa promoter caused
the removal of a general repressor binding sequence and that, although the
putative IFN-afl response element may have been involved in down-regulation
of CAT expression, it was not the sole element responsible.
These comparative data are represented graphically in figures 7.4 - 7.5.
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Figure 7.4. Comparison of IFN-y and IFN-aJi effects on CAT expression
between pDRa680CAT and pDRa320CAT-transfected U138MG
fold augmentation (%)
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Figure 7.S. Comparison of IFN-y and TGF-Ji effects on CAT expression
between pDRa680CAT and pDRa320CAT-transfected U138MG
fold augmentation (%)
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Notes:
The relative augmentation of CAT from the vectors pDRa320CAT and pDRa680CAT
was compared after stimulation with IFN-y alone or after costimulation of transfected
U138MG with IFN-y and IFN-a~ or with IFN-y and TGF-~. Results are expressed as a
percentage of the fold augmentation observed with IFN-y alone (100%). The lengths of
"IFN-y" bars represent the differences in IFN-y-induced CAT expression observed
between these two vectors.
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7.3. Transfection of human colorectal cell lines with reporter gene vectors
7.3.1. Introduction
Reporter gene assays were employed to explain the effects of IFN-y,
IFN~P and TGF-p upon the surface expression of MHC class II molecules in
the colorectal cell lines colo 205, HT29, LS180 and caco 2. Such experimental
strategy had proved successful in the human glioblastoma cell line U138MG
and the effects of these cytokines upon CAT expression driven by 680 and 320
base pair proximal promoter fragments of the HLA-DRa.gene had been shown
to be affected by deletion of a 360 base pair upstream sequence.
The responses of these cell lines to IFN-y and TGF-p with regard to
surface expression of class II MHC have been reported (Darley, et a/., (1993)).
None of the colorectal tumour cell lines displayed surface expression of these
antigens constitutively. As mentioned, previously, these cell lines were not
responsive to TGF-p with respect to inhibition of IFN-y-induced HLA-D
expression although colo 205 were growth-inhibited by culture in its presence.
No data were available for the colorectal cell lines' responses to IFN~P with
respect to down-regulation of induced MHC class II expression.
The transfection of these cell lines with pDRa.680CAT had not been
successful in providing information regarding the cytokine-mediated control of
MHC class II expression at the genetic level. It was determined that the 680
base pair HLA-DRa. promoter fragment employed previously in CAT assays
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either contained a tissue-specific repressor sequence or a lacked a tissue
specific enhancer element.
The use of the pORa320CAT vector in a series of experiments employing
the same strategy as described previously was intended to determine which of
the above possibilities for the unresponsiveness of the colorectal cell lines for
HLA-ORa.promoter-driven CAT expression was the most likely to be true.
7.3.2. Expression of reporter genes in colorectal tumour cell lines
7.3.2.1. Transfection of cells and treatment with cytokines
Colorectal tumour cell lines were transfected with reporter gene-
containing vectors (pORa320CAT, pSV2CAT and pRSVp-gal) in the same
proportions and by the same method as that described for the transfection of
U138MG cells.
7.3.2.2. CAT expression by IFN-y-treated, pORa320CAT-transfected colorectal
tumour cell lines
The response of pORa.320CAT-transfected cells to a range of IFN-y
concentrations was negligible as was the case when the same cell lines were
transfected with pORa.680CAT and treated with the same cytokine
concentrations. Transfected cells were treated with a range of IFN-y
concentrations from 1 to 100U/ml and no increase in CAT expression was
observed in any of the cell lines over this range. Again, this inability of these
cell lines to express the HLA-ORa. promoter-driven expression of CAT was
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irrespective of their transfection with and effective expression of both pSV2CAT
and pRSVf3-gal. The levels of CAT expression from pDRa,320CAT- and
pSV2CAT-transfected cells are shown in figure 7.6.
Figure 7.6. Relative expression of CAT by colorectal tumour cell lines
transfected with pDRa320CAT and pSV2CAT
fold augmentation
30
5
25
20
15
10
o
pDRa320CAT pDRa320CAT pDRa320CAT pDRa320CAT
pSV2CAT pSV2CAT pSV2CAT pSV2CAT
LS180 caco 2 HT29 col0205
CELL LINE
Notes:
The colorectal tumour cell lines LS 180, caco 2, HT29 and colo 205 were transfected with
the vectors pDRa,320CAT and pSV2CAT. CAT expression was induced by 100U/ml
IFN-y for 48hr and "pDRa,320CAT" axis labels refer to the fold expression compared to
untreated transfected cells. Constitutive CAT expression due to pSV2CAT (fold
difference from pCATbasic) is identified by the axis label "pSV2CAT".
7.3.2.3 Effects of IFN-af3and TGF-f3treatment on CAT expression
Attempts were made to assess the effects of these cytokines upon the
IFN-y-induced CAT expression from the pDRa,320CAT vector in the colorectal
tumour cell lines. The information obtained from such data would have been
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useful in the interpretation of the observations from the cell surface expression
of HLA-D antigens by these cell lines under the influence of the cytokines
studied here.
As was the case when these cells were transfected with pORa680CAT,
their response to IFN-y with respect to expression of the reporter gene was
negligible. Within an assay, transfected cells were treated with all cytokines in
a "blind" fashion. The responses of transfected cells to concurrent treatment
with IFN-y and IFN-aJ3or TGF-J3were as seen for treatment of the transfected
cells with IFN-y alone. Taking this into consideration, it was inappropriate to
infer anything from these data.
7.3.3. Discussion of reporter gene assays in colorectal tumour cell lines
The human colorectal tumour cell lines colo 205, HT29, LS180 and
caco 2 were employed in reporter gene assays with the vector pORa320CAT.
Expression of the bacterial gene for chloramphenicol acetyl transferase was
under the control of a 320 base pair proximal promoter fragment from the
HLA-DRa gene. The expression of CAT in the appropriately transfected cells
was attempted to be induced by their treatment with a range of IFN-y
concentrations. These cell lines did not express chloramphenicol acetyl
transferase after treatment with any concentration of IFN-y upto 100U/ml. This
lack of inducibility was also observed when these colorectal tumour cell lines
were transiently transfected with the vector pDRa680CAT. Again, this lack of
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HLA-DRa. promoter-driven CAT expression was irrespective of evidence of their
transfection, from the expression of pRSVp-gal. These cell lines also had the
ability to process CAT transcripts into the functional enzyme as observed by
their ability to express chloramphenicol acetyl transferase from pSV2CAT.
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7.4. Discussion
7.4.1. Reporter gene assays with pDRa320CAT in U138MG cells
The human multiform glioblastoma cell line U138MG was employed in
further investigations of HLA-DRa promoter-driven gene expression involving
the reporter gene expression vector pDRa320CAT. The effects of the cytokines
IFN-y, IFN-a(3 and TGF-(3 upon CAT expression were studied in cells transiently
transfected with this vector. Levels of expression were compared to those
observed for pDRa680CAT-transfected U138MG under the same cytokine
stimuli.
Levels of IFN-y-induced CAT expression were marginally greater for
pDRa320CAT-transfected cells. This suggested that this deletion of the
HLA-DRa promoter had removed an inhibitory sequence element located in the
upstream 360 base pair region of the HLA-DRa680 fragment.
The suppression of IFN-y-induced CAT expression in
pDRa680CAT-transfected cells which had been treated concurrently with
IFN-aP, was virtually abolished when pDRa320CAT-transfected cells were
treated with 1U/mIIFN-y and 100U/mIIFN-ap. Levels of inhibition equivalent to
those described for pORa680CAT -transfected cells under the stated cytokine
concentrations were achieved here when the transfected cells were treated with
1U/ml IFN-y concurrently with 1000U/ml IFN-a(3. The removal of the putative
IFN-ap response element had an effect on the ability of this cytokine to inhibit
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the IFN-y-induced expression of CAT. However, this was not the sole element
responsible due to the restoration of inhibition when treated with the greater
IFN-<tJ3concentration.
The inhibition of CAT expression by TGF-J3 was observed in
pDRa,320CAT-transfected cells and was evident when cells were treated
concurrently with 1U/ml IFN-y and 100U/ml TGF-J3. However, this
down-regulation of expression was not as great as when
pDRa,680CAT-transfected cells were treated with the same concentrations of
these cytokines.
In conclusion, results obtained with pDRa,320CAT-transfected U138MG
cells indicated that a general repressor element had been removed from the
promoter by the deletion of the 360 base pairs of the upstream portion of the
HLA-DRa,680promoter fragment.
This region contained a sequence with homology to an IFN-<tJ3response
element and it was considered that this sequence was responsible for mediation
of the repression of IFN-y-induced expression by IFN-<tJ3.However, due to the
greater levels of IFN-y-induced CAT expression and the reduced inhibition of
this expression by TGF-J3as well as by IFN-<tJ3,it was postulated that a more
general repressor element was responsible for overall down-regulation of gene
expression from this promoter instead of or as well as the proposed IFN-<tJ3
sequence element.
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The promoter sequence responsible for TGF-J3-mediated suppression
was contained within the 320 base pair HLA-DRa promoter fragment.
These results were in agreement with those of Reimold et al., (1993) in
the melanoma cell line Hs294T(c) and Devajyothi et al., (1993) in the CRT
astrocytoma cell line. The latter study suggested that TGF-J3suppression of
HLA-DRa expression was not due to global transcriptional inhibition in that the
IFN-y-induced expression of the intercellular adhesion molecule-1 (ICAM-1) was
unaffected by TGF-J3.Mutational analysis of the HLA-DRa promoter by Reimold
et al., resulted in the conclusion that TGF-J3exerts its effects through sequences
within the W-X1 region of the promoter. Repression due to IFN-J3was also
shown to be exerted through the 267 base pairs proximal to the transcriptional
start site and this repression of CAT expression was shown to be less than
displayed by a 2.2Kb HLA-DRa heterologous promoter (Devajyothi et al.,
1993). These results reflected those obtained in the present study and
indicated also that repression by TGF-J3 was reduced in the truncated
promoter constructs in addition to the increased levels of IFN-y-induced CAT
expression by cells transfected with such plasmids.
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Recent studies have speculated as to the cellular and molecular
mechanisms for the down-regulation of IFN-y-induced class II MHC
expression. Dose and time dependent inhibition of expression of class II
surface protein, mRNA, and promoter activity by TGF-p has been
demonstrated in primary astrocytes (Panek, et al., 1995). In this study,
evidence was provided for the specific inhibition of transcription of MHC
class II rather than a global effect. Furthermore, TGF-p did not affect events
that are involved in IFN-y-induced intracellular signalling such as tyrosine
phosphorylation of JAK1, JAK2 and STAT1a, nor did it affect IFN-y induction
of class II X2 box binding protein IFNEX.
It was speculated that TGF-p may exert its effects by modulation of
the expression or function of constitutively expressed factors responsible for
regulation of class II MHC gene expression.
The current studies into the down-regulation of class II MHC
expression are clearly at a preliminary stage, but evidence from this
investigation and those presently being undertaken are revealing important
aspects of the control of transcription of these genes. As yet, there are few
published data with respect to the molecular mechanisms of
IFN-a.p-mediated inhibition of IFN-y-induced class II MHC expression, but
those available support the observations recorded here (Devajyothi et al.,
1993). There has been no published observation of an IFN-ap or a
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TGF-J3-induced repressor factor binding to the HLA-DRa. promoter either in
the presence or absence of concurrent treatment of cells with IFN-y.
However, there was observation made in the present investigation that
IFN-aJ3 treatment of the colorectal tumour cell lines colo 205 and LS180
resulted in increased protection of the W-X box region of the HLA-DRa.
promoter. Again, this was an unsubstantiated observation which clearly
requires further investigation. Also, no such experiment was possible with
the U138MG cell lines due to technical difficulties in obtaining nuclear
proteins by the method described.
7.4.2. Reporter gene assays with pDRa320CAT in colorectal tumour cell
lines
An attempt was made to relate observations of the surface expression of
HLA-D antigens in response to cytokine treatment to the structure of the
HLA-DRa. promoter. The inability of the human colorectal tumour cell lines
caco 2 and LS180 to express class II MHC antigens in response to stimulation
by IFN-y was of particular interest. In vivo footprinting and complementation
studies involving HLA-DRa. expression in non-inducible cell types have
determined that promoter accessibility within the MHC is an important factor in
the transcription of these genes (Kara, 1993). This type of reporter gene study
was intended to clarify the status of the non-inducible colorectal cell lines in this
regard. Whether their uninducibility for the expression of class II MHC antigens
was a result of promoter structure not permitting organisation of the
transcriptional machinery would have been revealed should they have
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expressed chloramphenicol acetyl transferase driven by the HLA-DRa
promoter.
As was the situation with the vector pDRa680CAT, none of the colorectal
tumour cell lines studied here were capable of expressing CAT when
transfected with pORa320CAT. This lack of expression was again irrespective
of the cell lines' abilities to express CAT when driven by the SV40 late promoter
and was not explained by the cells not being transfected efficiently with the
vector. These observations remain fully unexplained although the ability of
these cells to respond to IFN-y with respect to induction of other genes post
transfection was not assessed.
These collective observations led to the postulate that uninducibility of
CAT from either of the HLA-DRa promoter vectors employed was most likely to
be the result of a missing tissue-specific enhancer element. This hypothesis
could have been tested by a series of reporter gene assays employing larger
HLA-DRa promoter fragments.
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CHAPTER 8: DISCUSSION
The experimentation described in this report was performed with the
intent of understanding further the mechanisms involved in the
cytokine-mediated induction and inhibition of Class II MHC gene expression in
human tumour cell lines. The following sections relate the results obtained in
this investigation with published data and offer an opinion of their possible
implications for the control of the expression of HLA-DRa..
8.1. DNA binding activities within nuclear extracts from inducible and
non-inducible tumour cell lines
Sequence elements important for the transcriptional regulation of
HLA-DRa. gene expression were investigated in bandshift (gel retardation,
electromobility shift) assays as to their abilities to bind nuclear factors from
human tumour cell lines prior to and after IFN-y stimulation. The cis-acting
elements chosen for this were the Wand X boxes which had been shown to be
important for IFN-y-stimulated expression of class II MHC genes (Basta, et al.,
1988; Tsang, et al., 1990; Sherman, et al., 1987, 1989). The primary objective
of this experimentation was to determine whether there were differences in the
populations of HLA-DRa. promoter element binding proteins between inducible
and non-inducible human tumour cell lines. Also important here was the effect
of IFN-y treatment of cells on the binding of such transcription factors. Though
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much research over some years has concentrated upon the IFN-y-stimulation of
HLA-DRa gene expression, no IFN-y-induced HLA-DRa promoter-associated
transcription factor has been identified. A probe corresponding to the whole
promoter region was also employed in this type of assay.
8.1.1. The HLA-DRa W box
The binding of transcription factors from uninduced and IFN-y-induced
human tumour cell lines to a probe corresponding to the HLA-DRa W box
revealed cell line- and cytokine treatment-dependent differences in the
proteins which bound prior to IFN-y-treatment of the cells.
The cell lines studied contained different populations of W box binding
proteins. It was not possible to equate the presence of the complexes observed
with those published by other authors who have described the presence of
complexes constitutively present in nuclear extracts from Raji, Jurkat and HeLa
cells. In lymphoid cells such as Raji, the W box-binding complexes W-B1 and
W-B2 have been described (Sakurai & Strominger, 1988; and Tsang et aI,
1990). While W-B1 is ubiquitous, W-B2 is a lymphoid-cell-specific protein
(Cogswell, et al., 1991 a). Of these two proteins, W-B2 displays the greatest
mobility in bandshift assays. It was difficult to assign these labels to any of the
bands obtained with the cell lines studied in this investigation.
The availability of antisera to W-B1/2 at the time of investigation VIIOuld
have enabled ·supershift" or competition assays to have been performed. The
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binding of an antibody to a DNA-associated factor results in further inhibition of
the complex's electrophoretic migration compared to the same protein-DNA
complex in the absence of antibody. Alternatively, an antibody with specificity
for the DNA binding site of a transcription factor could be utilised to block the
association of a factor with its recognition sequence.
Upon IFN-y-treatment of the class II-inducible cell lines colo 201, colo
205 and U373MG, an altered population of W box-binding transcription factors
was observed. In colo 201 and colo 205, this was manifested in the diminution
of complexes as well as the binding of a novel factor which migrated with the
same mobility for both cell lines. The novel complex migrated with similar, but
not the same, properties as the most retarded band observed in untreated and
IFN-y-treated LS180 and caco 2. It was postulated that the novel binding
complex in colo 201 and colo 205 was formed by the alteration of a previously
bound factor(s).
The modification of transcription factors upon stimulation of intracellular
signalling mechanisms is noted. For example cyclic AMP mediates the
hormonal induction of numerous eukaryotic genes through a conserved cAMP
response element (eRE). A rat somatostatin promoter eRE-binding
phosphoprotein was identified which is modulated by cAMP-dependent protein
kinase-mediated phosphorylation (Yamamoto, et al., 1988). In this situation
phosphorylation of eREB allows its dimerisation and the dimer is observed as a
more retarded complex than the monomer in gel retardation assays.
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For IFN-y-induced expression of HLA-DRu, it has been shown that
cytokine stimulation is associated with activation of protein kinase C in
astrocytes (Benveniste, et a/" 1991; Lee, et al., 1995). It might, therefore, be
postulated that covalent modification of transcription factors is important for
IFN-y-mediated stimulation of class II MHC expression. If the most retarded
complex observed with uninduced colo 201 and colo 205 became modified upon
IFN-y stimulation then its electrophoretic properties may be altered also.
The appearance of the "novel" retarded complex upon IFN-y treatment of
colo 201 and colo 205 was correlated with the reduced association of two
factors bound prior to stimulation. In colo 205 the binding of the fastest
migrating of these uninduced complexes was nearly completely abolished upon
treatment of cells for 6 hr with IFN-y, and similarly after 24 hr treatment. The
novel complex observed with this cell line was only observed after 24hr IFN-y
treatment. This suggested that the dissociated complex may have been
exerting a repressive effect at this site which was relieved upon cytokine
stimulation and that only after dissociation of this factor could the novel complex
bind. However, in colo 201 the association of the IFN-y-induced complex was
irrespective of the presence of this faster migrating "diminished" complex.
Three postulates could be drawn from these observations of the
IFN-y-stimulation of these colorectal tumour cell lines. Firstly, it was
hypothesised that the novel retarded complex induced by IFN-y treatment was
formed from two ubiquitously-bound factors which became modified upon
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cellular stimulation. The contributory factors were identified as those whose
intensity was reduced along with the binding of the induced complex after 6 and
24hr IFN-y treatment in colo 201. Secondly, a hypothesis could be constructed
in which the binding of a modified factor is permitted after the dissociation of a
repressor complex. This postulate might be applied to the IFN-y treatment of
colo 205 where the binding of the induced complex was only observed after
considerable reduction in the intensity of the complex which gave rise to
"band 2" (figure 3.3). Similarly, the association of the IFN-y-induced complex
observed with colo 201 may also be explained by these considerations. Thirdly,
the novel complex may not be a factor which resulted from the covalent
modification of a protein bound prior to IFN-y treatment, but a new species of
protein. In this scenario the diminution of factors upon IFN-y treatment is due to
their displacement by the induced factor. These hypotheses are represented
schematically in figure 8.1.
In the uninducible cell lines LS180 and caco 2 there was no alteration in
the binding of factors after IFN-y treatment. In addition, the most retarded
complex from these cell lines migrated with similar, but slower mobility than the
induced factor from IFN-y-stimulated colo 201 and colo 205. The binding of the
factor giving rise to "band 3" in colo 201 and colo 205 was disabled in the
uninducible cell lines. This factor may therefore have an important role in the
IFN-y-induced transcription of HLA-DRa through the W box sequence element.
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Figure 8.1. Hypotheses of the IFN-y-induced binding of transcription
factors to the HLA-DRa W box probe in colo 201 and colo 205
band 3. band 2
•X, Y, etcSRVIIW2 SRV21W
SRVIIW2 SRV21W SRVIIW2 SRV21W
SRVIIW2 SRV21W
Three possible scenarios for the IFN-y-induced binding of transcription factors to the
HLA-DRa. W box probe are indicated. Prior to IFN-y treatment of colo 201/205, two
major binding species are depicted corresponding to bands 2 and 3 in figure 3.3. The W
box is dissected into the W (SRV2) and W2 (SRVI) elements. A) IFN-y treatment
results in covalent modification of bound factors and their altered association with the
element. B) A "repressor" factor (band 2) dissociates from the W box and a
modification of "band 3" results in its altered association with the element. C) The
binding of an IFN-y-induced binding factor results in the dissociation of the previously
bound proteins.
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Competition for the binding of W-box bound factors by an X box
oligonucleotide indicated that homologous sequences within these elements
were targetted by W box-specific factors. The IFN-y-induced factor from colo
201 and colo 205 was particularly susceptible to displacement from the W box
by the presence of the X box competitor oligonucleotide (figure 3.7). This
indicated that the induced binding moiety was associated with the nucleotides of
the W box which showed greatest homology with the X box. The homologous
nucleotides are at the 5' extreme of the W element, a region called the W2 or
SRV1 element. Previously, this area of the W box had been shown to bind
W-B1 (Tsang, et al., 1990; Cogswell, et al., 1990), a ubiquitous transcription
factor. The most retarded complexes from LS180 and caco 2 which bound to
the W box were also partially competed out by the presence of the X box
oligonucleotide. This crude method, therefore, localised the colo 201/205
induced factor and the LS180/caco 2 constitutive factor to the 5' region of the W
box.
In the inducible astrocytoma cell line U373MG there was also novel
binding observed upon IFN-y treatment of cells. Again this was manifested in
the association of a slowly-migrating complex and a complex which migrated
with comparatively greater mobility (figure 3.2). In this instance, there was no
concurrent loss of binding of previously observed factors. On the contrary,
there was an increase in the association of all factors in addition to those which
bound upon IFN-y stimulation.
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8.1.2. The HLA-DRa X box
This sequence element was assessed for the binding of nuclear factors
in the same manner as that described for the W box. Again, differences were
observed between the inducible colorectal tumour cell lines and those which
were uninducible for class II MHC expression. This was manifested in the
presence of protein-DNA complexes which were similar for the uninducible
lines, yet those observed for the unstimulated, inducible cell lines were
markedly different. As for the association of proteins with the W box after IFN-y
treatment there were differences in the binding of factors to the X box upon
stimulation of the inducible colorectal cell lines colo 201 and colo 205.
Common to both of these cell lines was the appearance of a low-mobility
complex with the same migratory properties as the most retarded complex from
LS180, similarly with caco 2. In colo 201, a second induced factor was also
observed, this complex had greater mobility than the other induced factor and
no factor with its migratory properties was displayed by the other cell lines, ie,
this factor was unique to IFN-y-induced colo 201. In colo 205, the binding of the
induced factor was coincident with the dissociation of two complexes observed
prior to IFN-y-stimulation.
The involvement of the described X box-binding factors RF-X and
hX8P-1 in the formation of the observed complexes could not be assessed at
the time of investigation. RF-X is a large protein and has been reported to give
rise to two X box-binding moieties in bandshift assays, termed the 81 (slower
mobility) and 83 (faster mobility) (Cogswell et aI, 1991b). The RF-X which
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gave rise to the faster migrating 83 band was reported to have a DNase I
footprint covering the 5' region of the X box and a few upstream nucleotides.
However, the slower migrating 81 RF-X complex also made additional contacts
in the 3' Y element and with bases -126 and -127 within the upstream W
element; competition analyses have indicated that nucleotides within the W box
a required for stabilising the binding of the 81 band RF-X (Reith, et al., 1988).
With regards to the bandshift employing colorectal cell line nuclear extracts, it
was possible that band 4 was attributed to the binding of RF-X to the X box
nucleotides and that band 5, most noticeably observed in extracts from caco 2,
was due to the association of Wand Y box-binding proteins with RF-X resulting
in a retarded band. It is of note that, assuming band 4 was caused by the
binding of RF-X, this protein was absent from the nuclear extracts of
unstimulated colo 205 and was only present in small amounts in those of
untreated colo 201 and caco 2. The use of this terminology is in a purely
postulative manner in the absence of evidence from supershift-type
experiments, yet it is of use to explain speculatively the binding of the observed
factors to the X box.
Interferon-y, promoted a response in the MHC class" inducible cell lines
colo 201 and colo 205, but not U373MG, as regards the proteins which bound
to the X box of the HLA-DRa.promoter. In unstimulated colo 201, a band which
may be postulated as being due to the presence of RF-X was only bound to the
X box in small amounts and this binding was very much increased by the
treatment of the cells with IFN-y for 6hr. Such stimulation also resulted in the
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binding of a completely novel factor to this region (termed band A).
The altered binding of factors from IFN-y-stimulated colo 201 to this
probe may be explained by a number of hypotheses. Firstly, this factor may not
be present or is only present at low levels in the unstimulated cells;
treatment with IFN-y leads to increased copy number by transcriptional
regulatory mechanisms. A second hypothesis might suggest that the factor is
constitutively present in the nuclei of untreated cells, but it is in a form which
cannot bind efficiently to the X box; modification of the protein upon IFN-y
treatment of the cells results in a different form which is able to bind to the X
box. Thirdly, it is possible that the binding of the factor is assisted by the
binding of a protein cofactor. This is supported by the additional binding of a
second complex with the colo 201 extracts (band A).
In the case of colo 205, a fourth possibility was presented. Here, it was
possible that the binding of the novel complex is inhibited by repressor proteins
which are bound to the X box in unstimulated cells (bands 2 and 3). Treatment
of the cells with IFN-y results in their displacement by the induced complex and
transcription is activated. In nuclear extracts from LS180 and caco 2 (with and
without IFN-y treatment) a factor with the same mobility as the most retarded
induced factor in colo 201/205 is constantly present as is the complex which
gives rise to band 2, the postulated repressor. It is possible therefore, that
transcription is inhibited by the constitutive presence of this factor in these cell
lines which cannot be induced to express class II MHC antigens. A schematic
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representation of the hypotheses for the IFN-y-induced binding of the induced
factor(s) is given in figure 8.2.
Figure 8.2 Models for the interferon..-y-activation of transcription through
the X box
A) modiflcatlon model for activation of transcription
B) cooperation model for activation of transcription
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Figure 8.2. (contd.)
C) displacement model for activation of transcription
x
Notes:
The diagrams illustrate three possibilities for the IFN-y-activation of ID..,A-DRa.
transcription through the X box by the altered binding of an X box-specific factor. In
these figures, this factor is given the identity "factor-X (F-X)" - this does not indicate that
this has been confirmed as the same RF-X as described in the literature .. The mechanisms
shown are devised from results from band shift assays employing a consensus X box probe
and nuclear extracts from untreated and IFN-y-treated cells (refer to section 3.3). The
models are intended to illustrate the possible mechanisms for the IFN-y-induced binding
offactors to the X box in the cell lines colo 201 and colo 205.
IIII~X: indicates that transcription does not occur
IIII~r:indicates that transcription can proceed
Model A) suggests that the transcription factor F-X is present in cells but is unable to
interact with the X box until it has been modified following IFN-y treatment of cells.
Model B) indicates that the binding of F-X cannot occur until a third party factor also
binds to the X box region. This hypothesis is supported by the results obtained
employing nuclear extracts from colo 205.
Model C) shows the mechanism by which a repressor protein could inhibit the binding of
F-X and that IFN-y treatment of the cells results in the alteration of the repressor and its
displacement from the X box by F-X.
The binding of the factor human X box binding protein 1 (hXBP-l) is shown as
constitutive.
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The astrocytoma cell line U373MG did not display any difference in the
binding of nuclear factors after treatment with IFN-y. It was assumed that this
displayed a tissue-specific difference in the transcription factors required for
IFN-y-induced HLA-DRa. between colorectal and neural cells. There was a
moderate increase in the association of existing factors with this element.
However, there was no evidence for the binding of a single IFN-y-enhanced
factor similar to that described in rat primary astrocytes by Moses, et al., (1992).
These neural cells presumably contained all the required X box-binding factors
irrespective of IFN-y treatment and such treatment was responsible for changes
at the W box instead.
8.1.3. The HLA-DRa,470 promoter probe
This probe represented the region of the HLA-DRa. promoter form
nucleotide positions -423 to +47 relative to the cap site. Nuclear extracts from
the colorectal tumour cell lines colo 205, LS180 and caco 2 were employed in
the investigation of the binding of transcription factors to the fragment probe.
The effect of IFN-y treatment of cells was assessed and preliminary experiments
investigated the effects the concurrent treatment of cells with IFN-yand IFN-a.J3.
Constitutive binding of nuclear factors
Differences were observed in the binding of transcription factors to this
promoter probe between the colorectal tumour cell lines, although these
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differences were not as marked as those observed with oligonucleotide probes.
One prominent band was observed for all cell lines, other bands varied with cell
line and cytokine treatment. Again, the major difference was between the
inducible colo 205 and the other two non-inducible lines. This was manifested
in the presence of a slowly migrating complex 'Nhich formed the major binding
activity in colo 205 which was not present with LS180 or caco 2.
The use of competition bandshift assays, employing W, X and Y box
oligonucleotides as competitors, resolved the slowest migrating complex of colo
205 into two factors 'Nhich bound independently to the Wand X boxes and that
the majority of binding of factors was at the X box region. It was also shown
that the "invariant" band's intensity was altered, although it was never
completely abolished, by all combinations of competitor oligonucleotides. It was
possible that this band was due to the binding of factors to the W, X and Y
elements, that is to say that the association of many factors with the promoter
resulted in one major nucleoprotein-DNA complex observed by this method.
The incorporation of competitor oligonucleotides resulted in differences in
intensity of this intermediately migrating complex and the appearance of a
rapidly migrating complex in colo 205 and LS180 wnose intensity remained
unaltered by competition. The sequestration of constitutively bound W, X and Y
box-associated factors, therefore, allowed the binding of a high mobility
complex 'Nhose binding was not affected by the presence of competitor
oligonucleotides. It was postulated that this factor may have been a repressor
protein or a factor which bound to the promoter when the numbers of bound
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transcription factors was low. The role of such a factor might be to maintain
promoter structure in a "poised" manner until the stimulus for the binding of
more transcription factors. The function of the "repressor" factor might 'Nell be a
structural one such that it maintains the structure of the promoter in conditions
where the constitutive promoter binding proteins are not present or are not
present insufficient concentration. Binding of such a factor would allow the
promoter to be poised for the association of transcription factors with their
corresponding sequence elements once the concentration of the transcription
factors is great enough to displace the "repressor" factor. In vivo footprinting
data have suggested that class II MHC inducible non-lymphoid cells possess a
"poised" promoter in the absence of IFN-y (Wright & Ting, 1992) It was
proposed that the majority of protein-DNA interactions are in place prior to IFN-y
stimulation but with certain interactions being weak and non-productive.
Interferon-y stimulation was proposed to modify existing DNA binding factors
leading to a stronger and productive interaction with the promoter, or such
stimulation could cause de novo binding of an induced factor.
Binding of nuclear factors after IFN-ytreatment of cells
The treatment of colo 205 with IFN-y resulted in the disappearance of the
most retarded complex(es) which had been shown to bind to the Wand X boxes
prior to stimulation. Again, therefore, a difference was observed in the binding
of complexes to a probe after IFN-y treatment of an inducible cell line. In this
situation, it was manifested in the reduction in binding of proteins. This had
also been the case when the Wand X box oligonucleotides were used as
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probes with extracts from this cell line, although there had also been induced
binding of factors by upon IFN-y treatment in these instances.
The treatment of colo 205 with IFN-y also resulted in the absence of
binding of the fastest migrating repressor/maintenance factor which had been
observed when untreated nuclear extracts were incubated with probe and
competitor 01igonucleotides.
Treatment of the uninducible cell lines LS180 and caco 2 with IFN-y
resulted in no differences in the binding of factors to this probe. Also, the
fastest migrating complex was still observed in IFN-y-treated LS180. If this
complex did represent a "repressed-state" promoter maintenance factor then it
was present in LS180 nuclear extracts irrespective of stimulation - perhaps
indicating the inability of this cell line to transduce the IFN-y signal into the
binding of transcription factors to this promoter. Conversely, this complex was
not observed with caco 2 under any circumstances. If the postulate is to be
adhered to then it could be said that this cell line lacked a nuclear factor which
was responsible for the organisation of constitutively bound transcription factors
in readiness for stimulation of gene expression.
8.1.4. DNase I footprinting of the HLA-DRa 470 probe
This technique was employed to clarify the data obtained from bandshift
experiments such that contact paints of transcription factors could be identified
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and any differences in the contact points of apparently similar factors observed
in bandshifts could be determined. As discussed in chapter 5, there were many
technical difficulties encountered with this type of experiment and the
production of a clear footprint of the HLA-DRa470 probe was hard to come by.
When this probe was successfully footprinted, protected regions of the probe
were observed which corresponded to defined sequence elements of the
HLA-DRa promoter. There was no observed difference in the protected regions
between the cell lines, nor was there any difference with IFN-y-treated colo 205
nuclear extracts compared to unstimulated cells. However, when nuclear
extracts from IFN-a.J3& IFN-y costimulated colo 205 and LS180 resulted in an
increased protection at the W-X box region, the appearance of a novel binding
factor in the corresponding bandshift was not observed. This increased
protection was seen as the result of the proteins already bound to the Wand X
boxes altering their contacts with the promoter under the IFN-a.J3I1FN-y
costimulus.
Chapter 8 254
8.2. Functional analyses of the HLA-DRa promoter: inhibitory effects of
IFN-a~ and TGF-~ on IFN-y-induced gene expression
8.2.1. Reporter gene assays with HLA-DRa 680 promoter fragment
CAT reporter gene assays employing the glioblastoma cell line U138MG
transiently transfected with the vector pDRa680CAT demonstrated the effects of
IFN-y, IFN-y/IFN-aP and IFN-yITGF-p upon gene expression driven by a 680bp
fragment of the HLA-DRa promoter. This cell line was used after what had
seemed to be a failure of transfection and/or subsequent induced reporter gene
expression in similar experiments In the colorectal tumour cell lines employed in
the studies of DNA binding proteins.
In U138MG, it was shown that 1U/mIIFN-y could stimulate near maximal
expression of chloramphenicol acetyl transferase driven by the heterologous
HLA-DRa. promoter fragment. This fragment contained all those elements
shown to be essential for IFN-y-induced expression (see section 1.6.3.) as well
as a consensus IFN-aP response element. The treatment of U138MG
transiently transfected with pDRa680CAT with IFN-aP or TGF-p as well as
IFN-y resulted in the induced expression of CAT being much reduced compared
to those transfected cells treated with IFN-yalone (chapter 6).
When the assay technique was reassessed in the colorectal tumour cell
lines, no CAT expression from the pDRa680CAT plasmid was observed even
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though CAT expression was clearly evident in cells transfected with a positive
control vector, pSV2CAT.
It was concluded that, as demonstrated in U138MG, the HLA-DRa680
promoter fragment contained sequences responsible for the IFN-y-induced
expression of a reporter gene and also the IFN-aJ3 and TGF-J3-mediated
inhibition of this induction. The same promoter fragment was unable to direct
induced expression of CAT in colorectal tumour cell lines. It was proposed that
this promoter fragment either: a) possessed a tissue-specific repressor element
'Nhich silenced this promoter fragment in these cell lines; b) lacked a
tissue-specific enhancer element essential for gene expression directed by the
HLA-DRa promoter in cells derived from the colon epithelium.
8.2.2. Reporter gene assays with the HLA-DRa 320 promoter fragment
The expression vector pDRa320CAT contained a 320bp promoter
fragment 'Nhichhad been produced by the deletion of the 5' region of the 680bp
fragment. The deleted portion of the promoter contained a consensus IFN-a13
response element 'Nhichmay have contributed to the inhibition of IFN-y-induced
expression of CAT driven by the 680bp promoter fragment.
When pDRa320CAT was employed in reporter gene assays with
U138MG the relative expression of IFN-y-induced CAT was greater than was
observed with the pDRa680CAT vector.
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The IFN-a.p inhibition of IFN-y-induced CAT expression observed with
U138MG when transfected with pDRa,680CATwas not observed under similar
circumstances when the cells were transfected with pDRa,320CAT. The
inhibition of expression by IFN-a.p was restored when 1000U/ml was used
against 1U/ml of stimulating IFN-y. It appeared, therefore, that there was an
element which had been removed by truncation of the promoter which was
involved in IFN-a.p-mediated inhibition of gene expression driven by the
HLA-DRa,promoter. However, this was not the critical element since inhibition
was restorable with increased IFN-a.Pconcentration. It was proposed that the
320bp HLA-DRa promoter fragment was essential for IFN-a.p-mediated
inhibition of CAT expression and that a sequence upstream of this enabled a
more sensitive response.
The inhibition of IFN-y-induced CAT expression mediated by TGF-p was
also reduced in cells transfected with pDRa320CAT compared to those
transfected with pDRa,680CAT. However, this inhibition was still evident and it
was again proposed that the 320bp promoter fragment was sufficient to direct
TGF-p-mediated inhibition of expression.
The reduced inhibition of gene expression in cells transfected with
pORa,320CAT, compared to that when expression was driven by the larger
promoter fragment, was considered to be the result of the removal of a
negatively acting cis-element. A candidate element was the consensus IFN-ap
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response sequence. However, it was also possible that a general repressor
element had been removed due to the reduction in TGF-p effects and the
increase in IFN-y-induced expression.
Colorectal tumour cell lines were again assessed for their ability to
express CAT driven by an HLA-DRa promoter fragment. It had been proposed
that their inability to do so \Nhenexpression was driven by the 680bp promoter
fragment was because this fragment contained a cell-type-specific repressor
element or that it lacked an enhancer element essential for gene expression.
These postulates were assessed by the use of pDRa320CAT in reporter gene
assays.
None of the colorectal tumour cell lines expressed CAT \Nhendriven by
the deleted promoter fragment. Again, this was irrespective of their ability to
express CAT \Nhendriven by the SV40 late promoter. It was therefore assumed
that the fragment of the promoter removed in the construction of pDRa320CAT
did not contain a tissue-specific repressor element. The possibilities remaining
was that a tissue-specific silencer was present in the 320bp promoter fragment
or that a tissue-specific enhancer was absent from this region. These
hypotheses are yet to be tested experimentally.
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8.3. Proposals for further research
This investigation, apart from fulfilling the main objectives, raised many
questions which, due to the intensive nature of the research, have yet to be
answered. The research described in this thesis was of a demanding nature,
both technically and in terms of the time taken to complete certain experiments.
However, the data described here were included only after repeated
experiments had confirmed the result and, as such, are considered to be
valuable.
As stated above, this research raised many questions which need to be
addressed before a complete picture of the expression of HLA-DRa can be
painted. The scope for further research is described below.
The first priority is to establish the identity of those factors which were
shown to bind to the Wand X box oligonucleotides. Antibodies to cloned
HLA-DRa promoter-binding transcription factors were not available at the time
this investigation was undertaken. Had they been, it would have been possible
to determine which of those bound factors correlated with those which had
already been identified and characterised. Those factors peculiar to the
IFN-y-inducible cell lines would also be attractive for further research. Their
identification is central to answering those questions raised by the original
research.
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The involvement of IFN-y-induced "cofactor" CIITA also needs attention.
Some of the models for the binding of IFN-y-induced factors to the Wand X box
probes indicated the possible involvement of a cofactor-type protein. The
described cofactor has been shown to be necessary for IFN-y-induced
transactivation through the W (S) and X2 boxes (Zhou and Glimcher, 1995)
where its association has been termed as the "on/off' switch for transcription.
The actual interaction sites of CIITA with transcription factors bound to class II
MHC promoters was demonstrated at the time of completion of this work
Again, the positive identification of CIITA as being one of the factors involved in
IFN-y-regulation of HLA-DRa.transcription in the cell lines studied may rely on
the availability of appropriate antiserum, or antisense RNA which might alter its
binding in bandshift-type experiments or its presence in nuclear extracts from
these cell lines.
Although in vitro DNase I footprinting of the HLA-DRa.promoter revealed
no differences in the binding of nuclear extracts between inducible and
non-inducible cell lines, the analysis of bound factors in vivo was not assessed.
This technique might be useful in future research since it displays the
association of transcription factors in situ rather than the more artificial situation
imposed by the in vitro technique.
The delineation of the region(s) of the HLA-DRa.promoter responsible for
the inhibition of IFN-y-induced gene expression by IFN-a.13and TGF-13is yet to
be concluded. Research has shown, through reporter gene assays, that
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repression is mediated through the W-X-Y region of the promoter, although no
sequence element has been described, nor has a DNA binding factor binding
factor been identified. The identification of a sequence element responsible for
inhibition would be difficult if the cis-acting sequences essential for
IFN-y-induced expression are also involved. The mutation of W, X or Y boxes
abolishes expression of HLA-DRa. so the inhibition of gene expression by
IFN-ap or TGF-p could not be assessed against this. This is the probable
reason for no further publications regarding this matter since those which
originally described the phenomenon.
Also interesting is the potential for a tissue-specific enhancer which is
apparently required for HLA-DRa. expression by colorectal tumour cell lines.
The use of larger promoter fragments in reporter gene constructs or even
"enhancer-trap' reporter gene constructs employing intronic sequences from the
HLA-DRa.gene would be useful in concluding the situation with this type of cell
line.
Finally, this study has whetted the appetite for further research into a
wider range of cell types. It would be interesting to establish whether
differences described between inducible and non-inducible cell lines are
translated to cells of different tissue origin.
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APPENDIX: list of suppliers
APPENDIX A: LIST OF SUPPLIERS
Amersham International pic., Aylesbury, Buckinghamshire, UK
32p radioisotopes, restriction enzymes
BDH Laboratory Supplies, Ltd., Fourways, Carlyon Industrial Estate,
Atherstone, Warwickshire, UK
General chemicals
Bio-Rad Laboratories, Ltd., Caxton Way, Watford Business Park, Watford, UK
Protein assay reagent
Boehringer Mannheim, Ltd., Bell Lane, Lewes, East Sussex, UK
Calf intestine alkaline phosphatase, E. coli tRNA, restriction enzymes
British Biotechnology, Ltd., Barton Lane, Abingdon, Oxon., UK
Human transforming growth factor J3(TGF-J3)
Camlab, Ltd., Nuffield Road, Cambridge, UK
Phenol, phenol/chloroform
Costar, UK, Ltd., Victoria House, Desborough Street, High Wycombe, Bucks,
UK
Cell-freezing vials, tissue culture flasks, cell scrapers
Difco Laboratories, Ltd.,
Bacto-agar, bacto-tryptone
Du-Pont (UK), Ltd., NEN Research Products, Wedgewood Way, Stevenage,
Herts, UK.
[3Hl-acetyl Coenzyme A, Econofluor scintillation fluid
Suppliers 283
Eastman Kodak, Ltd., Acornfield Road, Knowsley Industrial Park North,
Liverpool, UK.
135mm transparency and print film, X-ray developer and fixative,
photgraphic paper, N'N-methylene bis-acrylamide
Fisons, Ltd., Bishop Meadow Road, Loughborough, Leicestershire, UK.
Acrylamide, butan-1-o1, chloroform, dimethyl sulphoxide, isoamyl alcohol
Fluka AG, CH-9470, Buchs.
Hydrazine
Fuji Photo Film Company (UK), Ltd., 125, Finchley Road, London, UK.
X-ray film
Gibco-BRL, Trident House, Renfrew Road, Paisley, UK.
DNase I, 1kb DNA ladder, foetal calf serum, trypsin-EDTA, glutamine,
penicillin/streptomycin, modification and restriction enzymes
Life Sciences, Inc., 72nd Street North, St. Petersberg, Florida, USA,
AMV reverse transcriptase
May and Baker, Ltd., Barton Road, Eccles, Manchster, UK.
Acetic acid, formic acid
Pharmacia Biosystems, Ltd., Davy Avenue, Knowlhill, Milton Keynes, UK.
Poly (dl:dC)-(dl:dC), restriction enzymes
Polaroid (UK) Ltd., Ashley Road, St. Albans, Herts, UK.
Type 55 land film
Suppliers 284
Promega (UK) Ltd., Epsilon House, Enterprise Road, Chilworth Research
Centre, Southampton, UK.
Modification enzymes, RNase-free DNase I, plasmid pCATbasic
Sigma Chemical Company Ltd., Fancy Road, Poole, Dorset, UK.
Agarose, ampicillin, CAT enzyme, chloramphenicol, DMEM, ethidium
bromide, foetal calf serum, hepes buffer, human IFN-a~, protease inhibitors:
antipain, leupeptin, pepstatin A and PMSF, RPMI1640 medium
Stratagene, Ltd., Cambridge Innovation Centre, Cambridge Science Park,
Milton Road, Cambridge, UK.
Plasmids pBSII-KS+,pSV2CAT
